10-Q

March 31,

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

☒        QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2022

OR

☐        TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission file number: 001-38399

AdaptHealth Corp.

(Exact name of registrant as specified in its charter)

Delaware	82-3677704
(State of Other Jurisdiction of incorporation or Organization)	(I.R.S. Employer Identification No.)
220 West Germantown Pike Suite 250, Plymouth Meeting, PA	19462
(Address of principal executive offices)	(Zip code)

Registrant’s telephone number, including area code: (610) 424-4515

Securities registered pursuant to Section 12(b) of the Act:

		Name Of Each Exchange
Title of Each Class	Trading Symbol(s)	On Which Registered
Common Stock, par value $0.0001 per share	AHCO	The Nasdaq Stock Market LLC

Securities registered pursuant to Section 12(g) of the Act: None

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.0405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).   Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☒	Accelerated filer ☐	Non-accelerated filer ☐	Smaller reporting company ☐
			Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of November 4, 2022, there were 134,731,665 shares of the Registrant’s Common Stock issued and outstanding.

ADAPTHEALTH CORP.

FORM 10-Q

TABLE OF CONTENTS

	Page Number
PART I FINANCIAL INFORMATION
Item 1. Interim Consolidated Financial Statements (Unaudited)
Consolidated Balance Sheets as of September 30, 2022 and December 31, 2021	4
Consolidated Statements of Operations for the three and nine months ended September 30, 2022 and 2021	5
Consolidated Statements of Comprehensive Income for the three and nine months ended September 30, 2022 and 2021	6
Consolidated Statements of Changes in Stockholders’ Equity for the three and nine months ended September 30, 2022 and 2021	7
Consolidated Statements of Cash Flows for the nine months ended September 30, 2022 and 2021	9
Notes to Interim Consolidated Financial Statements	10
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations	44
Item 3. Quantitative and Qualitative Disclosures About Market Risk	62
Item 4. Controls and Procedures	62
PART II OTHER INFORMATION	64
Item 1. Legal Proceedings	64
Item 1A. Risk Factors	64
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds	64
Item 3. Defaults upon Senior Securities	64
Item 4. Mine Safety Disclosure	64
Item 5. Other Information	65
Item 6. Exhibits	65
Signatures	67

1

CERTAIN DEFINED TERMS

Throughout this Quarterly Report on Form 10-Q, unless otherwise specified or the context so requires:

“AdaptHealth Holdings” means AdaptHealth Holdings LLC, a Delaware limited liability company;

“Business Combination” means the transactions completed pursuant to the Agreement and Plan of Merger, dated as of July 8, 2019, by and among DFB Healthcare Acquisitions Corp. a Delaware corporation, DFB Merger Sub LLC, a Delaware limited liability company, our wholly owned subsidiary, AdaptHealth Holdings, AH Representative LLC, BM AH Holdings, LLC, Access Point Medical Inc. and, solely for the purposes described therein, Clifton Offshore Investments L.P., a British Virgin Islands limited partnership, BlueMountain Foinaven Master Fund L.P., a Cayman Islands exempted limited partnership, BMSB L.P. a Delaware limited partnership, BlueMountain Fursan Fund L.P. a Cayman Islands exempted limited partnership, which we completed on November 8, 2019;

“Charter” means our Third Amended and Restated Certificate of Incorporation, filed with the Secretary of State of the State of Delaware on July 28, 2021;

“Class A Common Stock” means the Class A Common Stock, par value $0.0001 per share, created on the Closing of the Business Combination, which, following the filing of the Charter, has been renamed to “Common Stock” (as defined below);

“Class B Common Stock” means the Class B Common Stock, par value $0.0001 per share, created on the Closing of the Business Combination, which following the filing of the Charter, no longer exists;

“Closing of the Business Combination” means the closing of the Business Combination, which occurred on November 8, 2019;

“Common Stock” means our Common Stock, par value $0.0001 per share;

“Exchange Agreement” means the Exchange Agreement, dated as of November 8, 2019, by and among AdaptHealth, AdaptHealth Holdings, and holders of AdaptHealth Units;

“New AdaptHealth Units” common units representing limited liability company interests in AdaptHealth Holdings from and after the Closing of the Business Combination;

“Series B-1 Preferred Stock” means the series of preferred stock of the Company designated as “Series B-1 Convertible Preferred Stock,” par value $0.0001 per share;

“Sponsor” means Deerfield/RAB Ventures LLC;

“Tax Receivable Agreement” means the Tax Receivable Agreement, dated as of November 8, 2019, by and among AdaptHealth, AdaptHealth Holdings, and holders of AdaptHealth Units; and

“Warrants” means, collectively, the warrants that were issued in our initial public offering (our “IPO”) pursuant to the registration statement declared effective on February 15, 2018 and which were redeemed on September 2, 2020 (the “public warrants”) and the warrants initially issued to our Sponsor in a private placement that occurred simultaneously with our IPO (the “private placement warrants”), which private placement warrants have been distributed from the Sponsor to its members.

2

CAUTIONARY STATEMENT

In this Quarterly Report on Form 10-Q, including “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in Part I Item 2, and the documents incorporated by reference herein, we make forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to expectations for future financial performance, business strategies or expectations for our business. These statements may be preceded by, followed by or include the words “may,” “might,” “will,” “will likely result,” “should,” “estimate,” “plan,” “project,” “forecast,” “intend,” “expect,” “anticipate,” “believe,” “seek,” “continue,” “target” or similar expressions.

These forward-looking statements are based on information available to us as of the date they were made, and involve a number of risks and uncertainties which may cause them to turn out to be wrong. Accordingly, forward-looking statements should not be relied upon as representing our views as of any subsequent date, and we do not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. As a result of a number of known and unknown risks and uncertainties, our actual results or performance may be materially different from those expressed or implied by these forward- looking statements. Some factors that could cause actual results to differ include:

● competition and the ability of our business to grow and manage growth profitably;

● changes in applicable laws or regulations;

● fluctuations in the U.S. and/or global stock markets;

● the possibility that we may be adversely affected by other economic, business, and/or competitive factors;

● the impact of the coronavirus (COVID-19) pandemic and our response to it;

● failure to consummate or realize the expected benefits of acquisitions, and

● other risks and uncertainties set forth in this Form 10-Q, as well as the documents incorporated by reference herein.

3

PART I – FINANCIAL INFORMATION

Item 1. Interim Consolidated Financial Statements

ADAPTHEALTH CORP. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

(IN THOUSANDS, EXCEPT SHARE AND PER SHARE DATA)

(UNAUDITED)

	September 30,		December 31,
	2022		2021
Assets
Current assets:
Cash and cash equivalents	$	110,738	$	149,627
Accounts receivable		358,341		359,896
Inventory		125,362		123,095
Prepaid and other current assets		37,490		37,440
Total current assets		631,931		670,058
Equipment and other fixed assets, net		473,056		398,577
Operating lease right-of-use assets		128,635		147,760
Goodwill		3,524,999		3,512,567
Identifiable intangible assets, net		172,772		202,231
Other assets		20,453		15,098
Deferred tax assets		286,135		304,193
Total Assets	$	5,237,981	$	5,250,484
Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable and accrued expenses	$	346,920	$	358,384
Current portion of finance lease obligations		2,695		15,446
Current portion of operating lease obligations		28,769		31,418
Current portion of long-term debt		30,000		20,000
Contract liabilities		31,605		31,370
Other liabilities		26,938		43,194
Total current liabilities		466,927		499,812
Long-term debt, less current portion		2,162,088		2,183,552
Operating lease obligations, less current portion		103,859		120,180
Other long-term liabilities		306,641		322,487
Warrant liability		38,516		57,764
Total Liabilities		3,078,031		3,183,795
Commitments and contingencies (note 14)
Stockholders' Equity:
Common Stock, par value of $0.0001 per share, 300,000,000 shares authorized; 134,723,174 and 133,843,732 shares issued and outstanding as of September 30, 2022 and December 31, 2021, respectively		13		13
Preferred Stock, par value of $0.0001 per share, 5,000,000 shares authorized; 124,060 and 124,060 shares issued and outstanding as of September 30, 2022 and December 31, 2021, respectively		1		1
Treasury stock, at cost (750,835 shares)		(13,992)		—
Additional paid-in capital		2,126,468		2,107,267
Retained earnings (Accumulated deficit)		28,883		(43,021)
Accumulated other comprehensive income (loss)		12,994		(2,354)
Total stockholders' equity attributable to AdaptHealth Corp.		2,154,367		2,061,906
Noncontrolling interests in subsidiaries		5,583		4,783
Total Stockholders' Equity		2,159,950		2,066,689
Total Liabilities and Stockholders' Equity	$	5,237,981	$	5,250,484

See accompanying notes to unaudited interim consolidated financial statements.

4

ADAPTHEALTH CORP. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF OPERATIONS

(IN THOUSANDS, EXCEPT PER SHARE DATA)

(UNAUDITED)

	Three Months Ended September 30,				Nine Months Ended September 30,
	2022		2021		2022		2021
Net revenue	$	756,495	$	653,293	$	2,190,312	$	1,752,429
Costs and expenses:
Cost of net revenue		646,714		529,887		1,853,847		1,417,305
General and administrative expenses		40,681		33,006		124,673		132,584
Depreciation and amortization, excluding patient equipment depreciation		16,151		14,690		48,113		46,014
Total costs and expenses		703,546		577,583		2,026,633		1,595,903
Operating income		52,949		75,710		163,679		156,526
Interest expense, net		28,521		24,252		78,905		69,584
Change in fair value of warrant liability (note 10)		1,364		(16,737)		(17,145)		(57,359)
Change in fair value of contingent consideration common shares liability (note 10)		—		(10,006)		—		(34,050)
Loss on extinguishment of debt		—		8,240		—		20,189
Other loss (income), net		257		(452)		7,179		698
Income before income taxes		22,807		70,413		94,740		157,464
Income tax expense		5,580		12,147		20,036		22,782
Net income		17,227		58,266		74,704		134,682
Income attributable to noncontrolling interest		1,105		174		2,800		1,449
Net income attributable to AdaptHealth Corp.	$	16,122	$	58,092	$	71,904	$	133,233
Weighted average common shares outstanding - basic		134,227		131,684		134,186		124,228
Weighted average common shares outstanding - diluted		137,583		140,322		138,599		133,638
Basic net income per share (1)	$	0.11	$	0.40	$	0.49	$	0.97
Diluted net income per share (1)	$	0.11	$	0.20	$	0.35	$	0.27

(1) See Note 11, Earnings Per Share, to the unaudited interim consolidated financial statements for the calculations of basic and diluted net income per share.

See accompanying notes to unaudited interim consolidated financial statements.

5

ADAPTHEALTH CORP. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(IN THOUSANDS)

(UNAUDITED)

	Three Months Ended September 30,				Nine Months Ended September 30,
	2022		2021		2022		2021
Net income	$	17,227	$	58,266	$	74,704	$	134,682
Other comprehensive income:
Interest rate swap agreements, inclusive of reclassification adjustment		7,757		640		15,348		3,180
Comprehensive income		24,984		58,906		90,052		137,862
Income attributable to noncontrolling interest		1,105		174		2,800		1,449
Comprehensive income attributable to AdaptHealth Corp.	$	23,879	$	58,732	$	87,252	$	136,413

See accompanying notes to unaudited interim consolidated financial statements.

6

ADAPTHEALTH CORP. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY

(IN THOUSANDS)

(UNAUDITED)

														Accumulated
										Additional		Retained Earnings		other		Noncontrolling
	Common Stock			Preferred Stock			Treasury Stock			paid-in		(Accumulated		comprehensive		interests in
	Shares	Amount		Shares	Amount		Shares	Amount		capital		deficit)		income (loss)		subsidiaries		Total
Balance, December 31, 2021	133,844	$	13	124	$	1	—	$	—	$	2,107,267	$	(43,021)	$	(2,354)	$	4,783	$	2,066,689
Equity-based compensation	187		—	—		—	—		—		5,502		—		—		—		5,502
Exercise of stock options	184		—	—		—	—		—		723		—		—		—		723
Payments for tax withholdings from restricted stock vesting and stock option exercises	—		—	—		—	—		—		(1,269)		—		—		—		(1,269)
Common Stock issued in connection with employee stock purchase plan	31		—	—		—	—		—		753		—		—		—		753
Net income	—		—	—		—	—		—		—		41,750		—		480		42,230
Change in fair value of interest rate swaps, inclusive of reclassification adjustment	—		—	—		—	—		—		—		—		5,998		—		5,998
Balance, March 31, 2022	134,246	$	13	124	$	1	—	$	—	$	2,112,976	$	(1,271)	$	3,644	$	5,263	$	2,120,626
Equity-based compensation	117		—	—		—	—		—		5,720		—		—		—		5,720
Exercise of stock options	43		—	—		—	—		—		—		—		—		—		—
Payments for tax withholdings from restricted stock vesting and stock option exercises	—		—	—		—	—		—		(613)		—		—		—		(613)
Shares purchased under share repurchase program	—		—	—		—	199		(3,375)		—		—		—		—		(3,375)
Reclassification of warrant liability to equity for exercised warrants	19		—	—		—	—		—		495		—		—		—		495
Distribution to non-controlling interest	—		—	—		—	—		—		—		—		—		(2,000)		(2,000)
Net income	—		—	—		—	—		—		—		14,032		—		1,215		15,247
Change in fair value of interest rate swaps, inclusive of reclassification adjustment	—		—	—		—	—		—		—		—		1,593		—		1,593
Balance, June 30, 2022	134,425	$	13	124	$	1	199	$	(3,375)	$	2,118,578	$	12,761	$	5,237	$	4,478	$	2,137,693
Equity-based compensation	83		—	—		—	—		—		5,562		—		—		—		5,562
Exercise of stock options	99		—	—		—	—		—		665		—		—		—		665
Payments for tax withholdings from restricted stock vesting and stock option exercises	—		—	—		—	—		—		(808)		—		—		—		(808)
Shares purchased under share repurchase program	—		—	—		—	552		(10,617)		—		—		—		—		(10,617)
Common Stock issued in connection with employee stock purchase plan	47		—	—		—	—		—		863		—		—		—		863
Reclassification of warrant liability to equity for exercised warrants	69		—	—		—	—		—		1,608		—		—		—		1,608
Net income	—		—	—		—	—		—		—		16,122		—		1,105		17,227
Change in fair value of interest rate swaps, inclusive of reclassification adjustment	—		—	—		—	—		—		—		—		7,757		—		7,757
Balance, September 30, 2022	134,723	$	13	124	$	1	751	$	(13,992)	$	2,126,468	$	28,883	$	12,994	$	5,583	$	2,159,950

7

ADAPTHEALTH CORP. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY (Continued)

(IN THOUSANDS)

(UNAUDITED)

														Accumulated
										Additional				other		Noncontrolling
	Class A Common Stock			Class B Common Stock			Preferred Stock			paid-in		Accumulated		comprehensive		interests in
	Shares	Amount		Shares	Amount		Shares	Amount		capital		deficit		income (loss)		subsidiaries		Total
Balance, December 31, 2020	76,458	$	8	13,219	$	1	164	$	1	$	558,486	$	(199,196)	$	(4,411)	$	(74,044)	$	280,845
Issuance of Class A Common Stock for acquisitions	14,092		2	—		—	—		—		564,986		—		—		—		564,988
Issuance of Series C Preferred Stock for an acquisition	—		—	—		—	130		—		523,856		—		—		—		523,856
Issuance of stock options for an acquisition	—		—	—		—	—		—		134,683		—		—		—		134,683
Exchange of Class B Common Stock for Class A Common Stock	13,219		1	(13,219)		(1)	—		—		(77,919)		—		—		77,919		—
Equity-based compensation	172		—	—		—	—		—		8,582		—		—		—		8,582
Cashless exercise of stock options	9		—	—		—	—		—		—		—		—		—		—
Issuance of Class A Common Stock, net of offering costs of $13,832	8,450		1	—		—	—		—		265,017		—		—		—		265,018
Conversion of Series B-1 Preferred Stock to Class A Common Stock	3,950		—	—		—	(40)		—		—		—		—		—		—
Conversion of Series C-1 Preferred Stock to Class A Common Stock	13,047		1	—		—	(130)		—		(1)		—		—		—		—
Class A Common Stock issued in connection with employee stock purchase plan	8		—	—		—	—		—		314		—		—		—		314
Net loss	—		—	—		—	—		—		—		(3,966)		—		324		(3,642)
Equity activity resulting from the Tax Receivable Agreement	—		—	—		—	—		—		16,768		—		—		—		16,768
Change in fair value of interest rate swaps, inclusive of reclassification adjustment	—		—	—		—	—		—		—		—		1,876		—		1,876
Other	(19)		—	—		—	—		—		(810)		—		—		—		(810)
Balance, March 31, 2021	129,386	$	13	—	$	—	124	$	1	$	1,993,962	$	(203,162)	$	(2,535)	$	4,199	$	1,792,478
Issuance of Class A Common Stock for acquisitions	441		—	—		—	—		—		12,166		—		—		—		12,166
Equity-based compensation	37		—	—		—	—		—		7,447		—		—		—		7,447
Exercise of stock options	200		—	—		—	—		—		2,300		—		—		—		2,300
Distribution to non-controlling interest	—		—	—		—	—		—		—		—		—		(1,070)		(1,070)
Net income	—		—	—		—	—		—		—		79,107		—		951		80,058
Change in fair value of interest rate swaps, inclusive of reclassification adjustment	—		—	—		—	—		—		—		—		664		—		664
Balance, June 30, 2021	130,064	$	13	—	$	—	124	$	1	$	2,015,875	$	(124,055)	$	(1,871)	$	4,080	$	1,894,043
Issuance of Common Stock for acquisitions	977		—	—		—	—		—		25,507		—		—		—		25,507
Equity-based compensation	189		—	—		—	—		—		5,365		—		—		—		5,365
Exercise of stock options	898		—	—		—	—		—		9,840		—		—		—		9,840
Common Stock issued in connection with employee stock purchase plan	26		—	—		—	—		—		702		—		—		—		702
Net income	—		—	—		—	—		—		—		58,092		—		174		58,266
Change in fair value of interest rate swaps, inclusive of reclassification adjustment	—		—	—		—	—		—		—		—		640		—		640
Balance, September 30, 2021	132,154	$	13	—	$	—	124	$	1	$	2,057,289	$	(65,963)	$	(1,231)	$	4,254	$	1,994,363

See accompanying notes to unaudited interim consolidated financial statements.

8

ADAPTHEALTH CORP. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

(IN THOUSANDS)

(UNAUDITED)

	Nine Months Ended September 30,
	2022		2021
Cash flows from operating activities:
Net income	$	74,704	$	134,682
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization, including patient equipment depreciation		248,835		180,827
Equity-based compensation		16,784		21,394
Change in fair value of warrant liability		(17,145)		(57,359)
Change in fair value of contingent consideration common shares liability		—		(34,050)
Reduction in the carrying amount of operating lease right-of-use assets		16,924		23,832
Deferred income tax expense		18,058		11,666
Change in fair value of interest rate swaps, net of reclassification adjustment		(2,202)		(2,185)
Amortization of deferred financing costs		3,926		4,069
Write-off of deferred financing costs		—		4,054
Loss on extinguishment of debt from prepayment penalty		—		16,135
Other		(2,023)		(1,614)
Changes in operating assets and liabilities, net of effects from acquisitions:
Accounts receivable		2,357		(25,046)
Inventory		(3,992)		3,626
Prepaid and other assets		4,211		(137)
Operating lease obligations		(16,794)		(23,292)
Operating liabilities		(66,696)		(81,852)
Net cash provided by operating activities		276,947		174,750
Cash flows from investing activities:
Payments for business acquisitions, net of cash acquired		(16,134)		(1,417,946)
Purchases of equipment and other fixed assets		(248,511)		(139,686)
Payments for cost method investments		(731)		(875)
Net cash used in investing activities		(265,376)		(1,558,507)
Cash flows from financing activities:
Proceeds from borrowings on long-term debt and lines of credit		—		1,165,000
Repayments on long-term debt and lines of credit		(15,000)		(822,271)
Repayments of finance lease obligations		(14,219)		(31,043)
Payments for shares purchased under share repurchase program		(13,992)		—
Proceeds from the exercise of stock options		1,388		12,140
Proceeds received in connection with employee stock purchase plan		1,616		1,016
Proceeds from the issuance of senior unsecured notes		—		1,100,000
Proceeds from the issuance of Class A Common Stock		—		278,850
Payments for equity issuance costs		—		(13,832)
Payments for debt financing costs		—		(29,185)
Payments for tax withholdings from restricted stock vesting and stock option exercises		(2,690)		(810)
Payments of contingent consideration and deferred purchase price from acquisitions		(5,563)		(22,211)
Distributions to noncontrolling interests		(2,000)		(1,070)
Payments for debt prepayment penalties		—		(16,135)
Net cash (used in) provided by financing activities		(50,460)		1,620,449
Net (decrease) increase in cash and cash equivalents		(38,889)		236,692
Cash and cash equivalents at beginning of period		149,627		99,962
Cash and cash equivalents at end of period	$	110,738	$	336,654
Supplemental disclosures:
Cash paid for interest	$	97,389	$	67,409
Cash paid for income taxes		10,490		13,799
Noncash investing and financing activities:
Equipment acquired under finance lease obligations	$	1,335	$	22,902
Unpaid equipment and other fixed asset purchases at end of period		50,864		12,688
Assets subject to operating lease obligations		5,411		11,340
Operating lease obligations		(5,411)		(11,340)
Equity consideration issued in connection with acquisitions		—		1,261,200
Contingent purchase price in connection with acquisitions		—		2,000
Deferred purchase price in connection with acquisitions		422		1,162

See accompanying notes to unaudited interim consolidated financial statements.

9

ADAPTHEALTH CORP. AND SUBSIDIARIES

Notes to Interim Consolidated Financial Statements (Unaudited)

(1)          General Information

AdaptHealth Corp. and subsidiaries (AdaptHealth or the Company), a Delaware Corporation, is a national leader in providing patient-centered, healthcare-at-home solutions including home medical equipment (HME), medical supplies, and related services. AdaptHealth focuses primarily on providing (i) sleep therapy equipment, supplies and related services (including CPAP and bi PAP services) to individuals suffering from obstructive sleep apnea (OSA), (ii) medical devices and supplies to patients for the treatment of diabetes (including continuous glucose monitors (CGM) and insulin pumps), (iii) home medical equipment to patients discharged from acute care and other facilities, (iv) oxygen and related chronic therapy services in the home, and (v) other HME devices and supplies on behalf of chronically ill patients with wound care, urological, incontinence, ostomy and nutritional supply needs. AdaptHealth services beneficiaries of Medicare, Medicaid and commercial insurance payors.

The interim consolidated financial statements are unaudited, but reflect all normal recurring adjustments that are, in the opinion of management, necessary to fairly present the information set forth herein. The interim consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related notes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021. Interim results are not necessarily indicative of the results for a full year.

There have been no material changes in the Company’s significant accounting policies as compared to the significant accounting policies described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021.

(a)          Basis of Presentation

The interim consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP). In the opinion of management, the interim consolidated financial statements include all necessary adjustments for a fair presentation of the financial position and results of operations for the periods presented.

(b)         Basis of Consolidation

The accompanying interim consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.

(c)          Concentration of Credit Risk

Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents and trade accounts receivable. The Company maintains its cash in bank deposit accounts, which, at times, may exceed federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to any significant credit risk on cash and cash equivalents.

(d)          Accounting Estimates

The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and reported amounts of revenues and expenses during the reporting period. Management bases these estimates and assumptions upon historical experience, existing and known circumstances, authoritative accounting pronouncements and other factors that management believes to be reasonable. Significant areas requiring the use of management estimates relate to revenue recognition and the valuation of accounts receivable (implicit price concession), income taxes, equity-based

10

ADAPTHEALTH CORP. AND SUBSIDIARIES

Notes to Interim Consolidated Financial Statements (Unaudited) (Continued)

compensation, interest rate swaps, warrant liability and long-lived assets, including goodwill and identifiable intangible assets. Actual results could differ from those estimates.

(e)          Valuation of Goodwill

The Company has a significant amount of goodwill on its balance sheet that resulted from the business acquisitions the Company has made in recent years. Goodwill is not amortized and is assessed for impairment annually and upon the occurrence of a triggering event or change in circumstances indicating a possible impairment. Such triggering events potentially warranting an interim goodwill impairment assessment include, among other factors, declines in historical or projected revenue, operating income or cash flows, and declines in the Company’s stock price or market capitalization. Such changes in circumstance can include, among others, changes in the legal environment, reimbursement environment, operating performance, and/or future prospects. The Company performs its annual impairment assessment of goodwill during the fourth quarter of each year. The impairment assessment can be performed on either a quantitative or qualitative basis. The Company first assesses qualitative factors to determine whether it is necessary to perform a quantitative goodwill impairment analysis. If determined necessary, the Company applies the quantitative impairment test to identify and measure the amount of impairment, if any. During the three months ended March 31, 2022, the Company experienced a decline in its market capitalization as a result of a decline in the Company’s stock price. The Company considered such decline to represent a triggering event requiring management to perform a quantitative goodwill impairment assessment as of March 31, 2022. No such triggering events were identified during the three months ended September 30, 2022. Refer to note 5, Goodwill and Identifiable Intangible Assets, for additional details.

(f) Long-Lived Assets

The Company’s long-lived assets, such as equipment and other fixed assets, operating lease right-of-use assets and definite-lived identifiable intangible assets, are assessed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the asset.

Definite-lived identifiable intangible assets consist of tradenames, payor contracts, contractual rental agreements and developed technology. These assets are amortized using the straight-line method over their estimated useful lives, which reflects the pattern in which the economic benefits of the assets are expected to be consumed. In addition to consideration of impairment upon the events or changes in circumstances described above, management regularly evaluates the remaining useful lives of its long-lived assets. The following table summarizes the useful lives of the Company’s identifiable intangible assets acquired:

Tradenames	5 to 10	years
Payor contracts	10	years
Contractual rental agreements	2	years
Developed technology	5	years

The Company did not incur any impairment charges on long-lived assets for the three and nine months ended September 30, 2022 and 2021.

11

ADAPTHEALTH CORP. AND SUBSIDIARIES

Notes to Interim Consolidated Financial Statements (Unaudited) (Continued)

(g)          Business Segment

The Company’s chief operating decision-makers are its Chief Executive Officer and President, who make resource allocation decisions and assess performance based on financial information presented on an aggregate basis. There are no segment managers who are held accountable by the chief operating decision-makers, or anyone else, for any planning, strategy and key decision-making regarding operations. The corporate office is responsible for contract negotiation with vendors and payors, corporate compliance with healthcare laws and regulations, and revenue cycle management, among other corporate supporting functions. Accordingly, the Company has a single reportable segment and operating segment structure.

(h)          Accounting for Leases

The Company adopted FASB Accounting Standards Update (ASU) No. 2016-02, Leases (Topic 842) (ASC 842) with an effective date of January 1, 2021, using the modified retrospective approach, for leases that existed on January 1, 2021. ASC 842 requires the Company to recognize a lease liability, which represents the discounted obligation to make future minimum lease payments, and a corresponding right-of-use (ROU) asset on its consolidated balance sheet for most leases, and disclose key information about leasing arrangements. The Company elected to apply certain practical expedients permitted under the transition guidance within ASC 842 to leases that commenced before January 1, 2021, including the package of practical expedients, which, among other things, permits lease agreements that are twelve months or less to be excluded from the balance sheet, and permits the Company not to reassess under the new standard its prior conclusions about lease identification, lease classification and initial direct costs. Due to the Company’s election of these practical expedients, the Company carried forward certain historical conclusions for existing contracts, including conclusions related to the existence and classification of leases and to initial direct costs. ASC 842 applies to a number of arrangements to which the Company is a party.

Whenever the Company enters into a new arrangement, it must determine, at the inception date, whether the arrangement is or contains a lease. This determination generally depends on whether the arrangement conveys to the Company the right to control the use of an explicitly or implicitly identified asset for a period of time in exchange for consideration. Control of an underlying asset is conveyed to the Company if the Company obtains the rights to direct the use of and obtain substantially all the economic benefits from the use of the underlying asset.

If a lease exists, the Company must then determine the separate lease and non-lease components of the arrangement. Each right to use an underlying asset conveyed by a lease arrangement should generally be considered a separate lease component if it both: (i) can benefit the Company without depending on other resources not readily available to the Company and (ii) does not significantly affect and is not significantly affected by other rights of use conveyed by the lease. Aspects of a lease arrangement that transfer other goods or services to the Company but do not meet the definition of lease components are considered non-lease components. The consideration owed by the Company pursuant to a lease arrangement is generally allocated to each lease and non-lease component for accounting purposes. However, the Company has elected, for all of its leases, to not separate lease and non-lease components. Each lease component is accounted for separately from other lease components, but together with the associated non-lease components.

For each lease, the Company must then determine the lease term, the present value of lease payments and the classification of the lease as either an operating or finance lease.

The lease term is the period of the lease not cancellable by the Company, together with periods covered by: (i) renewal options the Company is reasonably certain to exercise, (ii) termination options the Company is reasonably certain not to exercise, and (iii) renewal or termination options that are controlled by the lessor.

12

ADAPTHEALTH CORP. AND SUBSIDIARIES

Notes to Interim Consolidated Financial Statements (Unaudited) (Continued)

The present value of lease payments is calculated based on:

● Lease payments – lease payments include fixed and certain variable payments, less lease incentives, together with amounts probable of being owed by the Company under residual value guarantees and, if reasonably certain of being paid, the cost of certain renewal options and early termination penalties set forth in the lease arrangement. Lease payments exclude consideration that is not related to the transfer of goods and services of the Company.

● Discount rate – the discount rate must be determined based on information available to the Company upon the commencement of the lease. Lessees are required to use the rate implicit in the lease whenever such rate is readily available; however, as the implicit rate in the Company’s leases is generally not readily determinable, the Company generally uses the hypothetical incremental borrowing rate it would have to pay to borrow an amount equal to the lease payments, on a collateralized basis, over a timeframe similar to the lease term.

In making the determination of whether a lease is an operating lease or a finance lease, the Company considers the lease term in relation to the economic life of the leased asset, the present value of lease payments in relation to the fair value of the leased asset and certain other factors, including the lessee’s and lessor’s rights, obligations, and economic incentives over the term of the lease.

Generally, upon the commencement of a lease, the Company will record a lease liability and a ROU asset. However, the Company has elected, for all underlying leases with initial terms of twelve months or less (known as short-term leases), to not recognize a lease liability or ROU asset. Lease liabilities are initially recorded at lease commencement as the present value of future lease payments. ROU assets are initially recorded at lease commencement as the initial amount of the lease liability, together with the following, if applicable: (i) initial direct costs incurred by the lessee and (ii) lease payments made by the lessor net of lease incentives received, prior to lease commencement.

Over the lease term, the Company generally increases its lease liabilities using the effective interest method and decreases its lease liabilities for lease payments made. For finance leases, amortization and interest expense are recognized separately in the consolidated statements of operations, with amortization expense generally recorded on a straight-line basis over the lease term and interest expense recorded using the effective interest method. For operating leases, a single lease cost is generally recognized in the consolidated statements of operations on a straight-line basis over the lease term unless an impairment has been recorded with respect to a leased asset. Lease costs for short-term leases not recognized in the consolidated balance sheets are recognized in the consolidated statements of operations on a straight-line basis over the lease term. Variable lease costs not initially included in the lease liability and ROU asset impairment charges are expensed as incurred. ROU assets are assessed for impairment, similar to other long-lived assets.

(i)        Recently Issued Accounting Pronouncements

In March 2020, the FASB issued ASU No. 2020-04, Reference Rate Reform (Topic 848), which provides optional guidance to ease the potential burden in accounting for (or recognizing the effects of) reference rate reform on financial reporting. Specifically, the guidance permits an entity, when certain criteria are met, to consider amendments to contracts made to comply with reference rate reform to meet the definition of a modification under U.S. GAAP. It further allows hedge accounting to be maintained and a one-time transfer or sale of qualifying held-to-maturity securities. The expedients and exceptions provided by the amendments are permitted to be adopted any time through December 31, 2022 and do not apply to contract modifications made and hedging relationships entered into or evaluated after December 31, 2022, except for certain optional expedients elected for certain hedging relationships existing as of December 31, 2022. In October 2022, the FASB approved a proposed amendment to Topic 848 which defers the required adoption date of Topic 848 to December 31, 2024, with early adoption permitted. The Company is currently evaluating the effect that this standard will have on its consolidated financial statements and related disclosures.

13

ADAPTHEALTH CORP. AND SUBSIDIARIES

Notes to Interim Consolidated Financial Statements (Unaudited) (Continued)

(2)         Revenue Recognition and Accounts Receivable

Revenue Recognition

The Company generates revenues for services and related products that the Company provides to patients for home medical equipment, related supplies, and other items. The Company’s revenues are recognized in the period in which services and related products are provided to customers and are recorded either at a point in time for the sale of supplies and disposables, or over the fixed monthly service period for equipment.

Revenues are recognized when control of the promised good or service is transferred to customers, in an amount that reflects the consideration to which the Company expects to receive from patients or under reimbursement arrangements with Medicare, Medicaid and third-party payors, in exchange for those goods and services.

The Company determines the transaction price based on contractually agreed-upon amounts or rates, adjusted for estimates of variable consideration, such as implicit price concessions. The Company utilizes the expected value method to determine the amount of variable consideration that should be included to arrive at the transaction price, using contractual agreements and historical reimbursement experience within each payor type. The Company applies constraint to the transaction price, such that net revenue is recorded only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in the future. If actual amounts of consideration ultimately received differ from the Company’s estimates, the Company adjusts these estimates, which would affect net revenue in the period such adjustments become known.

Sales revenue is recognized upon transfer of control of products or services to customers in an amount that reflects the consideration the Company expects to receive in exchange for those products or services. Revenues for the sale of sleep therapy equipment supplies (including CPAP resupply products), home medical equipment and related supplies (including wheelchairs, hospital beds and infusion pumps), diabetic medical devices and supplies (including continuous glucose monitors (CGM) and insulin pumps), and other HME products and supplies are recognized when control of the promised good or service is transferred to customers, which is generally upon shipment for direct to consumer medical devices and supplies and upon delivery to the home for home medical equipment.

The Company provides certain equipment to patients which is reimbursed periodically in fixed monthly payments for as long as the patient is using the equipment and medical necessity continues (in certain cases, the fixed monthly payments are capped at a certain amount). The equipment provided to the patient is based upon medical necessity as documented by prescriptions and other documentation received from the patient’s physician. The patient generally does not negotiate or select the manufacturer or model of the equipment prescribed by their physician and delivered by the Company. Once initial delivery of this equipment is made to the patient for initial setup, a monthly billing process is established based on the initial setup service date. The Company recognizes the fixed monthly revenue ratably over the service period as earned, less estimated adjustments, and defers revenue for the portion of the monthly bill that is unearned. No separate revenue is earned from the initial setup process. Included in fixed monthly revenue are unbilled amounts for which the revenue recognition criteria had been met as of period-end but were not yet billed to the payor. The estimate of net unbilled fixed monthly revenue recognized is based on historical trends and estimates of future collectability.

The Company’s billing system contains payor-specific price tables that reflect the fee schedule amounts in effect or contractually agreed upon by various government and commercial insurance payors for each item of equipment or supply provided to a customer. Revenues are recorded based on the applicable fee schedule. The Company has established a contractual allowance to account for adjustments that result from differences between the payment amount received and the expected realizable amount. If the payment amount received differs from the net realizable amount, an

14

ADAPTHEALTH CORP. AND SUBSIDIARIES

Notes to Interim Consolidated Financial Statements (Unaudited) (Continued)

adjustment is recorded to revenues in the period that these payment differences are determined. The Company reports revenues in its consolidated financial statements net of such adjustments.

The Company recognizes revenue in the consolidated statements of operations and contract assets on the consolidated balance sheets only when services have been provided. Since the Company has performed its obligation under the contract, it has unconditional rights to the consideration recorded as contract assets and therefore classifies those billed and unbilled contract assets as accounts receivable.

Fixed monthly payments that the Company receives from customers in advance of providing services represent contract liabilities. Such payments primarily relate to patients who are billed monthly in advance and are recognized over the period as earned.

The Company disaggregates net revenue from contracts with customers by payor type and by core service lines. The Company believes that disaggregation of net revenue into these categories depicts how the nature, amount, timing and uncertainty of revenue and cash flows are affected by economic factors. The payment terms and conditions within the Company’s revenue-generating contracts vary by payor type and payor source.

The composition of net revenue by payor type for the three and nine months ended September 30, 2022 and 2021 are as follows (in thousands):

	Three Months Ended September 30,				Nine Months Ended September 30,
	2022			2021	2022		2021
Insurance	$	465,625	$	399,748	$	1,322,694	$	1,061,627
Government		198,841		180,511		576,829		491,564
Patient pay		92,029		73,034		290,789		199,238
Net revenue	$	756,495	$	653,293	$	2,190,312	$	1,752,429

15

ADAPTHEALTH CORP. AND SUBSIDIARIES

Notes to Interim Consolidated Financial Statements (Unaudited) (Continued)

The composition of net revenue by core service lines for the three and nine months ended September 30, 2022 and 2021 are as follows (in thousands):

	Three Months Ended September 30,				Nine Months Ended September 30,
	2022			2021	2022		2021
Net sales revenue:
Sleep	$	198,206	$	173,359	$	585,234	$	465,372
Diabetes		169,075		134,228		482,693		352,559
Supplies to the home		47,793		42,441		131,539		126,479
Respiratory		9,734		6,228		25,770		25,003
HME		29,463		29,919		89,828		82,588
Other		58,252		45,996		166,068		98,032
Total net sales revenue	$	512,523	$	432,171	$	1,481,132	$	1,150,033
Net revenue from fixed monthly equipment reimbursements:
Sleep	$	72,423	$	62,755	$	196,022	$	177,199
Diabetes		4,211		3,722		12,191		9,791
Respiratory		130,618		117,918		392,063		312,900
HME		25,482		26,043		76,754		70,854
Other		11,238		10,684		32,150		31,652
Total net revenue from fixed monthly equipment reimbursements	$	243,972	$	221,122	$	709,180	$	602,396
Total net revenue:
Sleep	$	270,629	$	236,114	$	781,256	$	642,571
Diabetes		173,286		137,950		494,884		362,350
Supplies to the home		47,793		42,441		131,539		126,479
Respiratory		140,352		124,146		417,833		337,903
HME		54,945		55,962		166,582		153,442
Other		69,490		56,680		198,218		129,684
Total net revenue	$	756,495	$	653,293	$	2,190,312	$	1,752,429

Certain prior period amounts in the table above have been reclassified to conform to the current period presentation. These reclassifications are considered immaterial to all periods presented.

In response to the COVID-19 pandemic and the National Emergency Declaration, dated March 13, 2020, the Company increased its cash liquidity by, among other things, seeking recoupable advance payments of $45.8 million made available by the Centers for Medicare & Medicaid Services (CMS) under the Coronavirus Aid, Relief, and Economic Security Act (the CARES Act) legislation, which was received in April 2020. In addition, in connection with an acquisition completed in July 2020, the Company assumed a liability of $3.7 million relating to CMS recoupable advance payments received by the acquired company prior to the date of acquisition. The recoupment of the advance payments by CMS began in April 2021 and were applied to services provided and revenue recognized during the period in which the recoupment occurred, which impacted the Company’s cash receipts for services provided during the period in which amounts were recouped. As of September 30, 2022 the recoupment period has ended, and any remaining amounts not recouped will be repaid by the Company to CMS. During the three and nine months ended September 30, 2022, CMS recouped $0.5 million and $9.6 million, respectively, of the advance payments. During the three and nine months ended September 30, 2021, CMS recouped $11.1 million and $27.0 million, respectively, of the advance payments. As of September 30, 2022, the remaining amount of the CMS advance payments that had not yet been recouped was $3.2 million, which is included in other current liabilities in the consolidated balance sheets.

16

ADAPTHEALTH CORP. AND SUBSIDIARIES

Notes to Interim Consolidated Financial Statements (Unaudited) (Continued)

Accounts Receivable

Due to the continuing changes in the healthcare industry and third-party reimbursement environment, certain estimates are required to record accounts receivable at their net realizable values. Inherent in these estimates is the risk that they will have to be revised or updated as additional information becomes available. The complexity of third-party billing arrangements and laws and regulations governing Medicare and Medicaid may result in adjustments to amounts originally recorded.

The Company performs a periodic analysis to review the valuation of accounts receivable and collectability of outstanding balances. Management’s evaluation takes into consideration such factors as historical cash collections experience, business and economic conditions, trends in healthcare coverage, other collection indicators and information about specific receivables. The Company’s evaluation also considers the age and composition of the outstanding amounts in determining their estimated net realizable value.

Receivables are considered past due when not collected by established due dates. Specific patient balances are written off after collection efforts have been followed and the account has been determined to be uncollectible. Revisions in reserve estimates are recorded as an adjustment to net revenue in the period of revision.

Included in accounts receivable are earned but unbilled accounts receivables. Billing delays, ranging from several days to several weeks, can occur due to the Company’s policy of compiling required payor specific documentation prior to billing for its services rendered. As of September 30, 2022 and December 31, 2021, the Company’s unbilled accounts receivable was $22.9 million and $23.8 million, respectively.

(3)          Acquisitions

During the nine months ended September 30, 2022 and 2021, the Company completed several acquisitions to strengthen its current market share in existing markets or to expand into new markets. Each of the Company’s acquisitions was accounted for using the acquisition method pursuant to the requirements of FASB ASC Topic 805, Business Combinations, and are included in the Company’s consolidated financial statements since the respective acquisition date. The goodwill generated from these acquisitions is attributable to expected growth and cost synergies and the expected contribution of each acquisition to the Company’s overall strategy. The goodwill recorded during the nine months ended September 30, 2022 is not expected to be deductible for tax purposes. The estimated fair values of the net assets of acquired businesses as described below are subject to change resulting from such items as final analysis of valuations and working capital adjustments post-acquisition. As a result, the acquisition accounting for certain acquired businesses could change in subsequent periods resulting in adjustments to goodwill once finalized. Also, see subsection, “Pro forma information” of this Note 3 for pro forma information on net revenue and operating income.

Nine Months Ended September 30, 2022

During the nine months ended September 30, 2022, the Company acquired 100% of the equity interests of two providers of HME and acquired certain assets of the home medical equipment businesses of five providers of HME.

The following table summarizes the consideration paid at closing for all acquisitions during the nine months ended September 30, 2022 (in thousands):

Cash	$	16,477
Deferred payments		422
Total	$	16,899

17

ADAPTHEALTH CORP. AND SUBSIDIARIES

Notes to Interim Consolidated Financial Statements (Unaudited) (Continued)

The Company allocated the consideration paid to the net assets acquired based on their estimated acquisition date fair values. The Company is still evaluating the fair value of certain assets and liabilities for which provisional amounts were recorded and expects to finalize such valuations during the remainder of 2022. Based upon management’s evaluation, which is preliminary and subject to completion of working capital and other adjustments, the consideration paid for all acquisitions during 2022 was allocated as follows (in thousands):

Cash	$	155
Accounts receivable		2,206
Inventory		686
Prepaid and other current assets		16
Equipment and other fixed assets		4,502
Goodwill		11,788
Identifiable intangible assets		500
Accounts payable and accrued expenses		(2,820)
Contract liabilities		(134)
Net assets acquired	$	16,899

During the nine months ended September 30, 2022, the Company received net cash of $0.2 million relating to working capital and other adjustments associated with businesses that were acquired during 2021, which was recorded as a decrease to goodwill during the period.

Nine Months Ended September 30, 2021

On February 1, 2021, the Company acquired 100% of the equity interests of AeroCare Holdings, Inc. (AeroCare). AeroCare is a leading national technology-enabled respiratory and home medical equipment distribution platform in the United States and offers a comprehensive suite of direct-to-patient equipment and services including CPAP and BiPAP machines, oxygen concentrators, home ventilators, and other home medical equipment products. The total consideration paid consisted of (i) cash payments of $1.2 billion, (ii) the issuance of 13,992,615 shares of the Company’s Class A Common Stock, (iii) the issuance of 130,474.73 shares of the Company’s Series C Convertible Preferred Stock, and (iv) the issuance of 3,959,892 fully vested options to purchase shares of the Company’s Class A Common Stock in the future, which had a weighted-average exercise price of $6.24 per share and a weighted-average remaining exercise period of approximately 7 years from the date of closing. Refer to Note 10, Stockholders’ Equity, for additional discussion of the Series C Convertible Preferred Stock issued in connection with the acquisition of AeroCare.

On April 30, 2021, the Company acquired 100% of the equity interests of Spiro Health Services, LLC (Spiro). Spiro is a provider of home medical equipment and supplies. The total consideration paid at closing consisted of a cash payment of $66.1 million, the issuance of 244,641 shares of the Company’s Class A Common Stock, and a potential contingent consideration payment of up to $1.0 million, which was determined to be the fair value at the acquisition date and such amount was recorded as a contingent consideration liability in connection with the Company’s acquisition accounting.

On June 1, 2021, the Company acquired 100% of the equity interests of Healthy Living Medical Supply, LLC (Healthy Living). Healthy Living is a provider of continuous glucose monitors and insulin pumps. The total consideration paid at closing consisted of a cash payment of $47.0 million and the issuance of 196,779 shares of the Company’s Class A Common Stock.

On July 1, 2021, the Company acquired 100% of the equity interests of Agilis Med Holdings, LLC (Agilis). Agilis is an e-commerce retailer of sleep apnea and respiratory equipment in the United States. The total consideration paid at closing consisted of a cash payment of $30.8 million, the issuance of 538,079 shares of the Company’s Class A Common Stock, and a potential contingent consideration payment of up to $1.0 million, which was determined to be the

18

ADAPTHEALTH CORP. AND SUBSIDIARIES

Notes to Interim Consolidated Financial Statements (Unaudited) (Continued)

fair value at the acquisition date and such amount was recorded as a contingent consideration liability in connection with the Company’s acquisition accounting. Such amount is included in other current liabilities in the accompanying consolidated balance sheets at September 30, 2022 based on the expected payment date. In October 2020, the Company acquired a minority interest in Agilis, which was being accounted for under the equity method of accounting prior to the July 2021 transaction. The carrying value of such investment was $8.1 million at the July 2021 transaction date. The fair value of the equity method investment was $10.0 million at the July 2021 transaction date. In connection with the accounting for the July 2021 transaction, the Company recorded goodwill of $10.0 million and eliminated the carrying value of the equity method investment of $8.1 million and recorded a gain on equity method of investment of $1.9 million, which is included in other loss (income), net in the accompanying consolidated statements of operations during the three and nine months ended September 30, 2021.

On July 1, 2021, the Company acquired 100% of the equity interests of WeCare Medical, LLC (WeCare). WeCare is a distributor of durable medical equipment and supplies in the United States. The total consideration paid at closing consisted of a cash payment of $34.8 million and the issuance of 231,866 shares of the Company’s Class A Common Stock.

In addition, during the nine months ended September 30, 2021, the Company acquired 100% of the equity interests of ten providers of home medical equipment and acquired certain assets of the durable medical equipment business of a provider of home medical equipment. The aggregate total consideration paid for these acquisitions consisted of cash payments of $121.7 million, the issuance of 306,569 shares of the Company’s Class A Common Stock, and deferred payment liabilities of $1.2 million.

The following table summarizes the consideration paid at closing for all acquisitions during the nine months ended September 30, 2021 (in thousands):

	AeroCare		Spiro		Healthy Living		Agilis		We Care		Other		Total
Cash	$	1,152,768	$	66,101	$	47,048	$	30,842	$	34,833	$	121,710	$	1,453,302
Equity		1,220,342		7,109		5,057		14,668		6,321		7,703		1,261,200
Contingent consideration		—		1,000		—		1,000		—		—		2,000
Deferred payments		—		—		—		—		—		1,162		1,162
Total	$	2,373,110	$	74,210	$	52,105	$	46,510	$	41,154	$	130,575	$	2,717,664

The Company allocated the consideration paid to the net assets acquired based on their estimated acquisition date fair values. Based upon management’s evaluation, which was preliminary and subject to completion of working capital and other adjustments, the consideration paid for all acquisitions during the nine months ended September 30, 2021 was allocated as follows during that period (in thousands):

19

ADAPTHEALTH CORP. AND SUBSIDIARIES

Notes to Interim Consolidated Financial Statements (Unaudited) (Continued)

	AeroCare		Spiro		Healthy Living		Agilis		We Care		Other		Total
Cash	$	27,686	$	2,132	$	580	$	1,170	$	458	$	2,673	$	34,699
Accounts receivable		75,916		8,526		7,471		—		6,355		20,900		119,168
Inventory		27,612		4,939		2,948		2,478		1,488		6,219		45,684
Prepaid and other current assets		3,522		152		254		—		—		2,466		6,394
Equipment and other fixed assets		190,755		2,148		1,201		—		8,170		13,076		215,350
Operating lease right-of-use assets		55,132		2,738		1,366		490		970		12,176		72,872
Goodwill		2,096,850		62,640		41,955		52,938		29,080		102,688		2,386,151
Identifiable intangible assets		122,800		1,000		1,300		500		400		2,400		128,400
Other assets		1,178		16		—		—		—		—		1,194
Deferred tax liabilities		(64,916)		—		—		—		(3,358)		425		(67,849)
Accounts payable and accrued expenses		(82,722)		(5,148)		(3,604)		(576)		(1,439)		(13,921)		(107,410)
Contract liabilities		(14,495)		—		—		—		—		(124)		(14,619)
Other current liabilities		(10,021)		—		—		—		—		(1,555)		(11,576)
Other long-term liabilities		(1,055)		—		—		—		—		—		(1,055)
Operating lease obligations		(55,132)		(2,738)		(1,366)		(490)		(970)		(12,176)		(72,872)
Capital lease obligations		—		(2,195)		—		—		—		(4,672)		(6,867)
Net assets acquired	$	2,373,110	$	74,210	$	52,105	$	56,510	$	41,154	$	130,575	$	2,727,664

During the nine months ended September 30, 2021, the Company received net cash of $0.7 million relating to working capital and other adjustments associated with businesses that were acquired during 2020, which was recorded as a decrease to goodwill during the period.

Pro-Forma Information

The unaudited pro-forma financial information presented below has been prepared by adjusting the historical results of the Company to include the historical results of the acquisitions described above and to give effect to the GAAP accounting for the acquisitions had they been owned in the earliest period presented below. The unaudited pro-forma financial information is presented for illustrative purposes only and may not be indicative of the results of operations that would have actually occurred. In addition, future results may vary significantly from the results reflected in the pro-forma information. The unaudited pro-forma financial information does not reflect the impact of future events that may occur after the acquisitions, such as the impact of cost savings or other synergies that may result from these acquisitions, and does not include interest expense associated with debt incurred to fund the acquisitions.

(in thousands) (unaudited)	Three Months Ended September 30,				Nine Months Ended September 30,
	2022		2021		2022		2021
Net revenue	$	756,495	$	722,406	$	2,195,434	$	2,140,382

20

ADAPTHEALTH CORP. AND SUBSIDIARIES

Notes to Interim Consolidated Financial Statements (Unaudited) (Continued)

Operating income $ 52,949 $ 83,788 $ 163,630 $ 195,945

Results of Businesses Acquired

The following table presents the amount of net revenue and operating income (loss) in the period of acquisition since the respective acquisition dates for the acquisitions described above that is included in the Company’s consolidated statements of operations for the three and nine months ended September 30, 2022 and 2021:

(in thousands)	Three Months Ended September 30,				Nine Months Ended September 30,
	2022		2021		2022		2021
Net revenue	$	5,062	$	289,604	$	10,764	$	680,460
Operating income (loss)	$	(726)	$	37,454	$	(333)	$	95,143

(4)          Equipment and Other Fixed Assets

Equipment and other fixed assets as of September 30, 2022 and December 31, 2021 are as follows (in thousands):

	September 30,		December 31,
	2022		2021
Patient medical equipment	$	711,300	$	533,760
Delivery vehicles		36,089		36,213
Other		83,816		50,208
		831,205		620,181
Less accumulated depreciation		(358,149)		(221,604)
	$	473,056	$	398,577

For the three months ended September 30, 2022 and 2021, the Company recorded depreciation expense of $82.4 million and $59.7 million, respectively. For the nine months ended September 30, 2022 and 2021, the Company recorded depreciation expense of $218.9 million and $146.5 million, respectively.

(5)          Goodwill and Identifiable Intangible Assets

Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. The change in the carrying amount of goodwill for the nine months ended September 30, 2022 was as follows (in thousands):

	Gross carrying
	amount
Balance at December 31, 2021	$	3,512,567
Goodwill from acquisitions		11,788
Net cash receipts relating to prior acquisitions		(188)
Net increase relating to measurement period adjustments		832
Balance at September 30, 2022	$	3,524,999

Management is required to perform an assessment of the recoverability of goodwill on an annual basis and upon the identification of a triggering event. Triggering events potentially warranting an interim goodwill impairment assessment include, among other factors, declines in historical or projected revenue, operating results or cash flows, and

21

ADAPTHEALTH CORP. AND SUBSIDIARIES

Notes to Interim Consolidated Financial Statements (Unaudited) (Continued)

declines in the Company’s stock price or market capitalization. While management cannot predict if or when future goodwill impairments may occur, a non-cash goodwill impairment charge could have a material adverse effect on the Company’s operating results, net assets and the Company’s cost of, or access to, capital. During the three months ended March 31, 2022, the Company experienced a decline in its market capitalization as a result of a decline in the Company’s stock price. The Company considered such decline to represent a triggering event requiring management to perform a quantitative goodwill impairment assessment as of March 31, 2022. Based on the results of the quantitative goodwill impairment assessment, it was concluded that the estimated fair value of the Company’s reporting unit was greater than its carrying value, as such, the Company did not record a goodwill impairment charge during the three months ended March 31, 2022. No such triggering events were identified during the three months ended September 30, 2022. The Company did not record a goodwill impairment charge during the three and nine months ended September 30, 2022 and 2021. Subsequent to September 30, 2022, the Company has not experienced a decline in its market capitalization, however, if the Company were to experience a decline for a sustained period of time, the Company may be required to perform a quantitative goodwill impairment assessment at an interim or annual period and could be required to recognize a non-cash goodwill impairment charge at that time, which could be material.

As discussed in Note 3, Acquisitions, during the nine months ended September 30, 2022, the Company received net cash of $0.2 million relating to working capital and other adjustments associated with businesses that were acquired during 2021, which was recorded as a decrease to goodwill during the period.

Identifiable intangible assets that are separable and have determinable useful lives are valued separately and amortized over the period which reflects the pattern in which the economic benefits of the assets are expected to be consumed. Identifiable intangible assets consisted of the following at September 30, 2022 and December 31, 2021 (in thousands):

	September 30, 2022
			Weighted-Average
			Remaining Life (Years)
Tradenames, net of accumulated amortization of $22,294	$	90,506	7.7
Payor contracts, net of accumulated amortization of $17,966		64,034	7.8
Contractual rental agreements, net of accumulated amortization of $39,433		14,767	1.0
Developed technology, net of accumulated amortization of $2,835		3,465	2.8
Identifiable intangible assets, net	$	172,772

	December 31, 2021
			Weighted-Average
			Remaining Life (Years)
Tradenames, net of accumulated amortization of $12,705	$	99,595	8.4
Payor contracts, net of accumulated amortization of $11,816		70,184	8.6
Contractual rental agreements, net of accumulated amortization of $26,158		28,042	1.8
Developed technology, net of accumulated amortization of $1,890		4,410	3.5
Identifiable intangible assets, net	$	202,231

Amortization expense related to identifiable intangible assets, which is included in depreciation and amortization, excluding patient equipment depreciation, in the accompanying statements of operations, was $10.0 million and $30.0 million for the three and nine months ended September 30, 2022, respectively. Amortization expense related to identifiable intangible assets, which is included in depreciation and amortization, excluding patient equipment depreciation, in the accompanying statements of operations, was $10.1 million and $34.4 million for the three and nine months ended September 30, 2021, respectively.

Future amortization expense related to identifiable intangible assets is estimated to be as follows (in thousands):

22

ADAPTHEALTH CORP. AND SUBSIDIARIES

Notes to Interim Consolidated Financial Statements (Unaudited) (Continued)

Twelve months ending September 30,
2023	$	37,043
2024		22,276
2025		21,828
2026		19,618
2027		18,190
Thereafter		53,817
Total	$	172,772

The Company recorded no impairment charges related to identifiable intangible assets during the three and nine months ended September 30, 2022 and 2021.

(6)          Fair Value of Assets and Liabilities

FASB ASC Topic 820, Fair Value Measurements and Disclosures (ASC 820), creates a single definition of fair value, establishes a framework for measuring fair value in U.S. GAAP and expands disclosures about fair value measurements. Assets and liabilities adjusted to fair value in the balance sheet are categorized based upon the level of judgment associated with the inputs used to measure their fair value. Level inputs, as defined by ASC 820, are as follows:

Level input	Input Definition
Level 1	Inputs are unadjusted, quoted prices for identical assets or liabilities in active markets at the measurement date.
Level 2	Inputs, other than quoted prices included in Level 1 that are observable for the asset or liability through corroboration with market data at the measurement date.
Level 3	Unobservable inputs that reflect management’s best estimate of what market participants would use in pricing the asset or liability at the measurement date.

The following table presents the valuation of the Company’s financial assets and liabilities as of September 30, 2022 and December 31, 2021 measured at fair value on a recurring basis. The fair value estimates presented herein are based on information available to management as of September 30, 2022 and December 31, 2021. These estimates are not necessarily indicative of the amounts the Company could ultimately realize.

(in thousands)	Level 1		Level 2		Level 3
September 30, 2022
Assets
Money market accounts	$	11	$	—	$	—
Interest rate swap agreements-short term		—		4,471		—
Interest rate swap agreements-long term		—		5,621		—
Total assets measured at fair value	$	11	$	10,092	$	—
Liabilities
Acquisition-related contingent consideration-short term	$	—	$	—	$	14,527
Warrant liability		—		—		38,516
Total liabilities measured at fair value	$	—	$	—	$	53,043

23

ADAPTHEALTH CORP. AND SUBSIDIARIES

Notes to Interim Consolidated Financial Statements (Unaudited) (Continued)

(in thousands)	Level 1		Level 2		Level 3
December 31, 2021
Assets
Money market accounts	$	14	$	—	$	—
Total assets measured at fair value	$	14	$	—	$	—
Liabilities
Acquisition-related contingent consideration-short term	$	—	$	—	$	13,500
Acquisition-related contingent consideration-long term		—		—		6,800
Interest rate swap agreements-short term		—		5,098		—
Interest rate swap agreements-long term		—		2,359		—
Warrant liability		—		—		57,764
Total liabilities measured at fair value	$	—	$	7,457	$	78,064

Interest Rate Swaps

The Company uses interest rate swap agreements to manage interest rate risk by converting a portion of its variable rate borrowings to a fixed rate and recognizes these derivative instruments as either assets or liabilities in the accompanying consolidated balance sheets at fair value. The valuation of these derivative instruments is determined using widely accepted valuation techniques, including discounted cash flow analysis on the expected cash flows of each derivative. This analysis reflects the contractual terms of the derivatives, including the period to maturity, and uses observable market-based inputs, including interest rate curves and implied volatilities. The fair value of the Company’s interest rate swaps are determined using the market standard methodology of netting the discounted future fixed cash payments and the discounted expected variable cash payments receipts. The variable cash receipts are based on an expectation of future interest rates (forward curves) derived from observable market interest rate curves. To comply with the provisions of FASB ASC Topic 820, Fair Value Measurement, the Company incorporates credit valuation adjustments to appropriately reflect both its own nonperformance risk and the respective counterparty’s nonperformance risk in the fair value measurements. In adjusting the fair value of its derivative contracts for the effect of nonperformance risk, the Company has considered the impact of netting and any applicable credit enhancements, such as collateral postings, thresholds, mutual puts and guarantees.

Although the Company has determined that the majority of the inputs used to value its derivatives fall within Level 2 of the fair value hierarchy, the credit valuation adjustments associated with the Company’s derivatives utilize Level 3 inputs, such as estimates of current credit spreads to evaluate the likelihood of default by the Company and the respective counterparties. The Company has determined that the significance of the impact of the credit valuation adjustments made to its derivative contracts, which determination was based on the fair value of each individual contract, was not significant to the overall valuation. As a result, all of the Company’s derivatives held as of September 30, 2022 and December 31, 2021 were classified as Level 2 of the fair value hierarchy. Refer to Note 7, Derivative Instruments and Hedging Activities, for additional information regarding the Company’s derivative instruments.

Acquisition-Related Contingent Consideration

The Company estimates the fair value of acquisition-related contingent consideration liabilities by applying the income approach using a probability-weighted discounted cash flow model. This fair value measurement is based on significant inputs not observed in the market and thus represents a Level 3 measurement. Level 3 instruments are valued based on unobservable inputs that are supported by little or no market activity and reflect the Company’s own assumptions in measuring fair value. Each period, the Company evaluates the fair value of acquisition-related contingent consideration obligations and records any changes in the fair value of such liabilities in other income in the Company’s consolidated statements of operations. At September 30, 2022, contingent consideration liabilities of $14.5 million were included in other current liabilities in the accompanying consolidated balance sheets. At December 31, 2021, contingent

24

ADAPTHEALTH CORP. AND SUBSIDIARIES

Notes to Interim Consolidated Financial Statements (Unaudited) (Continued)

consideration liabilities of $13.5 million and $6.8 million were included in other current liabilities and other long-term liabilities, respectively, in the accompanying consolidated balance sheets.

A reconciliation of the Company’s contingent consideration liabilities related to acquisitions for the nine months ended September 30, 2022 and 2021 is as follows (in thousands):

Nine Months Ended September 30, 2022	Beginning Balance		Additions		Payments		Change in Fair Value		Other activity		Ending Balance
Contingent consideration - Level 3 liabilities	$	20,300	$	—	$	(6,250)	$	477	$	—	$	14,527
Nine Months Ended September 30, 2021
Contingent consideration - Level 3 liabilities	$	33,540	$	2,000	$	(18,200)	$	1,135	$	173	$	18,648

Warrant Liability

The warrant liability represents the estimated fair value of the Company’s outstanding private warrants. The fair value of the private warrants was estimated using the Black-Scholes option pricing model. Refer to Note 10, Stockholders’ Equity, for additional discussion of the warrant liability.

Non-Financial Assets Measured at Fair Value on a Non-Recurring Basis

The following table presents the Company’s hierarchy for non-financial assets measured at fair value on a non-recurring basis (in thousands):

	September 30,		December 31,
	2022		2021
Assets:
Goodwill (Level 3)	$	3,524,999	$	3,512,567
Identifiable intangible assets, net (Level 3)	$	172,772	$	202,231

The fair value allocation related to the Company’s acquisitions are determined using a discounted cash flow approach, or a replacement cost approach, which are based on significant unobservable inputs (Level 3). These valuation methods required management to make various assumptions, including, but not limited to, future profitability, cash flows, replacement costs, and discount rates. The Company’s estimates are based upon historical trends, management’s knowledge and experience and overall economic factors, including projections of future earnings potential.

Developing discounted future cash flows in applying the income approach requires the Company to evaluate its intermediate to longer-term strategies, including, but not limited to, estimates of revenue growth, operating margins, capital requirements, inflation and working capital management. The development of appropriate rates to discount the estimated future cash flows requires the selection of risk premiums, which can materially impact the present value of future cash flows.

The Company estimated the fair value of acquired identifiable intangible assets using discounted cash flow techniques that included an estimate of future cash flows, consistent with overall cash flow projections used to determine the purchase price paid to acquire the business, discounted at a rate of return that reflects the relative risk of the cash flows. The Company estimated the fair value of certain acquired identifiable intangible assets based on the cost approach using estimated costs consistent with historical experience. The Company believes the estimates and assumptions used in the valuation methods are reasonable.

25

ADAPTHEALTH CORP. AND SUBSIDIARIES

Notes to Interim Consolidated Financial Statements (Unaudited) (Continued)

(7)          Derivative Instruments and Hedging Activities

The Company records all derivatives on its consolidated balance sheet at fair value. As of September 30, 2022 and December 31, 2021, the Company had outstanding interest rate derivatives with third parties in which the Company pays a fixed interest rate and receives a rate equal to the one-month LIBOR. The notional amount associated with interest rate swap agreements that were outstanding as of September 30, 2022 and December 31, 2021 was $250 million and have maturity dates in February 2023 and March 2024. In April 2022, the Company entered into additional forward-dated interest rate swap agreements with third parties in which the Company will pay a fixed interest rate and receive a rate equal to the one month-LIBOR. The purpose of these forward-dated interest rate swap agreements is to ensure that the Company operates within its derivatives policy by maintaining a total notional amount of $250 million under the Company’s outstanding interest rate swap agreements through the maturity date of the Company’s current credit agreement. These forward-dated interest rate swap agreements become effective in February 2023 and March 2024 and mature in January 2026. The Company has designated its swaps as effective cash flow hedges of interest rate risk. Accordingly, changes in the fair value of the interest rate swaps are recorded as a component of accumulated other comprehensive income within stockholders’ equity and subsequently reclassified into interest expense in the same period during which the hedged transaction affects earnings.

The table below presents the fair value of the Company’s derivatives related to its interest rate swap agreements, which are designated as hedging instruments, as well as their classification in the consolidated balance sheets at September 30, 2022 and December 31, 2021 (in thousands):

		September 30, 2022		December 31, 2021
Balance Sheet Location	Asset (Liability)
Other current assets	$	4,471	$	—
Other long-term assets		5,621		—
Other current liabilities		—		(5,098)
Other long-term liabilities		—		(2,359)
Total	$	10,092	$	(7,457)

During the three months ended September 30, 2022 and 2021, as a result of the effect of cash flow hedge accounting, the Company recognized a gain of $8.5 million and $1.4 million, respectively, in other comprehensive income. In addition, during the three months ended September 30, 2022 and 2021, $0.8 million and $0.8 million, respectively, was reclassified from other comprehensive income and recognized as a reduction to interest expense, net, in the accompanying consolidated statements of operations. During the nine months ended September 30, 2022 and 2021, as a result of the effect of cash flow hedge accounting, the Company recognized a gain of $17.5 million and $5.4 million, respectively, in other comprehensive income. In addition, during the nine months ended September 30, 2022 and 2021, $2.2 million and $2.1 million, respectively, was reclassified from other comprehensive income and recognized as a reduction to interest expense, net, in the accompanying consolidated statements of operations.

(8)          Accounts Payable and Accrued Expenses

Accounts payable and accrued expenses as of September 30, 2022 and December 31, 2021 consisted of the following (in thousands):

26

ADAPTHEALTH CORP. AND SUBSIDIARIES

Notes to Interim Consolidated Financial Statements (Unaudited) (Continued)

	September 30,		December 31,
	2022		2021
Accounts payable	$	238,203	$	248,027
Employee-related accruals		50,539		34,370
Accrued interest		9,924		30,103
Other		48,254		45,884
Total	$	346,920	$	358,384

(9)          Debt

The following is a summary of long term-debt as of September 30, 2022 and December 31, 2021 (in thousands):

	September 30,		December 31,
	2022		2021
Secured term loans	$	770,000	$	785,000
Senior unsecured notes		1,450,000		1,450,000
Unamortized deferred financing fees		(27,912)		(31,448)
		2,192,088		2,203,552
Current portion		(30,000)		(20,000)
Long-term portion	$	2,162,088	$	2,183,552

On January 20, 2021, the Company refinanced its then existing debt borrowings and entered into a new credit agreement with its existing bank group, which was amended in April 2021 (the 2021 Credit Agreement). The 2021 Credit Agreement included borrowings of $800 million under a term loan (the 2021 Term Loan), and $450 million in commitments for revolving credit loans (the 2021 Revolver). The 2021 Revolver has a $55 million letter of credit sublimit. The 2021 Term Loan and the 2021 Revolver both have maturities in January 2026. Borrowings under the 2021 Term Loan were used in part to partially finance the cash portion of the purchase price for the acquisition of AeroCare, to repay amounts outstanding under the Company’s then existing credit agreement of $301.9 million plus accrued interest, to repay amounts outstanding under revolving credit loans under the 2021 Credit Agreement which were borrowed prior to the April 2021 amendment, and to pay related fees and expenses. Amounts borrowed under the 2021 Credit Agreement bear interest quarterly at variable rates based upon the sum of (a) the Adjusted LIBOR Rate (subject to a zero percent floor) equal to the LIBOR (as defined) for the applicable interest period multiplied by the statutory reserve rate, plus (b) an applicable margin (as defined) ranging from 1.50% to 3.25% per annum based on the Consolidated Senior Secured Leverage Ratio (as defined). The 2021 Revolver carries a commitment fee during the term of the 2021 Credit Agreement ranging from 0.25% to 0.50% per annum of the average daily undrawn portion of the 2021 Revolver based on the Consolidated Senior Secured Leverage Ratio. On August 16, 2021, the Company amended the 2021 Credit Agreement to expressly permit the issuance of the 5.125% Senior Notes (see discussion below) and the prepayment of the outstanding principal amount under a then existing promissory note with the proceeds of the 5.125% Senior Notes. In connection with the 2021 Credit Agreement, the Company paid financing costs of $7.6 million. Further, in connection with executing the 2021 Credit Agreement, the Company recognized a loss on debt extinguishment of $2.1 million consisting of the write off unamortized deferred financing costs related to the Company’s then existing credit agreement and other lender fees, which is included in loss on extinguishment of debt in the accompanying consolidated statements of operations for the nine months ended September 30, 2021.

Under the 2021 Credit Agreement, the Company is subject to a number of restrictive covenants that, among other things, impose operating and financial restrictions on the Company. Financial covenants include a Consolidated Total Leverage Ratio and a Consolidated Interest Coverage Ratio, both as defined in the 2021 Credit Agreement. The 2021 Credit Agreement also contains certain customary events of default, including, among other things, failure to make

27

ADAPTHEALTH CORP. AND SUBSIDIARIES

Notes to Interim Consolidated Financial Statements (Unaudited) (Continued)

payments when due thereunder, failure to observe or perform certain covenants, cross-defaults, bankruptcy and insolvency-related events, and non-compliance with healthcare laws. Any borrowing under the 2021 Credit Agreement may be repaid, in whole or in part, at any time and from time to time without premium or penalty, other than customary breakage costs, and any amounts repaid under the 2021 Revolver may be reborrowed. Mandatory prepayments are required under the 2021 Revolver when borrowings and letter of credit usage exceed the total commitments for revolving credit loans. Mandatory prepayments are also required in connection with the disposition of assets to the extent not reinvested, unpermitted debt transactions, and excess cash flow, as defined, if certain leverage tests are not met. The Company was in compliance with all debt covenants as of September 30, 2022.

Secured Term Loans

The borrowings under the 2021 Term Loan require quarterly principal repayments of $5.0 million beginning June 30, 2021 through March 31, 2023, increasing to $10.0 million beginning June 30, 2023 through December 31, 2025, and the unpaid principal balance is due at maturity in January 2026. At September 30, 2022 and December 31, 2021, there was $770 million and $785 million, respectively, outstanding under the 2021 Term Loan. The interest rate under the 2021 Term Loan was 4.56% at September 30, 2022.

Revolving Credit Facility

During the nine months ended September 30, 2022, the Company had no borrowings under the 2021 Revolver, and there was $0 outstanding under the 2021 Revolver at September 30, 2022. During the nine months ended September 30, 2021, the Company borrowed $365.0 million under revolving credit loans pursuant to the 2021 Credit Agreement, which were all repaid during the period. Borrowings under the 2021 Revolver may be used for working capital and other general corporate purposes, including for capital expenditures and acquisitions permitted under the 2021 Credit Agreement. At September 30, 2022, after consideration of stand-by letters of credit outstanding of $17.4 million, the remaining maximum borrowings available pursuant to the 2021 Revolver was $432.6 million.

Senior Unsecured Notes

On August 19, 2021, the Company issued $600.0 million aggregate principal amount of 5.125% senior unsecured notes due 2030 (the 5.125% Senior Notes). The 5.125% Senior Notes will mature on March 1, 2030. Interest on the 5.125% Senior Notes is payable on March 1st and September 1st of each year, beginning on March 1, 2022. The 5.125% Senior Notes will be redeemable at the Company’s option, in whole or in part, at any time on or after March 1, 2025, and the redemption price for the 5.125% Senior Notes if redeemed during the 12 months beginning (i) March 1, 2025 is 102.563%, (ii) March 1, 2026 is 101.281%, (iii) March 1, 2027 and thereafter is 100.000%, in each case together with accrued and unpaid interest. The Company may also redeem some or all of the 5.125% Senior Notes before March 1, 2025 at a redemption price of 100% of the principal amount of the 5.125% Senior Notes, plus a “make-whole” premium, together with accrued and unpaid interest. In addition, the Company may redeem up to 40% of the original aggregate principal amount of the 5.125% Senior Notes before March 1, 2025 with the proceeds from certain equity offerings at a redemption price equal to 105.125% of the principal amount of the 5.125% Senior Notes, together with accrued and unpaid interest. Furthermore, the Company may be required to make an offer to purchase the 5.125% Senior Notes upon the sale of certain assets or upon specific kinds of changes of control. Borrowings under the 5.125% Senior Notes were used to repay existing amounts outstanding under the 2021 Revolver, to prepay the outstanding principal amount under a then existing promissory note, and to pay related fees and expenses. In connection with the issuance of the 5.125% Senior Notes, the Company paid financing costs of $11.1 million.

On January 4, 2021, the Company issued $500.0 million aggregate principal amount of 4.625% senior unsecured notes due 2029 (the 4.625% Senior Notes). The 4.625% Senior Notes will mature on August 1, 2029. Interest on the 4.625% Senior Notes is payable on February 1st and August 1st of each year, beginning on August 1, 2021. The 4.625% Senior Notes will be redeemable at the Company’s option, in whole or in part, at any time on or after February 1, 2024, and the redemption price for the 4.625% Senior Notes if redeemed during the 12 months beginning (i) February

28

ADAPTHEALTH CORP. AND SUBSIDIARIES

Notes to Interim Consolidated Financial Statements (Unaudited) (Continued)

1, 2024 is 102.313%, (ii) February 1, 2025 is 101.156%, (iii) February 1, 2026 and thereafter is 100.000%, in each case together with accrued and unpaid interest. The Company may also redeem some or all of the 4.625% Senior Notes before February 1, 2024 at a redemption price of 100% of the principal amount of the 4.625% Senior Notes, plus a “make-whole” premium, together with accrued and unpaid interest. In addition, the Company may redeem up to 40% of the original aggregate principal amount of the 4.625% Senior Notes before February 1, 2024 with the proceeds from certain equity offerings at a redemption price equal to 104.625% of the principal amount of the 4.625% Senior Notes, together with accrued and unpaid interest. Furthermore, the Company may be required to make an offer to purchase the 4.625% Senior Notes upon the sale of certain assets or upon specific kinds of changes of control. Borrowings under the 4.625% Senior Notes were used to partially finance the cash portion of the purchase price for the acquisition of AeroCare, and to pay related fees and expenses. In connection with the issuance of the 4.625% Senior Notes, the Company paid financing costs of $10.4 million.

On July 29, 2020, the Company issued $350.0 million aggregate principal amount of 6.125% senior unsecured notes due 2028 (the 6.125% Senior Notes). The 6.125% Senior Notes will mature on August 1, 2028. Interest on the 6.125% Senior Notes is payable on February 1st and August 1st of each year, beginning on February 1, 2021. The 6.125% Senior Notes will be redeemable at the Company’s option, in whole or in part, at any time on or after August 1, 2023, and the redemption price for the 6.125% Senior Notes if redeemed during the 12 months beginning (i) August 1, 2023 is 103.063%, (ii) August 1, 2024 is 102.042%, (iii) August 1, 2025 is 101.021% and (iv) August 1, 2026 and thereafter is 100.000%, in each case together with accrued and unpaid interest. The Company may also redeem some or all of the 6.125% Senior Notes before August 1, 2023 at a redemption price of 100% of the principal amount of the 6.125% Senior Notes , plus a “make-whole” premium, together with accrued and unpaid interest. In addition, the Company may redeem up to 40% of the original aggregate principal amount of the 6.125% Senior Notes before August 1, 2023 with the proceeds from certain equity offerings at a redemption price equal to 106.125% of the principal amount of the 6.125% Senior Notes, together with accrued and unpaid interest. Furthermore, the Company may be required to make an offer to purchase the 6.125% Senior Notes upon the sale of certain assets or upon specific kinds of changes of control.

Note Payable

In March 2019, the Company signed a Note and Unit Purchase Agreement with an investor. Pursuant to the agreement, the Company issued a promissory note with a principal amount of $100 million (the Promissory Note). In connection with the transactions completed as part of the Business Combination, the Promissory Note was replaced with a new amended and restated promissory note with a principal amount of $100 million, and the investor converted certain of its members’ interests to a $43.5 million promissory note. The new $100 million promissory note, together with the $43.5 million promissory note, are collectively referred to herein as the New Promissory Note. In June 2021, the Company repaid $71.8 million of the outstanding principal balance under the New Promissory Note. In connection with such repayment, the Company paid a debt prepayment penalty of $8.5 million, reflecting the previously disclosed 10% prepayment penalty plus an incremental amount negotiated as part of the prepayment transaction. In addition, the Company wrote off $1.4 million of unamortized deferred financing costs relating to the principal balance that was repaid. The prepayment penalty and the write-off of the unamortized deferred financing costs are included in loss on extinguishment of debt in the accompanying consolidated statements of operations for the nine months ended September 30, 2021. In August 2021, the Company repaid the remaining outstanding principal balance of $71.7 million under the New Promissory Note. In connection with such repayment, the Company paid a debt prepayment penalty of $7.7 million, reflecting the previously disclosed 10% prepayment penalty plus an incremental amount negotiated as part of the prepayment transaction. In addition, the Company wrote off $0.6 million of unamortized deferred financing costs relating to the principal balance that was repaid. The prepayment penalty and the write-off of the unamortized deferred financing costs are included in loss on extinguishment of debt in the accompanying consolidated statements of operations for the three and nine months ended September 30, 2021. The outstanding principal balance under the New Promissory Note bore interest at 12%.

29

ADAPTHEALTH CORP. AND SUBSIDIARIES

Notes to Interim Consolidated Financial Statements (Unaudited) (Continued)

(10)        Stockholders’ Equity

AdaptHealth, f/k/a DFB Healthcare Acquisitions Corp. (DFB), was originally formed in November 2017 as a publicly traded special purpose acquisition company for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination involving one or more businesses. On July 8, 2019, AdaptHealth Holdings LLC (AdaptHealth Holdings) entered into an Agreement and Plan of Merger (the Merger Agreement), as amended on October 15, 2019, with DFB, pursuant to which AdaptHealth Holdings combined with DFB (the Business Combination). The Business Combination closed on November 8, 2019. In connection with the Business Combination, the name of the combined company was changed to AdaptHealth Corp.

Following the Closing of the Business Combination, AdaptHealth Corp. owned 56% of the combined company with the remaining 44% owned by the former owners of AdaptHealth Holdings in the form of common units representing limited liability company interests in AdaptHealth Holdings from and after the Closing of the Business Combination (New AdaptHealth Units). The former owners of AdaptHealth Holdings held New AdaptHealth Units and a corresponding number of non-economic Class B Common stock, which enabled the holder to one vote per share, and were exchangeable on a one-to-one basis for shares of Class A Common Stock. Subsequent to the Business Combination, all of the common unit interests of AdaptHealth Holdings and a corresponding number of shares of Class B Common Stock were exchanged for shares of Class A Common Stock, of which the final 13,218,758 of the exchanges occurred on January 1, 2021. As a result, the prior holders of the common unit interests of AdaptHealth Holdings no longer own a direct noncontrolling economic interest in AdaptHealth Holdings. In connection with the January 2021 exchanges, the Company recorded a decrease to the noncontrolling interest of $77.9 million in the accompanying consolidated statements of stockholders’ equity.

The Company filed its Third Amended and Restated Certificate of Incorporation (the Certificate of Incorporation) on July 28, 2021. Among other things, the Certificate of Incorporation (x) increased the authorized number of shares of Common Stock from 245,000,000 shares of Common Stock to 300,000,000 shares of Common Stock and (y) (i) deleted provisions no longer applicable following the exchange of all outstanding New AdaptHealth Units and shares of Class B Common Stock for shares of Class A Common Stock and (ii) renamed the Company’s Class A Common Stock to Common Stock. Holders of Common Stock are entitled to one vote for each share. The shares of Preferred Stock (see below) shall be issued with such designations, voting and other rights and preferences as may be determined from time to time by the Company’s board of directors.

Common Stock

In January 2021, the Company issued 8,450,000 shares of Class A Common Stock at a price of $33.00 per share pursuant to an underwritten public offering (the 2021 Stock Offering) for gross proceeds of $278.9 million. In connection with this transaction, the Company received proceeds of $265.0 million which is net of the underwriting discount. A portion of the proceeds from the 2021 Stock Offering were used to partially finance the cash portion of the purchase price for the acquisition of AeroCare, and to pay related fees and expenses. In connection with the 2021 Stock Offering, the Company paid offering costs, inclusive of the underwriting discount, of $13.8 million.

Preferred Stock

In June 2020, the Company entered into an exchange agreement (the Exchange Agreement) with an investor pursuant to which the investor exchanged 15,810,547 shares of the Company’s Class A Common Stock for 158,105.47 shares of Series B-1 Preferred Stock, par value $0.0001 per share. The Series B-1 Preferred Stock liquidation preference is limited to its par value of $0.0001 per share. The Series B-1 Preferred Stock will participate equally and ratably on an as-converted basis with the holders of Common Stock in all cash dividends paid on the Common Stock. The Series B-1 Preferred Stock is non-voting. The holder may convert each share of Series B-1 Preferred Stock into 100 shares of Common Stock (subject to certain anti-dilution adjustments) at its election, except to the extent that following such

30

ADAPTHEALTH CORP. AND SUBSIDIARIES

Notes to Interim Consolidated Financial Statements (Unaudited) (Continued)

conversion, the number of shares of Common Stock held by such holder and its affiliates exceed 4.9% of the outstanding Common Stock of the Company. During the nine months ended September 30, 2021, 39,500 shares of Series B-1 Preferred Stock were converted into 3,950,000 shares of Common Stock. There were no such conversions during the nine months ended September 30, 2022.

As discussed in Note 3, Acquisitions, the Company issued 130,474.73 shares of Series C Convertible Preferred Stock in connection with the acquisition of AeroCare. The Series C Convertible Preferred Stock liquidation preference was limited to its par value of $0.0001 per share. The Series C Convertible Preferred Stock participated equally and ratably on an as-converted basis with the holders of Common Stock in all potential cash dividends paid on the Common Stock. The Series C Convertible Preferred Stock was non-voting. On March 3, 2021, the Company’s stockholders approved, for purposes of complying with Nasdaq Listing Rule 5635, the issuance of shares of the Company’s Common Stock, representing equal to or greater than 20% of the outstanding Common Stock or voting power of the Company issuable upon conversion of the Series C Convertible Preferred Stock issued to the former equity holders of AeroCare, by removal of the conversion restriction that prohibits such conversion of Series C Convertible Preferred Stock. Following the receipt of the approval of the Company’s stockholders, the holders were able to elect to convert, and the Company was able to elect to effect a mandatory conversion of, each share of Series C Convertible Preferred Stock into 100 shares of Common Stock (subject to certain anti-dilution adjustments). The Company elected to effect a mandatory conversion of the Series C Convertible Preferred Stock, and the conversion of 130,474.73 shares of Series C Convertible Preferred Stock to 13,047,473 shares of Common Stock occurred on March 18, 2021.

Treasury Stock

On May 9, 2022, the Company’s board of directors authorized a share repurchase program for up to $200 million of the Company’s Common Stock through December 31, 2022 (the Share Repurchase Program). The timing and actual number of shares to be repurchased will depend upon market conditions and other factors. Shares of the Company’s Common Stock may be purchased from time to time on the open market, through privately negotiated transactions or otherwise. Purchases of the Company’s Common Stock may be started or stopped at any time without prior notice depending on market conditions and other factors. During the nine months ended September 30, 2022, the Company purchased 750,835 shares of the Company’s Common Stock for $14.0 million under the Share Repurchase Program, which is reflected in Treasury Stock in the accompanying consolidated statements of stockholders’ equity.

Warrants

At the Closing of the Business Combination, the Company had 12,666,666 warrants outstanding. Each warrant is exercisable into one share of Common Stock at a price of $11.50 per share. The exercise price and number of shares of Common Stock issuable upon exercise of the warrants may be adjusted in certain circumstances including in the event of a share dividend, or recapitalization, reorganization, merger or consolidation. However, the warrants will not be adjusted for the issuance of Common Stock at a price below its exercise price. During the nine months ended September 30, 2022, 184,870 warrants were exercised in cashless transactions resulting in the issuance of 87,553 shares of Common Stock. There were no warrants exercised during the nine months ended September 30, 2021. As of September 30, 2022, the Company had 3,871,557 warrants outstanding, which have an expiration date of November 20, 2024.

The Company classifies its warrants as a liability in its consolidated balance sheets because of certain terms included in the corresponding warrant agreement. The estimated fair value of the warrants is recorded as a liability, with such fair value reclassified to stockholders’ equity upon the exercise of such warrants. Prior to exercise, the change in the estimated fair value of such warrants each period is recognized as a non-cash charge or gain in the Company’s consolidated statements of operations.

31

ADAPTHEALTH CORP. AND SUBSIDIARIES

Notes to Interim Consolidated Financial Statements (Unaudited) (Continued)

A reconciliation of the changes in the warrant liability during the nine months ended September 30, 2022 and 2021 was as follows (in thousands):

Estimated fair value of warrant liability at December 31, 2021	$	57,764
Change in estimated fair value of the warrant liability		(17,145)
Reclassification of warrant liability to equity for exercised warrants		(2,103)
Estimated fair value of warrant liability at September 30, 2022	$	38,516
Estimated fair value of warrant liability at December 31, 2020	$	113,905
Change in estimated fair value of the warrant liability		(57,359)
Estimated fair value of warrant liability at September 30, 2021	$	56,546

Contingent Consideration Common Shares

Pursuant to the Merger Agreement, the former owners of AdaptHealth Holdings who received Class A Common Stock and Class B Common Stock in connection with the Business Combination are entitled to receive earn-out consideration to be paid in the form of Common Stock, if the average price of the Company’s Common Stock for the month of December prior to each measurement date equals or exceeds certain hurdles set forth in the Merger Agreement (Contingent Consideration Common Shares). The former owners of AdaptHealth Holdings were entitled to receive 1,000,000 shares of Common Stock on each of December 31, 2021 and 2020 based on an average stock price hurdle of $18 and $15, respectively. The average stock price of the Company’s Common Stock was greater than these hurdles for the applicable measurement periods as of the December 31, 2021 and 2020 measurement dates, which triggered the issuance of 1,000,000 shares of Common Stock on such dates. In addition, the former owners of AdaptHealth Holdings are entitled to receive an additional 1,000,000 shares of Common Stock on December 31, 2022 if the average stock price of the Company’s Common Stock equals or exceeds $22 during the month of December 2022.

The Contingent Consideration Common Shares would be issued immediately in the event of a change of control as defined in the Merger Agreement. The estimated fair value of the Contingent Consideration Common Shares was previously recorded as a liability in the Company’s consolidated balance sheets, with such fair value reclassified to stockholders’ equity upon the issuance of any shares that are earned. Prior to issuance, the change in the estimated fair value of such shares each period was recognized as a non-cash charge or gain in the Company’s consolidated statements of operations.

The Company estimated the fair value of the contingent consideration common shares liability using a Monte-Carlo simulation analysis. A Monte-Carlo simulation is a tool used to project asset prices based on a widely accepted drift calculation, the volatility of the asset, incremental time-steps and a random component known as a Weiner process that introduces the dynamic behavior in the asset price. In this framework, asset prices follow a log-normal distribution as they fluctuate through time, which the simulation process captures. A specific model can be developed around the projected stock price to capture the effects of any market performance conditions on value. Price path specific conditions can be captured in this type of open form model. The Monte-Carlo process expresses potential future scenarios that when simulated thousands of times can be viewed statistically to ascertain fair value. The contingent consideration common shares contain market conditions to determine whether the shares are earned based on the Company’s Common Stock price during specified measurement periods. Given the path-dependent nature of the requirement in which the shares are earned, a Monte-Carlo simulation was used to estimate the fair value of the liability. The Company’s Common Stock price was simulated to each measurement period based on the methodology described above. In each iteration, the simulated stock price was compared to the conditions under which the shares are earned. In iterations where the stock price corresponded to shares being earned, the future value of the earned shares was discounted back to present value. The fair value of the liability was estimated based on the average of all iterations of the simulation.

32

ADAPTHEALTH CORP. AND SUBSIDIARIES

Notes to Interim Consolidated Financial Statements (Unaudited) (Continued)

As discussed above, on each of December 31, 2021 and 2020, 1,000,000 shares of Common Stock were issued in connection with the portion of the Contingent Consideration Common Shares which were earned as of such dates. As a result, the estimated fair value related to such shares was reclassified to stockholders’ equity, with such shares reflected as issued and outstanding Common Stock. In accordance with U.S. GAAP, the estimated fair value related to the remaining 1,000,000 Contingent Consideration Common Shares was reclassified to stockholders’ equity at December 31, 2021. Since the fair value of these potential shares was reclassified to stockholders’ equity on December 31, 2021, these potential shares are no longer liability classified and therefore the changes in the estimated fair value of such potential shares are not recognized as a non-cash charge or gain in the Company’s consolidated statements of operations subsequent to December 31, 2021.

A reconciliation of the changes in the contingent consideration common shares liability during the nine months ended September 30, 2021 was as follows (in thousands):

Estimated fair value of contingent consideration common shares liability at December 31, 2020	$	70,477
Change in estimated fair value of the contingent consideration common shares liability		(34,050)
Estimated fair value of contingent consideration common shares liability at September 30, 2021	$	36,427

Equity-based Compensation

In connection with the Company’s 2019 Stock Incentive Plan (the 2019 Plan), the Company provides equity-based compensation to attract and retain employees while also aligning employees’ interest with the interests of its stockholders. The 2019 Plan permits the grant of various equity-based awards to selected employees and non-employee directors. At September 30, 2022, the 2019 Plan permits the grant of up to 10,000,000 shares of Common Stock, subject to certain adjustments and limitations. At September 30, 2022, 2,124,163 shares of the Company’s Common Stock were available for issuance under the 2019 Plan.

Stock Options

There were no stock options granted during the nine months ended September 30, 2022. The following table provides the activity regarding the Company’s outstanding stock options during the nine months ended September 30, 2022 that were granted in connection with the 2019 Plan (in thousands, except per share data):

			Weighted-Average
			Grant Date		Weighted-Average	Weighted-Average
	Number of		Fair Value		Exercise Price	Remaining
	Options		per Share		per Share	Contractual Term
Outstanding, December 31, 2021	2,219	$	3.75	$	19.36
Activity - none	—
Outstanding, September 30, 2022	2,219	$	3.75	$	19.36	6.3 Years

The following table provides the activity for all outstanding stock options during the nine months ended September 30, 2022 (in thousands, except per share data):

			Weighted-Average	Weighted-Average
	Number of		Exercise Price	Remaining
	Options		per Share	Contractual Term
Outstanding, December 31, 2021	5,766	$	11.26
Exercised	(509)	$	6.79
Outstanding, September 30, 2022	5,257	$	11.72	5.7 Years

33

ADAPTHEALTH CORP. AND SUBSIDIARIES

Notes to Interim Consolidated Financial Statements (Unaudited) (Continued)

During the nine months ended September 30, 2022, 194,002 stock options were exercised resulting in $1.4 million of cash proceeds received by the Company and the issuance of 194,002 shares of the Company’s Common Stock. Also, during the nine months ended September 30, 2022, 315,349 stock options were exercised on a cashless basis resulting in the issuance of 131,741 shares of the Company’s Common Stock.

Restricted Stock

During the nine months ended September 30, 2022, the Company granted 212,883 shares of restricted stock to various employees which vest ratably over the three or four-year periods following the vesting commencement date (which is generally the grant date), subject to the employees’ continuous employment through the applicable vesting date, and if applicable, subject to certain performance conditions. The grant-date fair value of these awards was $3.9 million. During the nine months ended September 30, 2022, the Company granted 81,347 shares of restricted stock to its non-employee directors, which vest approximately one year following the grant date. The grant-date fair value of these awards was $1.5 million.

During the nine months ended September 30, 2022, the Company granted 317,554 shares of restricted stock units to senior executive management of the Company. These awards vest ratably over the three-year period following the grant date, subject to the employees’ continuous employment through the applicable vesting date. The grant-date fair value of these awards was $5.7 million. In addition, during the nine months ended September 30, 2022, the Company granted 317,554 shares of performance-vested restricted stock units (Performance RSUs) to senior executive management of the Company. The Performance RSUs will vest on the third anniversary of the grant date subject to the achievement of specified goals relative to the Company’s three-year relative total shareholder return (Relative TSR) performance versus the Company’s defined peer group (the Peer Group), and is also subject to the employees’ continuous employment through the vesting date. The grant-date fair value of these awards, using a Monte-Carlo simulation analysis, was $8.7 million. The payout of shares on the vesting date are as follows based on the Company’s Relative TSR versus the Peer Group (for performance between the stated goals noted below, straight-line interpolation will be applied):

● Less than 25^th Percentile – No payout

● Greater than or equal to 25^th Percentile – 50% of Performance RSUs

● Equal to 50^th Percentile – 100% of Performance RSUs

● Greater than or equal to 75^th Percentile – 200% of Performance RSUs

Activity related to the Company’s non-vested restricted stock grants for the nine months ended September 30, 2022 is presented below (in thousands, except per share data):

	Number of Shares of		Weighted-Average Grant Date
	Restricted Stock		Fair Value per Share
Non-vested balance, December 31, 2021	2,195	$	19.58
Granted	929	$	21.26
Vested	(461)	$	24.43
Forfeited	(96)	$	21.96
Non-vested balance, September 30, 2022	2,567	$	22.60

Incentive Units

AdaptHealth Holdings granted Incentive Units in June 2019 (the 2019 Incentive Units) to certain members of management. The 2019 Incentive Units were intended to constitute profits interests and were granted for purposes of enabling such individuals to participate in the long-term growth and financial success of the Company and were issued

34

ADAPTHEALTH CORP. AND SUBSIDIARIES

Notes to Interim Consolidated Financial Statements (Unaudited) (Continued)

in exchange for services to be performed. The grant date fair value of the 2019 Incentive Units, as calculated under an Option Pricing Method, was $4.5 million. With respect to the 2019 Incentive Units, 50% of the awards were scheduled to vest in equal annual installments on each of the first four anniversaries of the Vesting Commencement Date as defined in the agreements (May 20, 2019). The first 25% of this portion of the 2019 Incentive Units vested in May 2020, and in January 2021, the vesting of the remaining unvested units associated with this portion of the 2019 Incentive Units was accelerated. The Company recorded $1.5 million of equity-based compensation expense during the nine months ended September 30, 2021 in connection with such acceleration. The remaining 50% of the awards had initial vesting terms based upon a performance condition. In connection with the Business Combination, the vesting condition for this portion of the 2019 Incentive Units was changed to vest quarterly during the one-year period subsequent to the closing of the Business Combination, and as such all of the units associated with this portion of the 2019 Incentive Units were fully vested in November 2020.

Equity-Based Compensation Expense

The Company recorded equity-based compensation expense of $5.6 million during the three months ended September 30, 2022, of which $4.0 million and $1.6 million is included in general and administrative expenses and cost of net revenue, respectively, in the accompanying consolidated statements of operations. The Company recorded equity-based compensation expense of $5.4 million during the three months ended September 30, 2021, of which $3.4 million and $2.0 million is included in general and administrative expenses and cost of net revenue, respectively, in the accompanying consolidated statements of operations. The Company recorded equity-based compensation expense of $16.8 million during the nine months ended September 30, 2022, of which $11.5 million and $5.3 million is included in general and administrative expenses and cost of net revenue, respectively, in the accompanying consolidated statements of operations. The Company recorded equity-based compensation expense of $21.4 million during the nine months ended September 30, 2021, of which $14.5 million and $6.9 million is included in general and administrative expenses and cost of net revenue, respectively, in the accompanying consolidated statements of operations. At September 30, 2022, there was $40.5 million of unrecognized compensation expense related to equity-based compensation awards, which is expected to be recognized over a weighted-average period of 2.1 years.

(11)        Earnings Per Share

Earnings Per Share (EPS) is computed by dividing net income by the weighted average number of common shares outstanding during the period on a basic and diluted basis. The Company computes diluted net income per share using the more dilutive of the treasury stock method and the two-class method after giving effect to all potential dilutive Common Stock.

The Company’s potentially dilutive securities include potential common shares related to outstanding warrants, contingent consideration common shares, unvested restricted stock, outstanding stock options and outstanding preferred stock. Refer to Note 10, Stockholders’ Equity, for additional discussion of these potential dilutive securities.

Diluted net income per share considers the impact of potentially dilutive securities except when the potential common shares have an antidilutive effect. The Company’s outstanding preferred stock are considered participating securities, thus requiring the two-class method of computing diluted net income per share. Computation of diluted net income per share under the two-class method excludes from the numerator any dividends paid or owed on participating securities and any undistributed earnings considered to be attributable to participating securities. The related participating securities are similarly excluded from the denominator.

35

ADAPTHEALTH CORP. AND SUBSIDIARIES

Notes to Interim Consolidated Financial Statements (Unaudited) (Continued)

Computations of basic and diluted net income per share were as follows (in thousands, except per share data):

	Three Months Ended September 30,				Nine Months Ended September 30,
	2022		2021		2022		2021
Numerator
Net income attributable to AdaptHealth Corp.	$	16,122	$	58,092	$	71,904	$	133,233
Less: Earnings allocated to participating securities (1)		1,360		5,002		6,079		12,572
Net income for basic EPS	$	14,762	$	53,090	$	65,825	$	120,661
Change in fair value of warrant liability (2)		—		(16,737)		(17,145)		(57,359)
Change in fair value of contingent consideration common shares liability (2)		—		(8,145)		—		(27,718)
Net income for diluted EPS	$	14,762	$	28,208	$	48,680	$	35,584
Denominator (1) (2)
Basic weighted-average common shares outstanding		134,227		131,684		134,186		124,228
Add: Warrants (2)		—		2,245		1,436		2,598
Add: Contingent Consideration Common Shares (2)		—		2,000		—		2,000
Add: Stock options		2,903		3,794		2,669		4,112
Add: Unvested restricted stock		453		599		308		700
Diluted weighted-average common shares outstanding		137,583		140,322		138,599		133,638
Basic net income per share	$	0.11	$	0.40	$	0.49	$	0.97
Diluted net income per share	$	0.11	$	0.20	$	0.35	$	0.27

(1) The Company’s preferred stock are considered participating securities. Computation of EPS under the two-class method excludes from the numerator any dividends paid or owed on participating securities and any undistributed earnings considered to be attributable to participating securities. The related participating securities are similarly excluded from the denominator.

(2) For the nine months ended September 30, 2022, and the three and nine months ended September 30, 2021, the impact to earnings from the change in fair value of the Company’s warrant liability is excluded from the numerator, and the corresponding security is included in the denominator, for purposes of computing diluted net income per share. For the three and nine months ended September 30, 2021, the impact to earnings from the change in fair value of the Company’s contingent consideration common shares liability is excluded from the numerator, and the corresponding security is considered for inclusion in the denominator, for purposes of computing diluted net income per share. These adjustments are included as the effect of the numerator and denominator adjustments for these derivative instruments is dilutive as a result of the non-cash gains recorded for the change in fair value of these instruments during the periods.

36

ADAPTHEALTH CORP. AND SUBSIDIARIES

Notes to Interim Consolidated Financial Statements (Unaudited) (Continued)

The table below provides the weighted-average number of potential common shares associated with outstanding securities not included in the Company’s computation of diluted net income per share for the three and nine months ended September 30, 2022 and 2021 because to do so would be antidilutive (in thousands):

	Three Months Ended September 30,					Nine Months Ended September 30,
	2022		2021		2022		2021
Preferred Stock		12,406		12,406		12,406		12,944
Warrants		1,706		—		—		—
Stock options		468		—		468		—
Unvested restricted stock		108		—		221		—
Total		14,688		12,406		13,095		12,944

In addition, there are 1,000,000 shares relating to the Contingent Consideration Common Shares that were not included in the diluted net income per share computation for the three and nine months ended September 30, 2022 as the corresponding average stock price hurdle for issuing these contingently issuable shares would not have been met as of the September 30, 2022 reporting date. As discussed in note 10, Stockholders’ Equity, the measurement date is December 31, 2022 for these shares and they will be issued at such time if they are earned.

(12)        Leases

The Company leases its office facilities and office equipment under noncancelable lease agreements which expire at various dates through March 2033. Some of these lease agreements include an option to renew at the end of the term. The Company also leases certain office facilities on a month-to-month basis. In some instances, the Company is also required to pay its pro rata share of real estate taxes and utility costs in connection with the premises. Some of the leases contain fixed annual increases of minimum rent.

The Company’s leases frequently allow for lease payments that could vary based on factors such as inflation and the incurrence of contractual charges such as those for common area maintenance or utilities.

Renewal and/or early termination options are common in the lease arrangements, particularly with respect to real estate leases. The Company’s right-of-use assets and lease liabilities generally include periods covered by renewal options and exclude periods covered by early termination options (based on the conclusion that it is reasonably certain that the Company will exercise such renewal options and not exercise such early termination options).

The Company is also party to certain sublease arrangements related to real estate leases, where the Company acts as the lessee and intermediate lessor.

The Company has acquired patient medical equipment and supplies, and office equipment through multiple finance leases. The finance lease obligations represent the present value of minimum lease payments under the respective agreement, payable monthly at various interest rates.

37

ADAPTHEALTH CORP. AND SUBSIDIARIES

Notes to Interim Consolidated Financial Statements (Unaudited) (Continued)

The following table presents information about the Company’s right-of-use assets and lease liabilities as of September 30, 2022 and December 31, 2021 (in thousands):

	Consolidated Balance Sheets Line Item	September 30, 2022		December 31, 2021
Right-of-use (ROU) assets:
Operating lease ROU assets	Operating lease right-of-use assets	$	128,635	$	147,760
Finance lease ROU assets	Equipment and other fixed assets, net		1,056		17,410
Total ROU assets		$	129,691	$	165,170
Operating lease liabilities:
Current operating lease liabilities	Current portion of operating lease obligations	$	28,769	$	31,418
Noncurrent operating lease liabilities	Operating lease obligations, less current portion		103,859		120,180
Total operating lease liabilities		$	132,628	$	151,598
Finance lease liabilities:
Current finance lease liabilities	Current portion of finance lease obligations	$	2,695	$	15,446
Noncurrent finance lease liabilities	Other long-term liabilities		—		132
Total finance lease liabilities		$	2,695	$	15,578

The following table presents information about lease costs and expenses and sublease income for the three and nine months ended September 30, 2022 and 2021 (in thousands). The amounts below are included in cost of net revenue in the accompanying consolidated statements of operations for the periods presented.

	Three Months Ended September 30,				Nine Months Ended September 30,
	2022		2021		2022		2021
Operating lease costs	$	9,248	$	9,837	$	28,547	$	27,695
Finance lease costs:
Amortization of ROU assets	$	640	$	8,487	$	7,266	$	27,549
Other lease costs and income:
Variable leases costs (1)	$	3,728	$	3,784	$	12,680	$	10,061
Sublease income	$	336	$	405	$	1,019	$	911
Short-term lease costs	$	—	$	4,093	$	—	$	19,905

(1) Amounts represent variable costs incurred that were not included in the initial measurement of the lease liability such as common area maintenance and utilities costs associated with leased real estate.

38

ADAPTHEALTH CORP. AND SUBSIDIARIES

Notes to Interim Consolidated Financial Statements (Unaudited) (Continued)

The following table provides the weighted average remaining lease terms and weighted average discount rates for the Company’s leases as of September 30, 2022 and December 31, 2021:

	September 30, 2022	December 31, 2021
Weighted average remaining lease term, weighted based on lease liability balances:
Operating leases	6.2 years	6.7 years
Finance leases	0.5 year	1.0 year
Weighted average discount rate, weighted based on remaining balance of lease payments:
Operating leases	3.9%	3.8%

The following table provides the undiscounted amount of future cash flows related to the Company’s operating and finance leases, as well as a reconciliation of such undiscounted cash flows to the amounts included in the Company’s lease liabilities as of September 30, 2022 (in thousands):

	Operating Leases		Finance Leases
2022	$	8,778	$	1,920
2023		31,757		795
2024		26,347		—
2025		21,966		—
2026		16,158		—
Thereafter		47,027		—
Total future undiscounted lease payments	$	152,033	$	2,715
Less: amount representing interest		(19,405)		(20)
Present value of future lease payments (lease liability)	$	132,628	$	2,695

The following table provides certain cash flow and supplemental non-cash information related to the Company’s lease liabilities for the nine months ended September 30, 2022 and 2021, respectively (in thousands):

	Nine Months Ended September 30,
Cash paid for amounts included in the measurement of lease liabilities:	2022		2021
Operating cash payments for operating leases	$	28,416	$	27,154
Financing cash payments for finance leases	$	14,219	$	31,043
Lease liabilities arising from obtaining right-of-use assets:
Operating leases	$	5,411	$	84,212
Finance leases	$	1,335	$	22,902

(13)          Income Taxes

The Company is subject to U.S. federal, state, and local income taxes. For the three months ended September 30, 2022 and 2021, the Company recorded income tax expense of $5.6 million and $12.1 million, respectively. For the nine months ended September 30, 2022 and 2021, the Company recorded income tax expense of $20.0 million and $22.8 million, respectively.

39

ADAPTHEALTH CORP. AND SUBSIDIARIES

Notes to Interim Consolidated Financial Statements (Unaudited) (Continued)

As of September 30, 2022 and December 31, 2021, the Company had an unrecognized tax benefit of $4.0 million.

Tax Receivable Agreement

AdaptHealth Corp. is party to a Tax Receivable Agreement (TRA) with certain current and former members of AdaptHealth Holdings. The TRA provides for the payment by AdaptHealth Corp. of 85% of the tax savings, if any, that AdaptHealth Corp. realizes (or is deemed to realize in certain circumstances) as a result of (i) certain increases in tax basis resulting from exchanges of New AdaptHealth Units and shares of Class B Common Stock; (ii) certain tax attributes of the corresponding sellers existing prior to an exchange; (iii) imputed interest deemed to be paid by AdaptHealth Corp. as a result of payments it makes under the TRA; and (iv) certain increases in tax basis resulting from payments AdaptHealth Corp. makes under the TRA.

During the nine months ended September 30, 2022, the Company recognized an expense of $4.5 million related to changes in the estimated liability related to the TRA as a result of settling the current portion of the contingent consideration common shares liability during the period, which is included in Other loss (income), net in the accompanying consolidated statement of operations. During the nine months ended September 30, 2021, the Company increased the estimated liability related to the TRA through an aggregate $146.5 million reduction in additional paid-in capital resulting from additional exchanges of New AdaptHealth Units and shares of Class B Common Stock. Correspondingly, during the nine months ended September 30, 2021, the Company increased its deferred tax asset by $163.3 million through an increase in additional paid-in-capital resulting from these exchanges and other increases of AdaptHealth Corp.’s ownership interest in AdaptHealth Holdings.

At September 30, 2022, the Company had a liability recorded relating to the TRA of $304.8 million, of which $5.9 million and $298.9 million is included in other current liabilities and other long-term liabilities, respectively, in the accompanying consolidated balance sheets. At December 31, 2021, the Company had a liability recorded relating to the TRA of $300.3 million, which is included in other long-term liabilities in the accompanying consolidated balance sheets.

(14)         Commitments and Contingencies

In the normal course of business, the Company is subject to loss contingencies, such as legal proceedings and claims arising out of its business that cover a wide range of matters. In accordance with FASB ASC Topic 450, Accounting for Contingencies, the Company records accruals for such loss contingencies when it is probable that a liability has been incurred and the amount of loss can be reasonably estimated. Significant judgment is required to determine both probability and the estimated amount. The Company reviews its accruals at least quarterly and adjusts accordingly to reflect the impact of negotiations, settlements, rulings, advice of legal counsel, and updated information. At this time, the Company has no material accruals related to lawsuits, claims, investigations and proceedings. While there can be no assurance, based on the Company’s evaluation of information currently available, the Company’s management believes any liability that may ultimately result from resolution of such loss contingencies will not have a material adverse effect on the Company’s financial conditions or results of operations. However, the Company’s assessment may be affected by limited information. Accordingly, the Company’s assessment may change in the future based upon availability of new information and further developments in the proceedings of such matters. The results of legal proceedings are inherently uncertain, and material adverse outcomes are possible.

In connection with the Company’s acquisition of PPS HME Holdings LLC (PPS), in May 2018, the Company assumed a Corporate Integrity Agreement (CIA) at one of PPS’ subsidiaries, Braden Partners L.P. d/b/a Pacific Pulmonary Services (BP). The CIA was entered into with the Office of Inspector General of the U.S. Department of Health and Human Services (OIG). The CIA has a five-year term which expires as of April 2022. In connection with the acquisition and integration of PPS by AdaptHealth, the OIG confirmed that the requirements of the CIA imposed upon BP would only apply to the operations of BP and therefore no operations of any other AdaptHealth affiliate are subject

40

ADAPTHEALTH CORP. AND SUBSIDIARIES

Notes to Interim Consolidated Financial Statements (Unaudited) (Continued)

to the requirements of the CIA following the acquisition. On December 16, 2021, the OIG-HHS notified PPS that its report for the period ended March 31, 2021 had been accepted and PPS had satisfied its obligations under the CIA as of such date. On May 24, 2022, the Company submitted its report for the period ended March 31, 2022.

On July 25, 2017, the Company was served with a subpoena by the U.S. Attorney’s Office for the United States District Court for the Eastern District of Pennsylvania (EDPA) pursuant to 18 U.S.C. §3486 to produce certain audit records and internal communications regarding ventilator billing. The investigation focused on billing practices regarding one payor that contracted for bundled payments for certain ventilators. The Company has cooperated with investigators and, through agreement with the EDPA, has submitted all information requested in the Company’s possession. An independent third party was retained by the Company that identified overpayments and underpayments for ventilator billings related to the payor, and a remittance was sent to reconcile that account. On October 3, 2019, the Company received a follow-up civil investigative demand from the EDPA regarding a document previously produced to the EDPA and patients included in the review by the independent third party. The Company has responded to the EDPA and supplemented its production as requested with any relevant documents in the Company’s possession. During subsequent communications, the EDPA indicated to the Company that the investigation remained ongoing. The EDPA also requested additional information regarding certain patient services and claims refunds processed by the Company in 2017. The Company produced this information in coordination with the EDPA. The EDPA has also raised questions regarding other aspects of ventilator billing. While the Company cannot provide any assurance as to whether the EDPA will seek additional information or pursue this matter further, it does not believe that the investigation will have a material adverse effect on the Company.

In March 2019, prior to its acquisition by the Company, AeroCare was served with a civil investigative demand (CID) issued by the United States Attorney for the Western District of Kentucky (WDKY). The CID seeks to investigate allegations that AeroCare improperly billed, or caused others to improperly bill, for oxygen tank contents that were not delivered to beneficiaries. The WDKY has requested documents related to such oxygen tank content billing as well as other categories of information. AeroCare has cooperated with the WDKY and has produced documents and provided explanations of its billing practices. In September 2020, the WDKY indicated the investigation includes alleged violations of the federal False Claims Act and as well as alleged violations of state Medicaid false claims acts in ten states. AeroCare has cooperated fully with the investigation and has indicated to the WDKY that concerns raised do not accurately identify Medicare coverage criteria and that state Medicaid coverage requirements generally do not provide for separate reimbursement for portable gaseous oxygen contents in the circumstances at issue. While the Company cannot provide any assurance as to whether the WDKY will seek additional information or pursue this matter further, it does not believe that the investigation will have a material adverse effect on the Company.

The Company and certain of its current and former officers were named as defendants in a lawsuit, as described below. The Company cannot reasonably predict the outcome of this legal proceeding, nor can it estimate the amount of loss or range of loss, if any, that may result. An adverse outcome in this proceeding could have a material adverse effect on the Company’s results of operations, cash flows or financial condition. The results of legal proceedings are inherently uncertain, and material adverse outcomes are possible.

On July 29, 2021, Robert Charles Faille Jr., a purported shareholder of the Company, filed a purported class action complaint against the Company and certain of its current and former officers in the United States District Court for the Eastern District of Pennsylvania (the Complaint). The Complaint purports to be asserted on behalf of a class of persons who purchased the Company’s stock between November 11, 2019 and July 16, 2021. The Complaint generally alleges that the Company and certain of its current and former officers violated federal securities laws by making allegedly false and misleading statements and/or failing to disclose material information regarding the Company’s organic growth trajectory. The Complaint seeks unspecified damages. On October 14, 2021, the Delaware County Employees Retirement System and the Bucks County Employees Retirement System were named Lead Plaintiffs. Pursuant to the scheduling order, Lead Plaintiffs filed a consolidated complaint on November 22, 2021 (the Consolidated Complaint), which asserts substantially the same claim, but adds a number of current and former directors of the Company as additional defendants and a new theory of recovery based on the Company’s alleged failure to disclose

41

ADAPTHEALTH CORP. AND SUBSIDIARIES

Notes to Interim Consolidated Financial Statements (Unaudited) (Continued)

information concerning the Company’s former Co-CEO’s alleged tax fraud arising from certain past private activity (the “Consolidated Class Action”). On January 20, 2022, the defendants filed a motion to dismiss the Consolidated Complaint. Lead Plaintiffs’ opposition to defendants’ motion was filed on March 21, 2022, and defendants’ reply was filed on April 15, 2022. On June 9, 2022, the court issued an opinion and order denying the defendants’ motion to dismiss the Consolidated Complaint.

On July 15, 2022, the court entered a scheduling order providing for, inter alia, a schedule for completing class certification discovery, as well as setting a briefing schedule for motions for class certification. Pursuant to the scheduling order, Lead Plaintiffs filed their motion for class certification on July 28, 2022. The defendants’ opposition to Lead Plaintiffs’ motion for class certification is due to be filed on January 20, 2023; and Lead Plaintiffs’ reply is due to be filed on March 10, 2023.The Company intends to vigorously defend against the allegations contained in the Consolidated Complaint, but there can be no assurance that the defense will be successful.

On December 6, 2021, a putative shareholder of the Company, Carol Hessler, filed a shareholder derivative complaint against certain current and former directors and officers of the Company in the United States District Court for the Eastern District of Pennsylvania (the “Derivative Complaint”). The Derivative Complaint generally alleges that the defendants breached their fiduciary duties owed to the company by allegedly causing or allowing misrepresentations and/or omissions regarding the Company’s organic growth and Luke McGee’s alleged criminal activity, failing to maintain an adequate system of oversight, disclosure controls and procedures, and internal controls over financial reporting and due diligence into the Company’s management team, and engaging in insider trading. The Derivative Complaint also alleges claims for waste of corporate assets and unjust enrichment. Finally, the Derivative Complaint alleges that certain of the individual defendants violated Section 14(a) of the Securities Exchange Act by allegedly negligently issuing, causing to be issued, and participating in the issuance of materially misleading statements to stockholders in the Company’s Proxy Statements on Schedule DEF 14A in connection with a Special Meeting of Stockholders, held on March 3, 2021, and the 2021 Annual Meeting of Stockholders, held on July 27, 2021. The Derivative Complaint seeks, among other things, an award of money damages.

On March 4, 2022, the parties stipulated to stay the Hessler action pending final resolution of the Consolidated Class Action. On March 7, 2022, the court so-ordered the parties’ stipulation.

The Company intends to vigorously defend against the allegations contained in the Derivative Complaint, but there can be no assurance that the defense will be successful.

On May 2, 2022, the U.S. Attorney’s Office for the Southern District of New York issued a civil investigative demand to Community Surgical Supply Inc. (CSS), a subsidiary of the Company, pursuant to the False Claims Act, 31 U.S.C. § 3733 (FCA) surrounding whether CSS submitted false claims in violation of the FCA related to CSS’s billing of, and reimbursements from, federal health care programs for ventilators provided to patients from January 1, 2015 to the present. The Company is fully cooperating with the investigation. Given the investigation is in the early stages, it is not possible to determine whether it will have a material adverse effect on the Company.

(15)        Related Party Transactions

The Company and one of its executive officers and shareholder own an equity interest in a vendor of the Company that provides automated order intake software. The individual’s equity ownership is less than 1%. The expense related to this vendor was $1.8 million and $1.2 million for the three months ended September 30, 2022 and 2021, respectively. The expense related to this vendor was $4.9 million and $3.4 million for the nine months ended September 30, 2022 and 2021, respectively. The Company accounts for this investment under the cost method of accounting based on its level of equity ownership. As of September 30, 2022 and December 31, 2021, the Company had an immaterial outstanding accounts payable balance to this vendor.

42

ADAPTHEALTH CORP. AND SUBSIDIARIES

Notes to Interim Consolidated Financial Statements (Unaudited) (Continued)

A director of the Company serves on the board of directors of a third-party payor that does business with the Company in the normal course of providing services to patients. Net revenue from this third-party payor was less than 1.0% of the Company’s consolidated net revenue during the three and nine months ended September 30, 2022 and 2021. As of September 30, 2022 and December 31, 2021, the Company had an immaterial outstanding accounts receivable balance from this third-party payor.

A director of the Company is an employee of a beneficial owner of more than 5% of the Company’s Common Stock as of September 30, 2022. This beneficial owner is also a minority shareholder of a vendor that provides equipment and supplies to the Company in the normal course of business. Purchases from this vendor were approximately $20.3 million and $49.8 million, respectively, for the three and nine months ended September 30, 2022. As of September 30, 2022, the Company had $12.6 million in outstanding accounts payable to this vendor. Purchases from this vendor for the three and nine months ended September 30, 2021 and the outstanding accounts payable to this vendor as of December 31, 2021 were immaterial.

A regional manager of the Company is a partial owner of a business which provides contract labor to the Company. Payments to this service provider were $5.7 million and $4.3 million, respectively, for the three months ended September 30, 2022 and 2021, and $16.2 million and $13.7 million, respectively, for the nine months ended September 30, 2022 and 2021. As of September 30, 2022, the Company had $2.2 million in outstanding accounts payable to this service provider. The outstanding accounts payable to this service provider as of December 31, 2021 was immaterial.

(16)        Subsequent Events

The Company has evaluated subsequent events through the filing of this Quarterly Report on Form 10-Q, and determined that there have been no events that have occurred that would require adjustment or disclosure in the interim consolidated financial statements.

43

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following discussion should be read in conjunction with AdaptHealth Corp.’s (“AdaptHealth” or the “Company”) consolidated financial statements and the accompanying notes included in this report. All amounts presented are in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”), except as noted. In addition to historical information, this discussion contains forward-looking statements that involve risks, uncertainties and assumptions that could cause actual results to differ materially from management’s expectations. Factors that could cause such differences include, but are not limited to, those discussed in Item 1A, “Risk Factors”, in our 2021 Annual Report on Form 10-K filed with the SEC on March 1, 2022.

AdaptHealth Corp. Overview

AdaptHealth is a national leader in providing patient-centered, healthcare-at-home solutions including home medical equipment (“HME”), medical supplies, and related services. The Company focuses primarily on providing (i) sleep therapy equipment, supplies and related services (including CPAP and bi PAP services) to individuals suffering from obstructive sleep apnea (“OSA”), (ii) medical devices and supplies to patients for the treatment of diabetes (including continuous glucose monitors and insulin pumps), (iii) home medical equipment to patients discharged from acute care and other facilities, (iv) oxygen and related chronic therapy services in the home, and (v) other HME devices and supplies on behalf of chronically ill patients with wound care, urological, incontinence, ostomy and nutritional supply needs. The Company services beneficiaries of Medicare, Medicaid and commercial insurance payors. As of September 30, 2022, AdaptHealth serviced approximately 3.9 million patients annually in all 50 states through its network of approximately 750 locations in 47 states. The Company’s principal executive offices are located at 220 West Germantown Pike, Suite 250, Plymouth Meeting, Pennsylvania 19462.

Impact of the COVID-19 Pandemic

The COVID-19 pandemic has impacted AdaptHealth’s business, as well as its patients, communities, and employees. AdaptHealth’s priorities during the COVID-19 pandemic remain protecting the health and safety of its employees (including patient-facing employees providing respiratory and other services), maximizing the availability of its services and products to support patient health needs, and maintaining the operational and financial stability of its business.

In response to the COVID-19 pandemic and the National Emergency Declaration, dated March 13, 2020, in the first quarter of 2020, AdaptHealth activated certain business interruption protocols, including acquisition and distribution of personal protective equipment (PPE) to its patient-facing employees, accelerated capital expenditures of certain products and relocation of significant portions of its workforce to “work-from-home” status. Federal, state, and local authorities have taken several actions designed to assist healthcare providers in providing care to COVID-19 and other patients and to mitigate the adverse economic impact of the COVID-19 pandemic. Legislative actions taken by the federal government include the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”), which was signed into law on March 27, 2020. Through the CARES Act, the federal government has authorized payments to be distributed to healthcare providers through the Public Health and Social Services Emergency Fund (“Provider Relief Fund” or “PRF”). Additionally, the CARES Act revised the Medicare accelerated and advance payment program in an attempt to disburse payments to healthcare providers more quickly to mitigate the financial impact on healthcare providers.

AdaptHealth increased its cash liquidity by, among other things, seeking recoupable advance payments of $45.8 million made available by CMS under the CARES Act legislation, which was received in April 2020. In addition, in connection with an acquisition completed in July 2020, AdaptHealth assumed a liability of $3.7 million relating to CMS recoupable advance payments received by the acquired company prior to the date of acquisition. The recoupment of the advance payments by CMS began in April 2021 and were applied to services provided and revenue recognized during the period in which the recoupment occurred, which impacted AdaptHealth’s cash receipts for services provided during the period in which amounts were recouped. As of September 30, 2022 the recoupment period has ended, and any remaining amounts not recouped will be repaid by AdaptHealth to CMS. As of September 30, 2022, the remaining amount of the CMS advance payments that had not yet been recouped was $3.2 million, which is included in other

44

current liabilities in the consolidated balance sheets. In addition, in April 2020, AdaptHealth received distributions of the CARES Act PRF of $17.2 million. Subsequent to April 2020, AdaptHealth completed several acquisitions in which the acquired companies received a total of $22.2 million of PRF payments prior to the applicable dates of acquisition. In connection with the accounting for these acquisitions, AdaptHealth recorded assumed liabilities of $7.7 million relating to the PRF payments received by the acquired companies. The PRF payments are targeted to offset lost revenue and expenditures incurred in connection with the COVID-19 pandemic. The PRF payments are subject to certain restrictions and are subject to recoupment if not used for designated purposes. As a condition to receiving distributions, providers were required to agree to certain terms and conditions, including, among other things, that the funds would be used for lost revenues and unreimbursed COVID-19 related expenses as defined by the U.S. Department of Health and Human Services (“HHS”). All recipients of PRF payments were required to comply with the reporting requirements described in the terms and conditions and as determined by HHS. AdaptHealth recognizes grant payments as income when there is reasonable assurance that it has complied with the conditions associated with the grant. As of December 31, 2021, AdaptHealth had recognized all of the PRF payments it has received and the liabilities assumed for PRF payments received from acquired companies as grant income, as it was determined that AdaptHealth has complied with the conditions associated with the grant. As such, there is no liability recorded in AdaptHealth’s interim consolidated financial statements relating to the PRF payments as of September 30, 2022.

HHS has indicated that the CARES Act PRF are subject to ongoing reporting and changes to the terms and conditions, and there have been several updates to such reporting requirements and terms and conditions since they were issued by HHS. Such updates have related to changes to the guidance regarding utilization of the funds granted from the PRF and updates to the reporting requirements of such funds, among other updates. To the extent that there is any future updated guidance from HHS or modifications to the terms and conditions, it may affect AdaptHealth’s ability to comply and AdaptHealth could be required to reverse the recognition of the grant income recorded and return a portion of the funds received, which could be material to AdaptHealth. AdaptHealth is continuing to monitor the terms and conditions issued by HHS. Furthermore, HHS has indicated that it will be closely monitoring and, along with the Office of Inspector General (United States) (OIG), auditing providers to ensure that recipients comply with the terms and conditions of relief programs and to prevent fraud and abuse. All providers will be subject to civil and criminal penalties for any deliberate omissions, misrepresentations or falsifications of any information given to HHS.

Also, as permitted under the CARES Act, AdaptHealth elected to defer certain portions of employer-paid FICA taxes otherwise payable from March 27, 2020 to January 1, 2021. In total, AdaptHealth deferred $8.6 million under this provision. AdaptHealth paid $4.3 million on January 4, 2022 and the remaining balance of $4.3 million is expected to be paid shortly after December 31, 2022. As of September 30, 2022, $4.3 million is included in other current liabilities in the consolidated balance sheets.

While the impact of the COVID-19 pandemic, the National Emergency Declaration and the various state and local government imposed stay-at-home restrictions did not have a material impact on AdaptHealth’s consolidated operating results initially, AdaptHealth has experienced declines in net revenue in certain services associated with elective medical procedures (such as commencement of new CPAP services and medical equipment and orthopedic supply related to facility discharges), and such declines may continue during the duration of the COVID-19 pandemic. Offsetting these declines in net revenue, AdaptHealth has experienced an increase in net revenue related to increased demand for certain respiratory products (such as oxygen), increased sales in its resupply businesses (primarily as a result of the increased ability to contact patients at home as a result of state and local government imposed stay-at-home orders) and the one-time sale of certain respiratory equipment (primarily ventilators, bi-level PAP devices and oxygen concentrators) to hospitals and local health agencies. Additionally, the suspension of Medicare sequestration (which had resulted in an approximate 2% increase in Medicare payments to all providers through March 31, 2022 and a 1% increase from April 1, 2022 through June 30, 2022), and regulatory guidance from CMS expanding telemedicine and reducing documentation requirements during the emergency period, have resulted in increased net revenues for certain products and services. However, while the emergency period has been extended, Medicare sequestration has resumed on July 1, 2022 and will result in a reduction of 2% applied to all Medicare Fee-for-Service claims.

The full extent of the impact of the COVID-19 pandemic on AdaptHealth’s business, results of operations, and financial condition is highly uncertain and will depend on future developments and numerous evolving factors that it

45

may not be able to accurately predict, and could be material to AdaptHealth’s consolidated financial statements in future reporting periods.

Impact of Inflation

Current and future inflationary effects may be driven by, among other things, general inflationary cost increases, supply chain disruptions and governmental stimulus or fiscal policies. The cost to manufacture and distribute the equipment and products that AdaptHealth provides to patients is influenced by the cost of materials, labor, and transportation, including fuel costs. AdaptHealth has recently experienced inflationary pressure and higher costs as a result of the increasing cost of materials, labor and transportation. The increase in the cost of equipment and products is due in part to a shortage in the availability of certain products, the higher cost of shipping, and general inflationary cost increases. Additionally, it is not certain that AdaptHealth will be able to pass increased costs onto customers to offset inflationary pressures. Continuing increases in inflation could impact the overall demand for AdaptHealth’s products and services, its costs for labor, equipment and products, and the margins it is able to realize on its products, all of which could have an adverse impact on AdaptHealth’s business, financial position, results of operations and cash flows. In addition, future volatility of general price inflation and the impact of inflation on costs and availability of materials, costs for shipping and warehousing and other operational overhead could adversely affect AdaptHealth’s financial results. Although there have been recent increases in inflation, AdaptHealth cannot predict whether these trends will continue. AdaptHealth’s primary mitigation efforts relating to these inflationary pressures include utilizing AdaptHealth’s purchasing power in negotiations with vendors and the increased use of technology to drive operating efficiencies and control costs, such as AdaptHealth’s digital platform for prescribing, ordering and delivery.

Key Components of Operating Results

Net Revenue. Net revenue is recorded for services that AdaptHealth provides to patients for home healthcare equipment, medical supplies to the home and related services. AdaptHealth’s primary service lines are (i) sleep therapy equipment, supplies and related services (including CPAP and bi PAP services) to individuals suffering from OSA, (ii) medical devices and supplies to patients for the treatment of diabetes (including continuous glucose monitors and insulin pumps), (iii) home medical equipment to patients discharged from acute care and other facilities, (iv) oxygen and related chronic therapy services in the home, and (v) other HME devices and supplies on behalf of chronically ill patients with wound care, urological, incontinence, ostomy and nutritional supply needs. Revenues are recorded either (x) at a point in time for the sale of supplies and disposables, or (y) over the service period for equipment rental (including, but not limited to, CPAP machines, hospital beds, wheelchairs and other equipment), at amounts estimated to be received from patients or under reimbursement arrangements with Medicare, Medicaid and other third-party payors, including private insurers. Certain trends or uncertainties that may have a material impact on revenue growth and operating results include the Company’s ability to obtain new patient starts and to generate referrals from patient referral sources and the ability to meet the increased demand considering supply chain issues and inflationary pressures.

Cost of Net Revenue. Cost of net revenue primarily includes the cost of non-capitalized medical equipment and supplies, distribution expenses, labor costs, facilities rental costs, revenue cycle management costs and depreciation for capitalized patient equipment. Distribution expenses represent the cost incurred to coordinate and deliver products and services to the patients. Included in distribution expenses are leasing, maintenance, licensing and fuel costs for the vehicle fleet; salaries, benefits and other costs related to drivers and dispatch personnel; and amounts paid to couriers.

General and Administrative Expenses. General and administrative expenses consist of corporate support costs including information technology, human resources, finance, contracting, legal, compliance, equity-based compensation, transaction expenses and other administrative costs.

Depreciation and Amortization, Excluding Patient Equipment Depreciation. Depreciation expense includes depreciation charges for capital assets other than patient equipment (which is included as part of the cost of net revenue). Amortization expense includes amortization of identifiable intangible assets.

Factors Affecting AdaptHealth’s Operating Results

46

AdaptHealth’s operating results and financial performance are influenced by certain unique events during the periods discussed herein, including the following:

Acquisitions

AdaptHealth accounts for its acquisitions in accordance with Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 805, Business Combinations, and the operations of the acquired entities are included in the historical results of AdaptHealth for the periods following the closing of the acquisition. Refer to Note 3, Acquisitions, included in our interim consolidated financial statements for the three and nine months ended September 30, 2022 included in this Quarterly Report on Form 10-Q for additional information regarding AdaptHealth’s acquisitions.

Debt

In August 2021, AdaptHealth issued $600.0 million aggregate principal amount of 5.125% senior unsecured notes due 2030 (the “5.125% Senior Notes”). The 5.125% Senior Notes will mature on March 1, 2030. Interest on the 5.125% Senior Notes is payable on March 1st and September 1st of each year, beginning on March 1, 2022. Refer to the section below, titled Liquidity and Capital Resources, for additional discussion related to AdaptHealth’s senior unsecured notes.

In January 2021, AdaptHealth refinanced its debt borrowings and entered into a new credit agreement with its existing bank group, which was subsequently amended in April 2021 (the “2021 Credit Agreement”). Refer to the section below, titled Liquidity and Capital Resources, for additional discussion related to the 2021 Credit Agreement.

In March 2019, AdaptHealth entered into a Note and Unit Purchase Agreement with an investor. Pursuant to the agreement, AdaptHealth issued a promissory note with a principal amount of $100 million (the Promissory Note). In November 2019, the Promissory Note was replaced with a new amended and restated promissory note with a principal amount of $100 million, and the investor converted certain of its equity interests to a $43.5 million promissory note. The new $100 million promissory note, together with the $43.5 million promissory note, are collectively referred to herein as the New Promissory Note. In June 2021, AdaptHealth repaid $71.8 million of the outstanding principal balance under the New Promissory Note. In August 2021, AdaptHealth repaid the remaining outstanding principal balance of $71.7 million under the New Promissory Note. The outstanding principal balance under the New Promissory Note bore interest at 12%.

Seasonality

AdaptHealth’s business experiences some seasonality. Its patients are generally responsible for a greater percentage of the cost of their treatment or therapy during the early months of the year due to co-insurance, co-payments and deductibles, and therefore may defer treatment and services of certain therapies until meeting their annual deductibles. In addition, changes to employer insurance coverage often go into effect at the beginning of each calendar year which may impact eligibility requirements and delay or defer treatment. Also, net revenue generated by the Company’s diabetes product line is typically higher in the fourth quarter compared to the earlier part of the year due to the timing of when patients meet their annual deductibles and their associated reordering patterns. These factors may lead to lower net revenue and cash flow in the early part of the year versus the latter half of the year. Additionally, the increased incidence of respiratory infections during the winter season may result in initiation of additional respiratory services such as oxygen therapy for certain patient populations. AdaptHealth’s quarterly operating results may fluctuate significantly in the future depending on these and other factors.

Key Business Metrics

AdaptHealth focuses on net revenue, EBITDA and Adjusted EBITDA as it reviews its performance. Total net revenue is comprised of net sales revenue and net revenue from fixed monthly equipment reimbursements less implicit price concessions. Net sales revenue consists of revenue recognized at a point in time for the sale of supplies and disposables. Net revenue from fixed monthly equipment reimbursements consists of revenue recognized over the service

47

period for equipment (including, but not limited to, CPAP machines, oxygen concentrators, ventilators, hospital beds, wheelchairs and other equipment).

	Three Months Ended
	September 30, 2022				September 30, 2021
Net Revenue			Revenue				Revenue
(dollars in thousands)	Dollars		Percentage		Dollars		Percentage
	(Unaudited)
Net sales revenue:
Sleep	$	198,206	26.2	%	$	173,359	26.5	%
Diabetes		169,075	22.3	%		134,228	20.5	%
Supplies to the home		47,793	6.3	%		42,441	6.5	%
Respiratory		9,734	1.3	%		6,228	1.0	%
HME		29,463	3.9	%		29,919	4.6	%
Other		58,252	7.7	%		45,996	7.0	%
Total net sales revenue	$	512,523	67.7	%	$	432,171	66.1	%
Net revenue from fixed monthly equipment reimbursements:
Sleep	$	72,423	9.6	%	$	62,755	9.7	%
Diabetes		4,211	0.6	%		3,722	0.6	%
Respiratory		130,618	17.3	%		117,918	18.0	%
HME		25,482	3.4	%		26,043	4.0	%
Other		11,238	1.4	%		10,684	1.6	%
Total net revenue from fixed monthly equipment reimbursements	$	243,972	32.3	%	$	221,122	33.9	%
Total net revenue:
Sleep	$	270,629	35.8	%	$	236,114	36.2	%
Diabetes		173,286	22.9	%		137,950	21.1	%
Supplies to the home		47,793	6.3	%		42,441	6.5	%
Respiratory		140,352	18.6	%		124,146	19.0	%
HME		54,945	7.3	%		55,962	8.6	%
Other		69,490	9.1	%		56,680	8.6	%
Total net revenue	$	756,495	100.0	%	$	653,293	100.0	%

	Nine Months Ended
	September 30, 2022				September 30, 2021
Net Revenue			Revenue				Revenue
(dollars in thousands)	Dollars		Percentage		Dollars		Percentage
	(Unaudited)
Net sales revenue:
Sleep	$	585,234	26.7	%	$	465,372	26.6	%
Diabetes		482,693	22.0	%		352,559	20.1	%
Supplies to the home		131,539	6.0	%		126,479	7.2	%
Respiratory		25,770	1.2	%		25,003	1.4	%
HME		89,828	4.1	%		82,588	4.7	%
Other		166,068	7.6	%		98,032	5.6	%
Total net sales revenue	$	1,481,132	67.6	%	$	1,150,033	65.6	%
Net revenue from fixed monthly equipment reimbursements:
Sleep	$	196,022	8.9	%	$	177,199	10.1	%
Diabetes		12,191	0.6	%		9,791	0.6	%
Respiratory		392,063	17.9	%		312,900	17.9	%
HME		76,754	3.5	%		70,854	4.0	%
Other		32,150	1.5	%		31,652	1.8	%
Total net revenue from fixed monthly equipment reimbursements	$	709,180	32.4	%	$	602,396	34.4	%

48

Total net revenue:
Sleep	$	781,256	35.6	%	$	642,571	36.7	%
Diabetes		494,884	22.6	%		362,350	20.7	%
Supplies to the home		131,539	6.0	%		126,479	7.2	%
Respiratory		417,833	19.1	%		337,903	19.3	%
HME		166,582	7.6	%		153,442	8.7	%
Other		198,218	9.1	%		129,684	7.4	%
Total net revenue	$	2,190,312	100.0	%	$	1,752,429	100.0	%

Certain prior period amounts in the tables above have been reclassified to conform to the current period presentation. These reclassifications are considered immaterial to all periods presented.

Results of Operations

Comparison of Three Months Ended September 30, 2022 and Three Months Ended September 30, 2021.

The following table summarizes AdaptHealth’s consolidated results of operations for the three months ended September 30, 2022 and 2021:

	Three Months Ended September 30,
	2022				2021
			Revenue				Revenue		Increase/(Decrease)
(in thousands, except percentages)	Dollars		Percentage		Dollars		Percentage		Dollars		Percentage
	(unaudited)
Net revenue	$	756,495	100.0	%	$	653,293	100.0	%	$	103,202	15.8	%
Costs and expenses:
Cost of net revenue		646,714	85.5	%		529,887	81.1	%		116,827	22.0	%
General and administrative expenses		40,681	5.4	%		33,006	5.1	%		7,675	23.3	%
Depreciation and amortization, excluding patient equipment depreciation		16,151	2.1	%		14,690	2.2	%		1,461	9.9	%
Total costs and expenses		703,546	93.0	%		577,583	88.4	%		125,963	21.8	%
Operating income		52,949	7.0	%		75,710	11.6	%		(22,761)	(30.1)	%
Interest expense, net		28,521	3.8	%		24,252	3.7	%		4,269	17.6	%
Change in fair value of warrant liability		1,364	0.2	%		(16,737)	(2.6)	%		18,101	NM	%
Change in fair value of contingent consideration common shares liability		—	—	%		(10,006)	(1.5)	%		10,006	NM	%
Loss on extinguishment of debt		—	—	%		8,240	1.3	%		(8,240)	NM	%
Other loss (income), net		257	—	%		(452)	(0.1)	%		709	NM	%
Income before income taxes		22,807	3.0	%		70,413	10.8	%		(47,606)	(67.6)	%
Income tax expense		5,580	0.7	%		12,147	1.9	%		(6,567)	NM	%
Net income		17,227	2.3	%		58,266	8.9	%		(41,039)	(70.4)	%
Income attributable to noncontrolling interest		1,105	0.1	%		174	—	%		931	NM	%
Net income attributable to AdaptHealth Corp.	$	16,122	2.2	%	$	58,092	8.9	%	$	(41,970)	(72.2)	%

49

Net Revenue. Net revenue for the three months ended September 30, 2022 and 2021 was $756.5 million and $653.3 million, respectively, an increase of $103.2 million or 15.8%. The increase in net revenue was driven primarily by acquisitions completed after July 1, 2021, which increased net revenue by $63.2 million. The increase in net revenue from non-acquired businesses was $39.6 million. Additionally, net revenue during the three months ended September 30, 2022 and 2021 was impacted by a recall of certain ventilator, BiPAP, and CPAP devices supplied to AdaptHealth by Philips Respironics (Philips). On June 14, 2021, AdaptHealth received notice from Philips that these devices would be included in a Philips voluntary recall due to potential health risks to patients. Currently, it is not possible to purchase these products from Philips, which has led to shortages in the supply chain, and other suppliers are unable to meet the strong patient demand for these products, which has materially affected AdaptHealth’s ability to service patient demand for these devices during the three months ended September 30, 2022.

For the three months ended September 30, 2022, net sales revenue (recognized at a point in time) comprised 68% of total net revenue, compared to 66% of total net revenue for the three months ended September 30, 2021. For the three months ended September 30, 2022, net revenue from fixed monthly equipment reimbursements comprised 32% of total net revenue, compared to 34% of total net revenue for the three months ended September 30, 2021.

Cost of Net Revenue.

The following table summarizes cost of net revenue for the three months ended September 30, 2022 and 2021:

	Three Months Ended September 30,
	2022				2021
			Revenue				Revenue		Increase/(Decrease)
(in thousands, except percentages)	Dollars		Percentage		Dollars		Percentage		Dollars		Percentage
	(unaudited)
Cost of products and supplies	$	299,532	39.6	%	$	246,459	37.7	%	$	53,073	21.5	%
Salaries, labor and benefits		195,669	25.9	%		160,363	24.5	%		35,306	22.0	%
Patient equipment depreciation		76,180	10.1	%		55,152	8.4	%		21,028	38.1	%
Other operating expenses		56,965	7.5	%		52,908	8.2	%		4,057	7.7	%
Rent and occupancy		16,789	2.2	%		13,068	2.0	%		3,721	28.5	%
Equity-based compensation		1,579	0.2	%		1,937	0.3	%		(358)	(18.5)	%
Total cost of net revenue	$	646,714	85.5	%	$	529,887	81.1	%	$	116,827	22.0	%

Cost of net revenue for the three months ended September 30, 2022 and 2021 was $646.7 million and $529.9 million, respectively, an increase of $116.8 million or 22.0%. Costs of products and supplies increased by $53.1 million primarily as a result of acquisition growth, increased product costs, increased net sales revenue, and general inflationary cost increases. Salaries, labor and benefits increased by $35.3 million, primarily related to acquisition growth, increased headcount, higher wages and commissions, and workforce wage pressure driven by inflation. The increase in rent and occupancy and other operating expenses is primarily related to acquisition growth and general inflationary cost increases. The increase in other operating expenses includes increased shipping costs, including fuel costs which have increased by $1.1 million for the three months ended September 30, 2022 compared to the three months ended September 30, 2021.

Cost of net revenue was 85.5% of net revenue for the three months ended September 30, 2022 compared to 81.1% for the three months ended September 30, 2021. The cost of products and supplies was 39.6% of net revenue in the 2022 period compared to 37.7% in the 2021 period. Salaries, labor and benefits was 25.9% of net revenue in the 2022 period compared to 24.5% in the 2021 period. Patient equipment depreciation was 10.1% of net revenue in the 2022 period compared to 8.4% in the 2021 period, primarily as a result of a change in product mix.

General and Administrative Expenses. General and administrative expenses for the three months ended September 30, 2022 and 2021 were $40.7 million and $33.0 million, respectively, an increase of $7.7 million or 23.3%. This increase is primarily due to higher professional fees including legal, accounting, information-technology, and

50

consulting expenses associated with systems implementation activities and post-implementation support services, offset by lower transaction costs as there was less acquisition activity in the third quarter of 2022 compared to the prior period. General and administrative expenses as a percentage of net revenue was 5.4% in the 2022 period, compared to 5.1% in the 2021 period. General and administrative expenses in the 2022 period included $1.2 million of transaction costs, $4.0 million of equity-based compensation expense, and other non-recurring expenses of $8.5 million. General and administrative expenses in the 2021 period included $4.3 million of transaction costs, $3.4 million of equity-based compensation expense, and other non-recurring expenses of $0.2 million. Excluding the impact of these charges, general and administrative expenses as a percentage of net revenue was 3.6% and 3.8% in the 2022 period and the 2021 period, respectively.

Depreciation and amortization, excluding patient equipment depreciation. Depreciation and amortization, excluding patient equipment depreciation, for the three months ended September 30, 2022 and 2021 was $16.2 million and $14.7 million, respectively, an increase of $1.5 million. The increase was primarily related to higher depreciation expense associated with fixed assets excluding patient equipment.

Interest Expense. Interest expense for the three months ended September 30, 2022 and 2021 was $28.5 million and $24.3 million, respectively. Interest expense related to long-term debt was higher in the 2022 period compared to the 2021 period as a result of higher long-term debt borrowings outstanding during that period and higher interest rates. Such borrowings were primarily used to fund acquisitions.

Change in Fair Value of Warrant Liability. AdaptHealth has outstanding warrants to purchase shares of Common Stock, as discussed in Note 10, Stockholders’ Equity, to the accompanying September 30, 2022 interim consolidated financial statements. These warrants are liability-classified, and the change in fair value of the warrant liability represents a non-cash charge in the 2022 period and a non-cash gain in the 2021 period for the change in the estimated fair value of such liability during the respective periods.

Change in Fair Value of Contingent Consideration Common Shares Liability. In connection with the Business Combination, certain former owners of AdaptHealth Holdings are entitled to contingent consideration common shares, as discussed in Note 10, Stockholders’ Equity, to the accompanying September 30, 2022 interim consolidated financial statements. These shares were liability-classified through December 31, 2021, and the change in fair value of the contingent consideration common shares liability represents a non-cash gain in the 2021 period for the change in the estimated fair value of such liability during the period.

Loss on Extinguishment of Debt. Loss on extinguishment of debt for the three months ended September 30, 2021 consisted of a debt prepayment penalty in connection with the prepayment of the remaining outstanding balance of AdaptHealth’s note payable and the write-off of the associated unamortized deferred financing costs.

Other Loss (Income), net. Other loss, net for the three months ended September 30, 2022 consisted of $0.2 million of expenses associated with legal settlements and $0.1 million of other net charges. Other income, net for the three months ended September 30, 2021 consisted of $0.6 million of expenses associated with lease terminations, a $0.9 million charge for the increase in the fair value of contingent consideration liabilities related to acquisitions, offset by a $1.9 million gain in connection with the consolidation of an equity method investment.

Income Tax Expense. Income tax expense for the three months ended September 30, 2022 and 2021 was $5.6 million and $12.1 million, respectively. The decrease in income tax expense was primarily related to lower pre-tax income.

Comparison of Nine Months Ended September 30, 2022 and Nine Months Ended September 30, 2021.

The following table summarizes AdaptHealth’s consolidated results of operations for the nine months ended September 30, 2022 and 2021:
​

51

	Nine Months Ended September 30,
	2022				2021
			Revenue				Revenue		Increase/(Decrease)
(in thousands, except percentages)	Dollars		Percentage		Dollars		Percentage		Dollars		Percentage
	(unaudited)
Net revenue	$	2,190,312	100.0	%	$	1,752,429	100.0	%	$	437,883	25.0	%
Costs and expenses:
Cost of net revenue		1,853,847	84.6	%		1,417,305	80.9	%		436,542	30.8	%
General and administrative expenses		124,673	5.7	%		132,584	7.6	%		(7,911)	(6.0)	%
Depreciation and amortization, excluding patient equipment depreciation		48,113	2.2	%		46,014	2.6	%		2,099	4.6	%
Total costs and expenses		2,026,633	92.5	%		1,595,903	91.1	%		430,730	27.0	%
Operating income		163,679	7.5	%		156,526	8.9	%		7,153	4.6	%
Interest expense, net		78,905	3.6	%		69,584	4.0	%		9,321	13.4	%
Change in fair value of warrant liability		(17,145)	(0.8)	%		(57,359)	(3.3)	%		40,214	NM	%
Change in fair value of contingent consideration common shares liability		—	—	%		(34,050)	(1.9)	%		34,050	NM	%
Loss on extinguishment of debt		—	—	%		20,189	1.2	%		(20,189)	NM	%
Other loss, net		7,179	0.3	%		698	—	%		6,481	NM	%
Income before income taxes		94,740	4.4	%		157,464	8.9	%		(62,724)	(39.8)	%
Income tax expense		20,036	0.9	%		22,782	1.3	%		(2,746)	NM	%
Net income		74,704	3.5	%		134,682	7.6	%		(59,978)	(44.5)	%
Income attributable to noncontrolling interest		2,800	0.1	%		1,449	0.1	%		1,351	NM	%
Net income attributable to AdaptHealth Corp.	$	71,904	3.4	%	$	133,233	7.5	%	$	(61,329)	(46.0)	%

Net Revenue. Net revenue for the nine months ended September 30, 2022 and 2021 was $2,190.3 million and $1,752.4 million, respectively, an increase of $437.9 million or 25.0%. Net revenue for the 2022 and 2021 periods included $0.4 million and $10.2 million, respectively, from referral partners and healthcare facilities in support of their urgent needs as the coronavirus pandemic led to an increased demand for respiratory equipment including ventilators and oxygen concentrators. Excluding this revenue, net revenue was $2,189.9 million and $1,742.2 million for the nine months ended September 30, 2022 and 2021, respectively, an increase of $447.7 million. The increase in net revenue was driven primarily by acquisitions completed after January 1, 2021, which increased net revenue by $412.1 million. The increase in net revenue from non-acquired businesses was $35.6 million. Additionally, net revenue during the nine months ended September 30, 2022, and to a lesser extent during the nine months ended September 30, 2021, was impacted by a recall of certain ventilator, BiPAP, and CPAP devices supplied to AdaptHealth by Philips Respironics (Philips). On June 14, 2021, AdaptHealth received notice from Philips that these devices would be included in a Philips voluntary recall due to potential health risks to patients. Currently, it is not possible to purchase these products from Philips, which has led to shortages in the supply chain, and other suppliers are unable to meet the strong patient demand for these products, which has materially affected AdaptHealth’s ability to service patient demand for these devices during the nine months ended September 30, 2022.

52

For the nine months ended September 30, 2022, net sales revenue (recognized at a point in time) comprised 68% of total net revenue, compared to 66% of total net revenue for the nine months ended September 30, 2021. For the nine months ended September 30, 2022, net revenue from fixed monthly equipment reimbursements comprised 32% of total net revenue, compared to 34% of total net revenue for the nine months ended September 30, 2021.

Cost of Net Revenue.

The following table summarizes cost of net revenue for the nine months ended September 30, 2022 and 2021:

	Nine Months Ended September 30,
	2022				2021
			Revenue				Revenue		Increase/(Decrease)
(in thousands, except percentages)	Dollars		Percentage		Dollars		Percentage		Dollars		Percentage
	(unaudited)
Cost of products and supplies	$	871,072	39.8	%	$	667,027	38.1	%	$	204,045	30.6	%
Salaries, labor and benefits		557,898	25.5	%		427,065	24.3	%		130,833	30.6	%
Patient equipment depreciation		200,722	9.2	%		134,813	7.7	%		65,909	48.9	%
Other operating expenses		171,904	7.8	%		146,014	8.4	%		25,890	17.7	%
Rent and occupancy		46,978	2.1	%		35,517	2.0	%		11,461	32.3	%
Equity-based compensation		5,273	0.2	%		6,869	0.4	%		(1,596)	(23.2)	%
Total cost of net revenue	$	1,853,847	84.6	%	$	1,417,305	80.9	%	$	436,542	30.8	%

Cost of net revenue for the nine months ended September 30, 2022 and 2021 was $1,853.8 million and $1,417.3 million, respectively, an increase of $436.5 million or 30.8%. Costs of products and supplies increased by $204.0 million primarily as a result of acquisition growth, increased product costs, increased net sales revenue, and general inflationary cost increases. Salaries, labor and benefits increased by $130.8 million, primarily related to acquisition growth, increased headcount, higher wages and commissions, and workforce wage pressure driven by inflation. The increase in rent and occupancy and other operating expenses is primarily related to acquisition growth and general inflationary cost increases. The increase in other operating expenses includes increased shipping costs, including fuel costs which have increased by $2.8 million for the nine months ended September 30, 2022 compared to the nine months ended September 30, 2021.

Cost of net revenue was 84.6% of net revenue for the nine months ended September 30, 2022 compared to 80.9% for the nine months ended September 30, 2021. The cost of products and supplies was 39.8% of net revenue in the 2022 period compared to 38.1% in the 2021 period. Salaries, labor and benefits was 25.5% of net revenue in the 2022 period compared to 24.3% in the 2021 period. Patient equipment depreciation was 9.2% of net revenue in the 2022 period compared to 7.7% in the 2021 period, primarily as a result of a change in product mix.

General and Administrative Expenses. General and administrative expenses for the nine months ended September 30, 2022 and 2021 were $124.7 million and $132.6 million, respectively, a decrease of $7.9 million or 6.0%. This decrease is primarily due to lower transaction costs as there was less acquisition activity in the 2022 period compared to the 2021 period and lower equity-based compensation expense, offset by higher professional fees including legal, accounting, information-technology, and consulting expenses associated with systems implementation activities and post-implementation support services, and higher labor costs associated with increased headcount and higher wages. General and administrative expenses as a percentage of net revenue was 5.7% in the 2022 period, compared to 7.6% in the 2021 period. General and administrative expenses in the 2022 period included $5.8 million of transaction costs, $11.5 million of equity-based compensation expense, and other non-recurring expenses of $11.9 million. General and administrative expenses in the 2021 period included $43.7 million of transaction costs, $14.5 million of equity-based

53

compensation expense, and other non-recurring expenses of $1.3 million. Excluding the impact of these charges, general and administrative expenses as a percentage of net revenue was 4.4% and 4.2% in the 2022 period and the 2021 period, respectively.

Depreciation and amortization, excluding patient equipment depreciation. Depreciation and amortization, excluding patient equipment depreciation, for the nine months ended September 30, 2022 and 2021 was $48.1 million and $46.0 million, respectively, an increase of $2.1 million. The increase was primarily related to higher depreciation expense associated with fixed assets excluding patient equipment, offset by lower amortization of intangible assets.

Interest Expense. Interest expense for the nine months ended September 30, 2022 and 2021 was $78.9 million and $69.6 million, respectively. Interest expense related to long-term debt was higher in 2022 compared to 2021 as a result of higher long-term debt borrowings outstanding during that period and higher interest rates. Such borrowings were primarily used to fund acquisitions.

Change in Fair Value of Warrant Liability. AdaptHealth has outstanding warrants to purchase shares of Common Stock, as discussed in Note 10, Stockholders’ Equity, to the accompanying September 30, 2022 interim consolidated financial statements. These warrants are liability-classified, and the change in fair value of the warrant liability represents a non-cash gain in the 2022 and 2021 periods for the change in the estimated fair value of such liability during the respective periods.

Change in Fair Value of Contingent Consideration Common Shares Liability. In connection with the Business Combination, certain former owners of AdaptHealth Holdings are entitled to contingent consideration common shares, as discussed in Note 10, Stockholders’ Equity, to the accompanying September 30, 2022 interim consolidated financial statements. These shares were liability-classified through December 31, 2021, and the change in fair value of the contingent consideration common shares liability represents a non-cash gain in the 2021 period for the change in the estimated fair value of such liability during the period.

Loss on Extinguishment of Debt. Loss on extinguishment of debt for the nine months ended September 30, 2021 consisted of the write-off of unamortized deferred financing costs and other expenses related to AdaptHealth refinancing its credit facility in January 2021 and amending such agreement in April 2021, and also includes a debt prepayment penalty in connection with the prepayment of the outstanding balance of AdaptHealth’s note payable and the write-off of the associated unamortized deferred financing costs.

Other Loss (Income), net. Other loss, net for the nine months ended September 30, 2022 consisted of a $4.5 million expense related to changes in AdaptHealth’s estimated TRA liability, $1.2 million of expenses associated with legal settlements, $0.8 million loss related to the write-off of an investment, and $0.7 million of expenses associated with lease terminations. Other loss, net for the nine months ended September 30, 2021 consisted of $0.9 million of expenses associated with legal settlements, $1.6 million of expenses associated with lease terminations, and a $1.1 million charge for the increase in the fair value of contingent consideration liabilities related to acquisitions, offset by $0.5 million of equity income related to equity method investments, a gain of $0.5 million for the receipt of earnout proceeds in connection with an investment that was sold in 2020, and a $1.9 million gain in connection with the consolidation of an equity method investment.

Income Tax Expense. Income tax expense for the nine months ended September 30, 2022 and 2021 was $20.0 million and $22.8 million, respectively. The decrease in income tax expense was primarily related to lower pre-tax income.

EBITDA and Adjusted EBITDA

AdaptHealth uses EBITDA and Adjusted EBITDA, which are financial measures that are not prepared in accordance with generally accepted accounting principles in the United States, or U.S. GAAP, to analyze its financial results and believes that they are useful to investors, as a supplement to U.S. GAAP measures. In addition, AdaptHealth’s ability to incur additional indebtedness and make investments under its existing credit agreement is governed, in part, by its ability to satisfy tests based on a variation of Adjusted EBITDA.

54

AdaptHealth defines EBITDA as net income (loss) attributable to AdaptHealth Corp., plus net income (loss) attributable to noncontrolling interests, interest expense, net, income tax expense (benefit), and depreciation and amortization.

AdaptHealth defines Adjusted EBITDA as EBITDA (as defined above), plus loss on extinguishment of debt, equity‑based compensation expense, transaction costs, change in fair value of the contingent consideration common shares liability, change in fair value of the warrant liability, and other non-recurring items of expense or income.

AdaptHealth believes Adjusted EBITDA is useful to investors in evaluating AdaptHealth’s financial performance. AdaptHealth uses this metric as the profitability measure in its incentive compensation plans that have a profitability component and to evaluate acquisition opportunities, where it is most often used for purposes of contingent consideration arrangements.

EBITDA and Adjusted EBITDA should not be considered as measures of financial performance under U.S. GAAP, and the items excluded from EBITDA and Adjusted EBITDA are significant components in understanding and assessing financial performance. Accordingly, these key business metrics have limitations as an analytical tool. They should not be considered as an alternative to net income or any other performance measures derived in accordance with U.S. GAAP or as an alternative to cash flows from operating activities as a measure of AdaptHealth’s liquidity.

The following unaudited table presents the reconciliation of net income attributable to AdaptHealth to EBITDA and Adjusted EBITDA for the three and nine months ended September 30, 2022 and 2021:

	Three Months Ended September 30,				Nine Months Ended September 30,
(in thousands)	2022		2021		2022		2021
		(Unaudited)
Net income attributable to AdaptHealth Corp.	$	16,122	$	58,092	$	71,904	$	133,233
Income attributable to noncontrolling interest		1,105		174		2,800		1,449
Interest expense, net		28,521		24,252		78,905		69,584
Income tax expense		5,580		12,147		20,036		22,782
Depreciation and amortization, including patient equipment depreciation		92,331		69,828		248,835		180,827
EBITDA		143,659		164,493		422,480		407,875
Loss on extinguishment of debt (a)		—		8,240		—		20,189
Equity-based compensation expense (b)		5,562		5,365		16,784		21,394
Transaction costs (c)		519		4,616		5,832		44,570
Change in fair value of warrant liability (d)		1,364		(16,737)		(17,145)		(57,359)
Change in fair value of contingent consideration common shares liability (e)		—		(10,006)		—		(34,050)
Other non-recurring expense, net (f)		9,059		303		19,863		5,221
Adjusted EBITDA	$	160,163	$	156,274	$	447,814	$	407,840

(a) Represents the write-off of unamortized deferred financing costs and other expenses related to refinancing of debt and prepayment penalties for early debt payoff.

(b) Represents equity-based compensation expense for awards granted to employees and non-employee directors.

55

(c) Represents transaction costs and expenses related to integration efforts related to acquisitions.

(d) Represents a non-cash charge or gain for the change in the estimated fair value of the warrant liability. Refer to Note 10, Stockholders’ Equity, included in the accompanying notes to the interim consolidated financial statements for the three and nine months ended September 30, 2022 for additional discussion of such non-cash charge or gain.

(e) Represents a non-cash gain for the change in the estimated fair value of the contingent consideration common shares liability. Refer to Note 10, Stockholders’ Equity, included in the accompanying notes to the interim consolidated financial statements for the three and nine months ended September 30, 2022 for additional discussion of such non-cash gain.

(f) The 2022 year-to-date period consists of $9.0 million of consulting expenses associated with systems implementation activities and post-implementation support services, a $4.5 million expense related to changes in AdaptHealth’s estimated TRA liability, $3.8 million of expenses associated with litigation, claims and settlements, $0.7 million of expenses associated with lease terminations, a $0.8 million loss related to the write-off of an investment, and $1.1 million of net other non-recurring expenses. The 2021 year-to-date period consists of $1.9 million of expenses related to legal and other costs associated with the separation of the Company’s former Co-CEO, $0.9 million of expenses associated with litigation, claims and settlements, $1.6 million of expenses associated with lease terminations, and $0.8 million of net other non-recurring charges.

Liquidity and Capital Resources

AdaptHealth’s principal sources of liquidity are its operating cash flows, borrowings under its credit agreements and other debt arrangements, and proceeds from equity issuances. AdaptHealth has used these funds to meet its capital requirements, which primarily consist of salaries, labor, benefits and other employee-related costs, product and supply costs, third-party customer service, billing and collections and logistics costs, capital expenditures including patient equipment, acquisitions and debt service, and to fund share repurchases. AdaptHealth’s future capital expenditure requirements will depend on many factors, including its patient volume and revenue growth rates.

AdaptHealth’s capital expenditures are made in advance of patients beginning service. Certain operating costs are incurred at the beginning of the equipment service period and during initial patient set up.

AdaptHealth believes that its expected operating cash flows, together with its existing cash, cash equivalents, and amounts available under its existing credit agreement, will continue to be sufficient to fund its operations and growth strategies for at least the next twelve months.

AdaptHealth may seek additional equity or debt financing in connection with the growth of its business, primarily for acquisitions. In addition, the COVID-19 pandemic may cause disruption in the capital markets, which could make financing more difficult and/or expensive. In the event that additional financing is required from outside sources, AdaptHealth may not be able to raise it on acceptable terms or at all. If additional capital is unavailable when desired, AdaptHealth’s business, results of operations, and financial condition would be materially and adversely affected.

As of September 30, 2022, AdaptHealth had approximately $110.7 million of cash and cash equivalents. To supplement its cash liquidity, in April 2020, AdaptHealth received recoupable advance payments of $45.8 million, which were made available by CMS under the CARES Act. In addition, in connection with an acquisition completed in July 2020, AdaptHealth assumed a liability of $3.7 million relating to CMS recoupable advance payments received by the acquired company prior to the date of acquisition. The recoupment of the advance payments by CMS began in April 2021 and were applied to services provided and revenue recognized during the period in which the recoupment occurred, which impacted AdaptHealth’s cash receipts for services provided during the period in which amounts were recouped. As of September 30, 2022 the recoupment period has ended, and any remaining amounts not recouped will be repaid by AdaptHealth to CMS. As of September 30, 2022, the remaining amount of the CMS advance payments that had not yet been recouped was $3.2 million, which is included in other current liabilities in the consolidated balance sheets. In

56

addition, in April 2020, AdaptHealth received distributions of the CARES Act PRF of $17.2 million. Subsequent to April 2020, AdaptHealth completed several acquisitions in which the acquired companies received a total of $22.2 million of PRF payments prior to the applicable dates of acquisition. In connection with the accounting for these acquisitions, AdaptHealth recorded assumed liabilities of $7.7 million relating to the PRF payments received by the acquired companies. The PRF payments are targeted to offset lost revenue and expenditures incurred in connection with the COVID-19 pandemic. The PRF payments are subject to certain restrictions and are subject to recoupment if not used for designated purposes. As a condition to receiving distributions, providers were required to agree to certain terms and conditions, including, among other things, that the funds would be used for lost revenues and unreimbursed COVID-19 related expenses as defined by the U.S. Department of Health and Human Services (“HHS”). All recipients of PRF payments were required to comply with the reporting requirements described in the terms and conditions and as determined by HHS. AdaptHealth recognizes grant payments as income when there is reasonable assurance that it has complied with the conditions associated with the grant. As of December 31, 2021, AdaptHealth has recognized all of the PRF payments it has received and the liabilities assumed for PRF payments received from acquired companies as grant income, as it was determined that AdaptHealth has complied with the conditions associated with the grant. As such, there is no liability recorded in AdaptHealth’s interim consolidated financial statements relating to the PRF payments as of September 30, 2022.

HHS has indicated that the CARES Act PRF are subject to ongoing reporting and changes to the terms and conditions, and there have been several updates to such reporting requirements and terms and conditions since they were issued by HHS. Such updates have related to changes to the guidance regarding utilization of the funds granted from the PRF and updates to the reporting requirements of such funds, among other updates. To the extent that there is any future updated guidance from HHS or modifications to the terms and conditions, it may affect AdaptHealth’s ability to comply and AdaptHealth could be required to reverse the recognition of the grant income recorded and return a portion of the funds received, which could be material to AdaptHealth. AdaptHealth is continuing to monitor the terms and conditions issued by HHS. Furthermore, HHS has indicated that it will be closely monitoring and, along with the Office of Inspector General (United States) (OIG), auditing providers to ensure that recipients comply with the terms and conditions of relief programs and to prevent fraud and abuse. All providers will be subject to civil and criminal penalties for any deliberate omissions, misrepresentations or falsifications of any information given to HHS.

Also, as permitted under the CARES Act, AdaptHealth elected to defer certain portions of employer-paid FICA taxes otherwise payable from March 27, 2020 to January 1, 2021. In total, AdaptHealth deferred $8.6 million under this provision. AdaptHealth paid $4.3 million on January 4, 2022 and the remaining balance of $4.3 million is expected to be paid shortly after December 31, 2022. As of September 30, 2022, $4.3 million is included in other current liabilities in the consolidated balance sheets.

At September 30, 2022, AdaptHealth had $770.0 million outstanding under its existing credit facility. In January 2021, AdaptHealth refinanced its debt borrowings and entered into a new credit agreement, which was subsequently amended in April 2021 (the “2021 Credit Agreement”). The 2021 Credit Agreement consists of a $800 million term loan (the “2021 Term Loan”) and $450 million in commitments for revolving credit loans with a $55 million letter of credit sublimit (the “2021 Revolver”), both with maturities in January 2026. The borrowing under the 2021 Term Loan requires quarterly principal repayments of $5.0 million beginning June 30, 2021 through March 31, 2023, increasing to $10.0 million beginning June 30, 2023 through December 31, 2025, and the unpaid principal balance is due at maturity in January 2026. Borrowings under the 2021 Revolver may be used for working capital and other general corporate purposes, including for capital expenditures and acquisitions permitted under the 2021 Credit Agreement. As of September 30, 2022, and the date of this filing, there were no outstanding borrowings under the 2021 Revolver. Amounts borrowed under the 2021 Credit Agreement bear interest quarterly at variable rates based upon the sum of (a) the Adjusted LIBOR Rate (subject to a zero percent floor) equal to the LIBOR (as defined) for the applicable interest period multiplied by the statutory reserve rate, plus (b) an applicable margin (as defined) ranging from 1.50% to 3.25% per annum based on the Consolidated Senior Secured Leverage Ratio (as defined). The 2021 Revolver carries a commitment fee during the term of the 2021 Credit Agreement ranging from 0.25% to 0.50% per annum of the actual daily undrawn portion of the 2021 Revolver based on the Consolidated Senior Secured Leverage Ratio.

Under the 2021 Credit Agreement, AdaptHealth is subject to a number of restrictive covenants that, among other things, impose operating and financial restrictions on AdaptHealth. Financial covenants include a Consolidated

57

Total Leverage Ratio and a Consolidated Interest Coverage Ratio, both as defined in the 2021 Credit Agreement. The 2021 Credit Agreement also contains certain customary events of default, including, among other things, failure to make payments when due thereunder, failure to observe or perform certain covenants, cross-defaults, bankruptcy and insolvency-related events, and non-compliance with healthcare laws. Any borrowing under the 2021 Credit Agreement may be repaid, in whole or in part, at any time and from time to time without premium or penalty, other than customary breakage costs, and any amounts repaid under the 2021 Revolver may be reborrowed. Mandatory prepayments are required under the 2021 Revolver when borrowings and letter of credit usage exceed the total commitments for revolving credit loans. Mandatory prepayments are also required in connection with the disposition of assets to the extent not reinvested, unpermitted debt transactions, and excess cash flow, as defined, if certain leverage tests are not met. AdaptHealth was in compliance with all debt covenants as of September 30, 2022.

In August 2021, AdaptHealth LLC issued $600.0 million aggregate principal amount of 5.125% senior unsecured notes due 2030 (the “5.125% Senior Notes”). The 5.125% Senior Notes will mature on March 1, 2030. Interest on the 5.125% Senior Notes is payable on March 1st and September 1st of each year, beginning on March 1, 2022. The 5.125% Senior Notes will be redeemable at AdaptHealth’s option, in whole or in part, at any time on or after March 1, 2025, and the redemption price for the 5.125% Senior Notes if redeemed during the 12 months beginning (i) March 1, 2025 is 102.563%, (ii) March 1, 2026 is 101.281%, (iii) March 1, 2027 and thereafter is 100.000%, in each case together with accrued and unpaid interest. AdaptHealth may also redeem some or all of the 5.125% Senior Notes before March 1, 2025 at a redemption price of 100% of the principal amount of the 5.125% Senior Notes, plus a “make-whole” premium, together with accrued and unpaid interest. In addition, AdaptHealth may redeem up to 40% of the original aggregate principal amount of the 5.125% Senior Notes before March 1, 2025 with the proceeds from certain equity offerings at a redemption price equal to 105.125% of the principal amount of the 5.125% Senior Notes, together with accrued and unpaid interest. Furthermore, AdaptHealth may be required to make an offer to purchase the 5.125% Senior Notes upon the sale of certain assets or upon specific kinds of changes of control.

In January 2021, AdaptHealth LLC issued $500.0 million aggregate principal amount of 4.625% senior unsecured notes due 2029 (the “4.625% Senior Notes”). The 4.625% Senior Notes will mature on August 1, 2029. Interest on the 4.625% Senior Notes is payable on February 1st and August 1st of each year, beginning on August 1, 2021. The 4.625% Senior Notes will be redeemable at AdaptHealth’s option, in whole or in part, at any time on or after February 1, 2024, and the redemption price for the 4.625% Senior Notes if redeemed during the 12 months beginning (i) February 1, 2024 is 102.313%, (ii) February 1, 2025 is 101.156%, and (iii) February 1, 2026 and thereafter is 100.000%, in each case together with accrued and unpaid interest. AdaptHealth may also redeem some or all of the 4.625% Senior Notes before February 1, 2024 at a redemption price of 100% of the principal amount of the 4.625% Senior Notes, plus a “make-whole” premium, together with accrued and unpaid interest. In addition, AdaptHealth may redeem up to 40% of the original aggregate principal amount of the 4.625% Senior Notes before February 1, 2024 with the proceeds from certain equity offerings at a redemption price equal to 104.625% of the principal amount of the 4.625% Senior Notes, together with accrued and unpaid interest. Furthermore, AdaptHealth may be required to make an offer to purchase the 4.625% Senior Notes upon the sale of certain assets or upon specific kinds of changes of control.

In July 2020, AdaptHealth LLC issued $350.0 million aggregate principal amount of 6.125% senior unsecured notes due 2028 (the “6.125% Senior Notes”). The 6.125% Senior Notes will mature on August 1, 2028. Interest on the 6.125% Senior Notes is payable on February 1st and August 1st of each year, beginning on February 1, 2021. The 6.125% Senior Notes will be redeemable at AdaptHealth’s option, in whole or in part, at any time on or after August 1, 2023, and the redemption price for the 6.125% Senior Notes if redeemed during the 12 months beginning (i) August 1, 2023 is 103.063%, (ii) August 1, 2024 is 102.042%, (iii) August 1, 2025 is 101.021% and (iv) August 1, 2026 and thereafter is 100.000%, in each case together with accrued and unpaid interest. AdaptHealth may also redeem some or all of the 6.125% Senior Notes before August 1, 2023 at a redemption price of 100% of the principal amount of the 6.125% Senior Notes, plus a “make-whole” premium, together with accrued and unpaid interest. In addition, AdaptHealth may redeem up to 40% of the original aggregate principal amount of the 6.125% Senior Notes before August 1, 2023 with the proceeds from certain equity offerings at a redemption price equal to 106.125% of the principal amount of the 6.125% Senior Notes, together with accrued and unpaid interest. Furthermore, AdaptHealth may be required to make an offer to purchase the 6.125% Senior Notes upon the sale of certain assets or upon specific kinds of changes of control.

58

As of September 30, 2022 and December 31, 2021, AdaptHealth had working capital of $165.0 million and $170.2 million, respectively. A significant portion of AdaptHealth’s assets consists of accounts receivable from third-party payors that are responsible for payment for the products and services that AdaptHealth provides.

Cash Flow. The following table presents selected data from AdaptHealth’s consolidated statements of cash flows for nine months ended September 30, 2022 and 2021:

	Nine Months Ended September 30,
(in thousands)	2022		2021
	(unaudited)
Net cash provided by operating activities	$	276,947	$	174,750
Net cash used in investing activities		(265,376)		(1,558,507)
Net cash (used in) provided by financing activities		(50,460)		1,620,449
Net (decrease) increase in cash and cash equivalents		(38,889)		236,692
Cash and cash equivalents at beginning of period		149,627		99,962
Cash and cash equivalents at end of period	$	110,738	$	336,654

Net cash provided by operating activities for the nine months ended September 30, 2022 and 2021 was $276.9 million and $174.8 million, respectively, an increase of $102.1 million. The increase was the result of (1) a $60.0 million reduction in net income, (2) a net increase of $118.9 million in non-cash charges, primarily from depreciation and amortization, the change in the estimated fair value of the warrant liability and contingent consideration common shares liability, equity-based compensation expense, and loss on extinguishment of debt, (3) payments of $2.5 million for contingent consideration related to acquisitions, and (4) a net $45.7 million increase resulting from the change in operating assets and liabilities, primarily from the change in accounts receivable, inventory and accounts payable and accrued expenses.

Net cash used in investing activities for the nine months ended September 30, 2022 and 2021 was $265.4 million and $1,558.5 million, respectively. The use of funds in the 2022 period consisted of $16.1 million for business acquisitions, $248.5 million for equipment and other fixed asset purchases and $0.8 million for other investments. The use of funds in the 2021 period consisted of $1,417.9 million for business acquisitions, primarily from the AeroCare acquisition, and $139.7 million for equipment and other fixed asset purchases and $0.9 million of other investments.

Net cash used in financing activities for the nine months ended September 30, 2022 was $50.5 million compared to net cash provided by financing activities of $1,620.4 million for the nine months ended September 30, 2021. Net cash used in financing activities for the 2022 period consisted of repayments of $29.2 million on long-term debt and finance lease obligations, payments of $5.6 million for contingent consideration and deferred purchase price in connection with acquisitions, a payment of $14.0 million for Common Stock purchases under a share repurchase program, a payment of $2.0 million for a distribution to noncontrolling interests, and payments of $2.7 million for tax withholdings associated with equity-based compensation and stock option exercises, offset by proceeds of $1.6 million in connection with the employee stock purchase plan and proceeds of $1.4 million relating to stock option exercises. Net cash provided by financing activities for the nine months ended September 30, 2021 consisted of proceeds of $1,165.0 million from borrowings on long-term debt and lines of credit, proceeds of $1,100.0 million from the issuance of senior unsecured notes, proceeds of $278.9 million from the issuance of shares of Common Stock in connection with a public underwritten offering, proceeds of $12.1 million from the exercise of options, and proceeds of $1.0 million in connection with the employee stock purchase plan, offset by total repayments of $853.4 million on long-term debt and capital lease obligations, payments of $13.8 million for equity issuance costs, payments of $29.2 million for debt issuance costs, payments of $22.2 million for contingent consideration and deferred purchase price related to acquisitions, payments of $16.1 million for debt prepayment penalties, payments of $1.1 million for distributions to noncontrolling interests, and payments of $0.8 million relating to tax withholdings associated with equity-based compensation activity.

Critical Accounting Estimates

59

The discussion and analysis of the Company’s financial condition and results of operations is based upon the Company’s consolidated financial statements, which have been prepared in accordance with U.S. GAAP. The preparation of the Company’s consolidated financial statements requires its management to make estimates and judgments that affect the reported amounts of assets, liabilities, revenue and expenses and related disclosures of contingent assets and liabilities. The Company’s management bases its estimates, assumptions and judgments on historical experience and various other factors that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Different assumptions and judgments would change the estimates used in the preparation of the Company’s consolidated financial statements which, in turn, could change the results from those reported. In addition, actual results may differ from these estimates and such differences could be material to the Company’s financial position and results of operations.

Critical accounting estimates are those that the Company’s management considers the most important to the portrayal of the Company’s financial condition and results of operations because they require management’s most difficult, subjective or complex judgments, often as a result of the need to make estimates about the effect of matters that are inherently uncertain. The Company’s critical accounting estimates in relation to its consolidated financial statements include those related to revenue recognition, accounts receivable, business combinations, and valuation of goodwill and long-lived assets. There have been no material changes in the Company’s critical accounting estimates as compared to the critical accounting estimates described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021.

Recent Accounting Pronouncements

Recently issued accounting pronouncements that may be relevant to the Company’s operations but have not yet been adopted are outlined in Note 1 (i), Recently Issued Accounting Pronouncements, to its interim consolidated financial statements included elsewhere in this report.

Commitments and Contingencies

In the normal course of business, the Company is subject to loss contingencies, such as legal proceedings and claims arising out of its business that cover a wide range of matters. In accordance with FASB ASC Topic 450, Accounting for Contingencies, the Company records accruals for such loss contingencies when it is probable that a liability has been incurred and the amount of loss can be reasonably estimated. Significant judgment is required to determine both probability and the estimated amount. The Company reviews its accruals at least quarterly and adjusts accordingly to reflect the impact of negotiations, settlements, rulings, advice of legal counsel, and updated information. At this time, the Company has no material accruals related to lawsuits, claims, investigations and proceedings. While there can be no assurance, based on the Company’s evaluation of information currently available, the Company’s management believes any liability that may ultimately result from resolution of such loss contingencies will not have a material adverse effect on the Company’s financial conditions or results of operations. However, the Company’s assessment may be affected by limited information. Accordingly, the Company’s assessment may change in the future based upon availability of new information and further developments in the proceedings of such matters. The results of legal proceedings are inherently uncertain, and material adverse outcomes are possible.

In connection with the Company’s acquisition of PPS HME Holdings LLC (PPS), in May 2018, the Company assumed a Corporate Integrity Agreement (CIA) at one of PPS’ subsidiaries, Braden Partners L.P. d/b/a Pacific Pulmonary Services (BP). The CIA was entered into with the Office of Inspector General of the U.S. Department of Health and Human Services (OIG). The CIA has a five-year term which expires as of April 2022. In connection with the acquisition and integration of PPS by AdaptHealth, the OIG confirmed that the requirements of the CIA imposed upon BP would only apply to the operations of BP and therefore no operations of any other AdaptHealth affiliate are subject to the requirements of the CIA following the acquisition. On December 16, 2021, the OIG-HHS notified PPS that its report for the period ended March 31, 2021 had been accepted and PPS had satisfied its obligations under the CIA as of such date. On May 24, 2022, the Company submitted its report for the period ended March 31, 2022.

60

On July 25, 2017, AdaptHealth Holdings LLC, a Delaware limited liability company (AdaptHealth Holdings), was served with a subpoena by the U.S. Attorney’s Office for the United States District Court for the Eastern District of Pennsylvania (“EDPA”) pursuant to 18 U.S.C. §3486 to produce certain audit records and internal communications regarding ventilator billing. The investigation focused on billing practices regarding one payor that contracted for bundled payments for certain ventilators. AdaptHealth Holdings has cooperated with investigators and, through agreement with the EDPA, has submitted all information requested in the Company’s possession. An independent third party was retained by AdaptHealth Holdings that identified overpayments and underpayments for ventilator billings related to the payor, and a remittance was sent to reconcile that account. On October 3, 2019, the Company received a follow-up civil investigative demand from the EDPA regarding a document previously produced to the EDPA and patients included in the review by the independent third party. The Company has responded to the EDPA and supplemented its production as requested with any relevant documents in the Company’s possession. During subsequent communications, the EDPA indicated to the Company that the investigation remained ongoing. The EDPA also requested additional information regarding certain patient services and claims refunds processed by the Company in 2017. The Company produced this information in coordination with the EDPA. The EDPA has also raised questions regarding other aspects of ventilator billing. While the Company cannot provide any assurance as to whether the EDPA will seek additional information or pursue this matter further, it does not believe that the investigation will have a material adverse effect on the Company.

In March 2019, prior to its acquisition by the Company, AeroCare was served with a civil investigative demand (CID) issued by the United States Attorney for the Western District of Kentucky (WDKY). The CID seeks to investigate allegations that AeroCare improperly billed, or caused others to improperly bill, for oxygen tank contents that were not delivered to beneficiaries. The WDKY has requested documents related to such oxygen tank content billing as well as other categories of information. AeroCare has cooperated with the WDKY and has produced documents and provided explanations of its billing practices. In September 2020, the WDKY indicated the investigation includes alleged violations of the federal False Claims Act and as well as alleged violations of state Medicaid false claims acts in ten states. AeroCare has cooperated fully with the investigation and has indicated to the WDKY that concerns raised do not accurately identify Medicare coverage criteria and that state Medicaid coverage requirements generally do not provide for separate reimbursement for portable gaseous oxygen contents in the circumstances at issue. While the Company cannot provide any assurance as to whether the WDKY will seek additional information or pursue this matter further, it does not believe that the investigation will have a material adverse effect on the Company.

On July 29, 2021, Robert Charles Faille Jr., a purported shareholder of the Company, filed a purported class action complaint against the Company and certain of its current and former officers in the United States District Court for the Eastern District of Pennsylvania (the “Complaint”). The Complaint purports to be asserted on behalf of a class of persons who purchased the Company’s stock between November 11, 2019 and July 16, 2021. The Complaint generally alleges that the Company and certain of its current and former officers violated federal securities laws by making allegedly false and misleading statements and/or failing to disclose material information regarding the Company’s organic growth trajectory. The Complaint seeks unspecified damages. On October 14, 2021, the Delaware County Employees Retirement System and the Bucks County Employees Retirement System were named Lead Plaintiffs. Pursuant to the scheduling order, Lead Plaintiffs filed a consolidated complaint on November 22, 2021 (the “Consolidated Complaint”), which asserts substantially the same claim, but adds a number of current and former directors of the Company as additional defendants and a new theory of recovery based on the Company’s alleged failure to disclose information concerning the Company’s former Co-CEO’s alleged tax fraud arising from certain past private activity (the “Consolidated Class Action”). On January 20, 2022, the defendants filed a motion to dismiss the Consolidated Complaint. Lead Plaintiffs’ opposition to defendants’ motion was filed on March 21, 2022, and defendants’ reply was filed April 15, 2022. On June 9, 2022, the court issued an opinion and order denying the defendants’ motion to dismiss the Consolidated Complaint.

On July 15, 2022, the court entered a scheduling order providing for, inter alia, a schedule for completing class certification discovery, as well as setting a briefing schedule for motions for class certification. Pursuant to the scheduling order, Lead Plaintiffs filed their motion for class certification on July 28, 2022. The defendants’ opposition to Lead Plaintiffs’ motion for class certification is due to be filed on January 20, 2023; and Lead Plaintiffs’ reply is due to be filed on March 10, 2023. The Company intends to vigorously defend against the allegations contained in the Consolidated Complaint, but there can be no assurance that the defense will be successful.

61

On December 6, 2021, a putative shareholder of the Company, Carol Hessler, filed a shareholder derivative complaint against certain current and former directors and officers of the Company in the United States District Court for the Eastern District of Pennsylvania (the “Derivative Complaint”). The Derivative Complaint generally alleges that the defendants breached their fiduciary duties owed to the Company by allegedly causing or allowing misrepresentations and/or omissions regarding the Company’s organic growth and the Company’s former Co-CEO’s alleged criminal activity, failing to maintain an adequate system of oversight, disclosure controls and procedures, and internal controls over financial reporting and due diligence into the Company’s management team, and engaging in insider trading. The Derivative Complaint also alleges claims for waste of corporate assets and unjust enrichment. Finally, the Derivative Complaint alleges that certain of the individual defendants violated Section 14(a) of the Securities Exchange Act by allegedly negligently issuing, causing to be issued, and participating in the issuance of materially misleading statements to stockholders in the Company’s Proxy Statements on Schedule DEF 14A in connection with a Special Meeting of Stockholders, held on March 3, 2021, and the 2021 Annual Meeting of Stockholders, held on July 27, 2021. The Derivative Complaint seeks, among other things, an award of money damages.

On March 4, 2022, the parties stipulated to stay the Hessler action pending final resolution of the Consolidated Class Action. On March 7, 2022, the court so-ordered the parties’ stipulation.

The Company intends to vigorously defend against the allegations contained in the Derivative Complaint, but there can be no assurance that the defense will be successful.

On May 2, 2022, the U.S. Attorney’s Office for the Southern District of New York issued a civil investigative demand to Community Surgical Supply Inc. (CSS), a subsidiary of the Company, pursuant to the False Claims Act, 31 U.S.C. § 3733 (FCA) surrounding whether CSS submitted false claims in violation of the FCA related to CSS’s billing of, and reimbursements from, federal health care programs for ventilators provided to patients from January 1, 2015 to the present. The Company is fully cooperating with the investigation. Given the investigation is in the early stages, it is not possible to determine whether it will have a material adverse effect on the Company.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

Our exposure to market risk relates to fluctuations in interest rates from borrowings under the 2021 Credit Facility. Our interest accrued on our debt borrowings is based on a variable rate which is tied to the Adjusted LIBOR Rate plus an applicable margin and therefore is exposed to changes in interest rates. As of September 30, 2022, there was $770.0 million outstanding under the 2021 Term Loan, $17.4 million outstanding under letters of credit, and additional availability under the 2021 Revolver, net of letters of credit outstanding, was $432.6 million.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, we conducted an evaluation of the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934 (the “Exchange Act”)) as of September 30, 2022. Disclosure controls and procedures are designed to ensure that information required to be disclosed by us in our Exchange Act reports are recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer or persons performing similar functions, as appropriate, to allow timely decisions regarding required disclosure. Based on this evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that, during the period covered by this Quarterly Report, our disclosure controls and procedures were not effective due to material weaknesses in internal control over financial reporting as further described below in Management’s Report on Internal Control Over Financial Reporting.

As previously disclosed in Part II, Item 9A of our Annual Report on Form 10-K for the fiscal year ended December 31, 2021, management identified material weaknesses in internal control over financial reporting relating to an insufficient complement of resources resulting in an ineffective risk assessment (the “Insufficient Complement of Resources, Risk Assessment and General Information Technology Material Weaknesses”). Our ineffective risk

62

assessment resulted in material weaknesses from both lack of implementation and ineffectiveness of process level controls in substantially all processes that support our financial statements and reporting. The ineffective risk assessment also resulted in ineffective general information technology controls due to an incomplete understanding of the risks associated with information technology systems relevant to our financial reporting processes.

As previously disclosed in Part II, Item 9A of our Annual Reports on Form 10-K for the fiscal years ended December 31, 2021, 2020 and 2019, management identified a material weakness in internal control over financial reporting relating to the timeliness of our review controls over non-routine transactions (the “Non-routine Transaction Material Weakness”). Additionally, in connection with the preparation of the Company’s consolidated financial statements for the fiscal year ended December 31, 2020, as it relates to the Non-routine Transaction Material Weakness, we further identified that, specifically we lacked a sufficient number of professionals with an appropriate level of accounting knowledge, training, and experience to appropriately analyze, record and disclose accounting matters timely and accurately.

As previously disclosed in Part II, Item 9A of our Annual Report on Form 10-K for the fiscal years ended December 31, 2021 and 2020, management identified a material weakness in internal control over financial reporting relating to the accounts payable process, specifically relating to the maintenance and approvals of vendors and the invoice approval process (the “Accounts Payable Material Weakness”). The Company has not identified any fraud or loss relating to such material weakness.

Notwithstanding the identified material weaknesses, management, including our principal executive officer and principal financial officer, believes the consolidated financial statements included in this Quarterly Report on Form 10-Q fairly represent in all material respects our financial condition, results of operations and cash flows at and for the periods presented in accordance with U.S. GAAP.

Remediation of Previously Reported Material Weaknesses in Internal Control Over Financing Reporting

With respect to the Insufficient Complement of Resources, Risk Assessment and General Information Technology Material Weaknesses, management is taking steps to remediate such material weaknesses, including (1) establishing an executive steering committee to monitor the remediation of the material weaknesses, (2) adding professionals to the executive team with expertise in process mapping and internal controls; (3) process mapping each business cycle to identify relevant process risk points, service and sub-service organizations, information technology systems and information, and designing and implementing responsive manual and automated controls, (4) engaging third-party consultants to assist management in this effort, and (5) implementing an enterprise resource planning system which went live in the first quarter of 2022, which has impacted a variety of processes and our review and approval of journal entries. While management has begun the remediation process, these material weaknesses cannot be considered remediated until the enhanced controls have been designed, implemented and operated effectively for a sufficient period of time.

With respect to the previously reported Non-routine Transaction Material Weakness, we have (1) implemented processes to improve our analysis, recording and disclosure of non-routine transactions and (2) while we still lack sufficient resources to effectively manage our overall system of internal control over financial reporting as described above, we have added experienced technical accounting resources to perform timely analysis and review of non-routine transactions.

With respect to the previously reported Accounts Payable Material Weakness, we have implemented additional processes and controls with respect to vendor masterfile changes in conjunction with the implementation of an enterprise accounts payable system.

Changes in Internal Control over Financial Reporting

Except with respect to the changes in connection with the implementation of the initiatives to remediate the material weaknesses noted above, there were no changes in the Company’s internal control over financial reporting that

63

occurred during the fiscal quarter ended September 30, 2022 that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

PART II. OTHER INFORMATION

Item 1. Legal Proceedings

See Item 2. “Management’s Discussion and Analysis of Financial Condition and Results of Operations —Commitments and Contingencies”.

Item 1A. Risk Factors

Factors that could cause our actual results to differ materially from those in this report are any of the risks disclosed under the heading “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2021 filed with the SEC on March 1, 2022. Any of those factors could result in a significant or material adverse effect on our results of operations or financial condition. Additional risk factors not presently known to us or that we currently deem immaterial may also impair our business or results of operations. In addition, our results of operations and financial condition may be adversely affected by the COVID-19 pandemic, which is discussed in greater detail in our Management’s Discussion and Analysis of Financial Condition and Results of Operations elsewhere herein.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

We had no sales of unregistered equity securities during the period covered by this report that were not previously reported in a Quarterly Report on Form 10-Q or a Current Report on Form 8-K.

The following table shows information with respect to purchases of our Common Stock made during the three months ended September 30, 2022 by us or any of our “affiliated purchasers” as defined in Rule 10b-18(a)(3) under the Exchange Act:

Period	Total number of shares purchased (1)	Average price paid per share (1)		Total number of shares purchased as part of publicly announced plans or programs (1)		Approximate dollar amount remaining that may be used to purchase shares under the plans or programs (in thousands) (1)
July 1 - 31, 2022	—	$	—		—	$	196,625
August 1 - 31, 2022	436,914	$	19.63		436,914	$	188,088
September 1 - 30, 2022	114,503	$	18.90		114,503	$	186,008
Total	551,417				551,417

(1) On May 9, 2022, the Company’s board of directors authorized a share repurchase program for up to $200 million of the Company’s Common Stock through December 31, 2022. Shares may be repurchased from time to time on the open market, through privately negotiated transactions or otherwise, as permitted under Exchange Act Rule 10b-18. The timing and actual number of shares to be repurchased will depend upon market conditions and other factors. Purchases may be started or stopped at any time without prior notice depending on market conditions and other factors.

Item 3. Defaults upon Senior Securities

None.

Item 4. Mine Safety Disclosures

Not applicable.

64

Item 5. Other Information

None.

Item 6. Exhibits

See Exhibit Index for documents filed or furnished herewith and incorporated herein by reference.

65

EXHIBIT INDEX

HIDDEN_ROW
Exhibit Number	Description
3.1	Third Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 of the Company’s Current Report on Form 8-K, filed with the SEC on July 29, 2021).
3.2	Amended and Restated Bylaws (incorporated by reference to Exhibit 3.2 of the Company’s Current Report on Form 8-K, filed with the SEC on November 14, 2019).
3.3	Certificate of Designation of Preferences, Rights and Limitations of Series B-1 Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed with the SEC on June 26, 2020).
31.1*	Certification of Chief Executive Officer Pursuant to Securities Exchange Act Rules 13a-14(a) and 15(d)-14(a), as adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2*	Certification of Chief Financial Officer Pursuant to Securities Exchange Act Rules 13a-14(a) and 15(d)-14(a), as adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32**	Certification of Chief Executive Officer and Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS***	XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
101.SCH***	XBRL Taxonomy Extension Schema Document
101.CAL***	XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF***	XBRL Taxonomy Extension Definition Linkbase Document
101.LAB***	XBRL Taxonomy Extension Label Linkbase Document
101.PRE***	XBRL Taxonomy Extension Presentation Linkbase Document
Exhibit 104 ***	Cover Page Interactive Data File - The cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document

* Filed herewith.

** Furnished herewith.

*** XBRL (eXtensible Business Reporting Language) information is furnished and not filed or a part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, is deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and otherwise is not subject to liability under these sections.

† Management contract or compensatory plan or arrangement.

+ Portions of this exhibit (indicated by “[***]”) have been omitted in accordance with Item 601(b)(10)(iv) of Regulation S-K.

66

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	AdaptHealth Corp.
November 8, 2022	By:	/s/ Stephen P. Griggs
		Stephen P. Griggs
		Chief Executive Officer and Director
		(Principal Executive Officer)

November 8, 2022	By:	/s/ Jason Clemens
		Jason Clemens
		Chief Financial Officer
		(Principal Financial Officer and Principal Accounting Officer)

67

EX-31.1

Exhibit 31.1

CERTIFICATION

PURSUANT TO RULES 13A-14 AND 15D-14

UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

I, Stephen P. Griggs, certify that:

1.           I have reviewed this Quarterly Report on Form 10-Q of AdaptHealth Corp.;

2.           Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.           Based on my knowledge, the financial statements and other financial information included in this report, fairly present, in all material respects, the financial condition, results of operations, and cash flows of the registrant as of, and for, the periods presented in this report;

4.           The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)          Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)          Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of the financial statements for external purposes in accordance with generally accepted accounting principles;

(c)          Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)          Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.           The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors:

(a)          All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize, and report financial information; and

(b)          Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

November 8, 2022	/s/ Stephen P. Griggs
	Stephen P. Griggs
	Chief Executive Officer and Director
	(Principal Executive Officer)

EX-31.2

Exhibit 31.2

CERTIFICATION

PURSUANT TO RULES 13A-14 AND 15D-14

UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

I, Jason Clemens, certify that:

1.           I have reviewed this Quarterly Report on Form 10-Q of AdaptHealth Corp.;

2.           Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.           Based on my knowledge, the financial statements and other financial information included in this report, fairly present, in all material respects, the financial condition, results of operations, and cash flows of the registrant as of, and for, the periods presented in this report;

4.           The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)          Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)          Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of the financial statements for external purposes in accordance with generally accepted accounting principles;

(c)          Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)          Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.           The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors:

(a)          All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize, and report financial information; and

(b)          Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

November 8, 2022	/s/ Jason Clemens
	Jason Clemens
	Chief Financial Officer
	(Principal Financial Officer and Principal Accounting Officer)

EX-32

Exhibit 32

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350

AS REQUIRED BY

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of AdaptHealth Corp. (the “Company”) on Form 10-Q for the quarter ended September 30, 2022, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned hereby certify that to the best of our knowledge:

1.     The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2.     The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

November 8, 2022	/s/ Stephen P. Griggs	Chief Executive Officer and Director
	Stephen P. Griggs	(Principal Executive Officer)
November 8, 2022	/s/ Jason Clemens	Chief Financial Officer
	Jason Clemens	(Principal Financial Officer and Principal Accounting Officer)

XML

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2022	Nov. 04, 2022
Document and Entity Information
Document Type	10-Q
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Sep. 30, 2022
Entity File Number	001-38399
Entity Registrant Name	AdaptHealth Corp.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	82-3677704
Entity Address, Address Line One	220 West Germantown Pike
Entity Address, Address Line Two	Suite 250
Entity Address, City or Town	Plymouth Meeting
Entity Address, State or Province	PA
Entity Address, Postal Zip Code	19462
City Area Code	610
Local Phone Number	424-4515
Title of 12(b) Security	Common Stock, par value $0.0001 per share
Trading Symbol	AHCO
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		134,731,665
Entity Central Index Key	0001725255
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q3
Amendment Flag	false

XML

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 110,738	$ 149,627
Accounts receivable	358,341	359,896
Inventory	125,362	123,095
Prepaid and other current assets	37,490	37,440
Total current assets	631,931	670,058
Equipment and other fixed assets, net	473,056	398,577
Operating lease right-of-use assets	128,635	147,760
Goodwill	3,524,999	3,512,567
Identifiable intangible assets, net	172,772	202,231
Other assets	20,453	15,098
Deferred tax assets	286,135	304,193
Total Assets	5,237,981	5,250,484
Current liabilities:
Accounts payable and accrued expenses	346,920	358,384
Current portion of finance lease obligations	2,695	15,446
Current portion of operating lease obligations	28,769	31,418
Current portion of long-term debt	30,000	20,000
Contract liabilities	31,605	31,370
Other liabilities	26,938	43,194
Total current liabilities	466,927	499,812
Long-term debt, less current portion	2,162,088	2,183,552
Operating lease obligations, less current portion	103,859	120,180
Other long-term liabilities	306,641	322,487
Warrant liability	38,516	57,764
Total Liabilities	3,078,031	3,183,795
Commitments and contingencies (note 14)
Stockholders' Equity:
Common Stock, par value of $0.0001 per share, 300,000,000 shares authorized; 134,723,174 and 133,843,732 shares issued and outstanding as of September 30, 2022 and December 31, 2021, respectively	13	13
Preferred Stock, par value of $0.0001 per share, 5,000,000 shares authorized; 124,060 and 124,060 shares issued and outstanding as of September 30, 2022 and December 31, 2021, respectively	1	1
Treasury stock, at cost (750,835 shares)	(13,992)
Additional paid-in capital	2,126,468	2,107,267
Retained earnings (Accumulated deficit)	28,883	(43,021)
Accumulated other comprehensive income (loss)	12,994	(2,354)
Total stockholders' equity attributable to AdaptHealth Corp.	2,154,367	2,061,906
Noncontrolling interests in subsidiaries	5,583	4,783
Total Stockholders' Equity	2,159,950	2,066,689
Total Liabilities and Stockholders' Equity	$ 5,237,981	$ 5,250,484

XML

CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Sep. 30, 2022	Dec. 31, 2021
CONSOLIDATED BALANCE SHEETS
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	300,000,000	300,000,000
Common stock, shares issued (in shares)	134,723,174	133,843,732
Common stock, shares outstanding (in shares)	134,723,174	133,843,732
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Preferred stock, shares issued (in shares)	124,060	124,060
Preferred stock, shares outstanding (in shares)	124,060	124,060
Treasury stock, at cost (in shares)	750,835

XML

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Revenue:
Net revenue	$ 756,495	$ 653,293	$ 2,190,312	$ 1,752,429
Revenue, Product and Service [Extensible List]	us-gaap:HealthCarePatientServiceMember	us-gaap:HealthCarePatientServiceMember	us-gaap:HealthCarePatientServiceMember	us-gaap:HealthCarePatientServiceMember
Costs and expenses:
Cost of net revenue	$ 646,714	$ 529,887	$ 1,853,847	$ 1,417,305
Cost, Product and Service [Extensible List]	us-gaap:HealthCarePatientServiceMember	us-gaap:HealthCarePatientServiceMember	us-gaap:HealthCarePatientServiceMember	us-gaap:HealthCarePatientServiceMember
General and administrative expenses	$ 40,681	$ 33,006	$ 124,673	$ 132,584
Depreciation and amortization, excluding patient equipment depreciation	16,151	14,690	48,113	46,014
Total costs and expenses	703,546	577,583	2,026,633	1,595,903
Operating income	52,949	75,710	163,679	156,526
Interest expense, net	28,521	24,252	78,905	69,584
Change in fair value of warrant liability (note 10)	1,364	(16,737)	(17,145)	(57,359)
Change in fair value of contingent consideration common shares liability (note 10)		(10,006)		(34,050)
Loss on extinguishment of debt		8,240		20,189
Other loss (income), net	257	(452)	7,179	698
Income before income taxes	22,807	70,413	94,740	157,464
Income tax expense	5,580	12,147	20,036	22,782
Net income	17,227	58,266	74,704	134,682
Income attributable to noncontrolling interest	1,105	174	2,800	1,449
Net income attributable to AdaptHealth Corp.	$ 16,122	$ 58,092	$ 71,904	$ 133,233
Weighted average common shares outstanding
Weighted average common shares outstanding - basic	134,227	131,684	134,186	124,228
Weighted average common shares outstanding - diluted	137,583	140,322	138,599	133,638
Net income per common share
Basic net income per share	$ 0.11	$ 0.40	$ 0.49	$ 0.97
Diluted net income per share	$ 0.11	$ 0.20	$ 0.35	$ 0.27

XML

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
Net income	$ 17,227	$ 58,266	$ 74,704	$ 134,682
Other comprehensive income:
Interest rate swap agreements, inclusive of reclassification adjustment	7,757	640	15,348	3,180
Comprehensive income	24,984	58,906	90,052	137,862
Income attributable to noncontrolling interest	1,105	174	2,800	1,449
Comprehensive income attributable to AdaptHealth Corp.	$ 23,879	$ 58,732	$ 87,252	$ 136,413

XML

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY - USD ($) $ in Thousands	Class A Common Stock Common Stock	Class A Common Stock Additional paid-in capital	Class A Common Stock	Class B Common Stock Common Stock	Series C Preferred Stock Preferred Stock	Series C Preferred Stock Additional paid-in capital	Series C Preferred Stock	Common Stock	Preferred Stock	Treasury Stock	Additional paid-in capital	Retained Earnings (Accumulated Deficit).	Accumulated other comprehensive income (loss)	Noncontrolling interests in subsidiaries	Total
Balance at beginning of period at Dec. 31, 2020	$ 8			$ 1					$ 1		$ 558,486	$ (199,196)	$ (4,411)	$ (74,044)	$ 280,845
Shares, Outstanding, Beginning Balance at Dec. 31, 2020	76,458,000			13,219,000					164,000
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]
Issuance of stock for acquisitions	$ 2	$ 564,986	$ 564,988			$ 523,856	$ 523,856
Issuance of stock for acquisitions (in shares)	14,092,000				130,000
Issuance of stock options for acquisition											134,683				134,683
Exchange of Class B Common Stock for Class A Common Stock	$ 1			$ (1)							(77,919)			77,919
Exchange of Class B Common Stock for Class A Common Stock (in shares)	13,219,000			(13,219,000)
Equity-based compensation											8,582				8,582
Equity-based compensation (in shares)	172,000
Cashless exercise of options (in shares)	9,000
Sale of stock, net of offering costs	$ 1										265,017				265,018
Sale of stock (in shares)	8,450,000
Conversion of Series B-1 Preferred Stock to Class A Common Stock (in shares)	3,950,000								(40,000)
Conversion of Series C-1 Preferred Stock to Class A Common Stock	$ 1										(1)
Conversion Of Series C-1 Preferred Stock to Class A Common Stock (in shares)	13,047,000								(130,000)
Common Stock issued in connection with employee stock purchase plan											314				314
Common Stock issued in connection with employee stock purchase plan (in shares)	8,000
Net income (loss)												(3,966)		324	(3,642)
Equity activity resulting from Tax Receivable Agreement											16,768				16,768
Change in fair value of interest rate swaps, inclusive of reclassification adjustment													1,876		1,876
Other											(810)				(810)
Other (in shares)	(19,000)
Balance at end of period at Mar. 31, 2021	$ 13								$ 1		1,993,962	(203,162)	(2,535)	4,199	1,792,478
Shares, Outstanding, Ending Balance at Mar. 31, 2021	129,386,000								124,000
Balance at beginning of period at Dec. 31, 2020	$ 8			$ 1					$ 1		558,486	(199,196)	(4,411)	(74,044)	280,845
Shares, Outstanding, Beginning Balance at Dec. 31, 2020	76,458,000			13,219,000					164,000
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]
Exchange of Class A Common Stock for Series B-1 Preferred Stock (in shares)			3,950,000
Net income (loss)															134,682
Balance at end of period at Sep. 30, 2021	$ 13								$ 1		2,057,289	(65,963)	(1,231)	4,254	1,994,363
Shares, Outstanding, Ending Balance at Sep. 30, 2021	132,154,000								124,000
Balance at beginning of period at Dec. 31, 2020	$ 8			$ 1					$ 1		558,486	(199,196)	(4,411)	(74,044)	$ 280,845
Shares, Outstanding, Beginning Balance at Dec. 31, 2020	76,458,000			13,219,000					164,000
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]
Issuance of Class A Common Stock in connection with Contingent Consideration Shares (in shares)															1,000,000
Balance at end of period at Dec. 31, 2021								$ 13	$ 1		2,107,267	(43,021)	(2,354)	4,783	$ 2,066,689
Shares, Outstanding, Ending Balance at Dec. 31, 2021								133,844,000	124,000
Balance at beginning of period at Mar. 31, 2021	$ 13								$ 1		1,993,962	(203,162)	(2,535)	4,199	1,792,478
Shares, Outstanding, Beginning Balance at Mar. 31, 2021	129,386,000								124,000
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]
Issuance of stock for acquisitions											12,166				12,166
Issuance of stock for acquisitions (in shares)	441,000
Equity-based compensation											7,447				7,447
Equity-based compensation (in shares)	37,000
Exercise of stock options											2,300				2,300
Exercise of stock options (in shares)	200,000
Distributions to noncontrolling interest														(1,070)	(1,070)
Net income (loss)												79,107		951	80,058
Change in fair value of interest rate swaps, inclusive of reclassification adjustment													664		664
Balance at end of period at Jun. 30, 2021	$ 13								$ 1		2,015,875	(124,055)	(1,871)	4,080	1,894,043
Shares, Outstanding, Ending Balance at Jun. 30, 2021	130,064,000								124,000
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]
Issuance of stock for acquisitions											25,507				25,507
Issuance of stock for acquisitions (in shares)	977,000
Equity-based compensation											5,365				5,365
Equity-based compensation (in shares)	189,000
Exercise of stock options											9,840				9,840
Exercise of stock options (in shares)	898,000
Common Stock issued in connection with employee stock purchase plan											702				702
Common Stock issued in connection with employee stock purchase plan (in shares)	26,000
Net income (loss)												58,092		174	58,266
Change in fair value of interest rate swaps, inclusive of reclassification adjustment													640		640
Balance at end of period at Sep. 30, 2021	$ 13								$ 1		2,057,289	(65,963)	(1,231)	4,254	1,994,363
Shares, Outstanding, Ending Balance at Sep. 30, 2021	132,154,000								124,000
Balance at beginning of period at Dec. 31, 2021								$ 13	$ 1		2,107,267	(43,021)	(2,354)	4,783	2,066,689
Shares, Outstanding, Beginning Balance at Dec. 31, 2021								133,844,000	124,000
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]
Equity-based compensation											5,502				5,502
Equity-based compensation (in shares)								187,000
Exercise of stock options											723				723
Exercise of stock options (in shares)								184,000
Payments for tax withholdings from restricted stock vesting and stock option exercises											(1,269)				(1,269)
Common Stock issued in connection with employee stock purchase plan											753				753
Common Stock issued in connection with employee stock purchase plan (in shares)								31,000
Net income (loss)												41,750		480	42,230
Change in fair value of interest rate swaps, inclusive of reclassification adjustment													5,998		5,998
Balance at end of period at Mar. 31, 2022								$ 13	$ 1		2,112,976	(1,271)	3,644	5,263	2,120,626
Shares, Outstanding, Ending Balance at Mar. 31, 2022								134,246,000	124,000
Balance at beginning of period at Dec. 31, 2021								$ 13	$ 1		2,107,267	(43,021)	(2,354)	4,783	$ 2,066,689
Shares, Outstanding, Beginning Balance at Dec. 31, 2021								133,844,000	124,000
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]
Cashless exercise of options (in shares)															315,349
Exercise of stock options															$ 1,400
Exercise of stock options (in shares)															509,000
Number of shares purchased under repurchase program										750,835
Warrant liability adjustment															$ 2,103
Net income (loss)															74,704
Balance at end of period at Sep. 30, 2022								$ 13	$ 1	$ (13,992)	2,126,468	28,883	12,994	5,583	2,159,950
Shares, Outstanding, Ending Balance at Sep. 30, 2022								134,723,000	124,000	751,000
Balance at beginning of period at Mar. 31, 2022								$ 13	$ 1		2,112,976	(1,271)	3,644	5,263	2,120,626
Shares, Outstanding, Beginning Balance at Mar. 31, 2022								134,246,000	124,000
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]
Equity-based compensation											5,720				5,720
Equity-based compensation (in shares)								117,000
Exercise of stock options (in shares)								43,000
Payments for tax withholdings from restricted stock vesting and stock option exercises											(613)				(613)
Shares purchased under share repurchase program										$ (3,375)					(3,375)
Number of shares purchased under repurchase program										199,000
Distributions to noncontrolling interest														(2,000)	(2,000)
Warrant liability adjustment											495				495
Reclassification of warrant liability to equity for exercised warrants (in shares)								19,000
Net income (loss)												14,032		1,215	15,247
Change in fair value of interest rate swaps, inclusive of reclassification adjustment													1,593		1,593
Balance at end of period at Jun. 30, 2022								$ 13	$ 1	$ (3,375)	2,118,578	12,761	5,237	4,478	2,137,693
Shares, Outstanding, Ending Balance at Jun. 30, 2022								134,425,000	124,000	199,000
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]
Equity-based compensation											5,562				5,562
Equity-based compensation (in shares)								83,000
Exercise of stock options											665				665
Exercise of stock options (in shares)								99,000
Payments for tax withholdings from restricted stock vesting and stock option exercises											(808)				(808)
Shares purchased under share repurchase program										$ (10,617)					(10,617)
Number of shares purchased under repurchase program										552,000
Common Stock issued in connection with employee stock purchase plan											863				863
Common Stock issued in connection with employee stock purchase plan (in shares)								47,000
Warrant liability adjustment											1,608				1,608
Reclassification of warrant liability to equity for exercised warrants (in shares)								69,000
Net income (loss)												16,122		1,105	17,227
Change in fair value of interest rate swaps, inclusive of reclassification adjustment													7,757		7,757
Balance at end of period at Sep. 30, 2022								$ 13	$ 1	$ (13,992)	$ 2,126,468	$ 28,883	$ 12,994	$ 5,583	$ 2,159,950
Shares, Outstanding, Ending Balance at Sep. 30, 2022								134,723,000	124,000	751,000

XML

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (Parenthetical) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended	9 Months Ended
	Jan. 31, 2021	Mar. 31, 2021	Sep. 30, 2021
Offering costs			$ 13,832
Public Offering
Offering costs	$ 13,800	$ 13,832

XML

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Cash flows from operating activities:
Net income	$ 74,704	$ 134,682
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization, including patient equipment depreciation	248,835	180,827
Equity-based compensation	16,784	21,394
Change in fair value of warrant liability	(17,145)	(57,359)
Change in fair value of contingent consideration common shares liability		(34,050)
Reduction in the carrying amount of operating lease right-of-use assets	16,924	23,832
Deferred income tax expense	18,058	11,666
Change in fair value of interest rate swaps, net of reclassification adjustment	(2,202)	(2,185)
Amortization of deferred financing costs	3,926	4,069
Write-off of deferred financing costs		4,054
Loss on extinguishment of debt from prepayment penalty		16,135
Other	(2,023)	(1,614)
Changes in operating assets and liabilities, net of effects from acquisitions:
Accounts receivable	2,357	(25,046)
Inventory	(3,992)	3,626
Prepaid and other assets	4,211	(137)
Operating lease obligations	(16,794)	(23,292)
Operating liabilities	(66,696)	(81,852)
Net cash provided by operating activities	276,947	174,750
Cash flows from investing activities:
Payments for business acquisitions, net of cash acquired	(16,134)	(1,417,946)
Purchases of equipment and other fixed assets	(248,511)	(139,686)
Payments for cost method investments	(731)	(875)
Net cash used in investing activities	(265,376)	(1,558,507)
Cash flows from financing activities:
Proceeds from borrowings on long-term debt and lines of credit		1,165,000
Repayments on long-term debt and lines of credit	(15,000)	(822,271)
Repayments of finance lease obligations	(14,219)	(31,043)
Payments for shares purchased under share repurchase program	(13,992)
Proceeds from the exercise of stock options	1,388	12,140
Proceeds received in connection with employee stock purchase plan	1,616	1,016
Proceeds from the issuance of senior unsecured notes		1,100,000
Proceeds from the issuance of Class A Common Stock		278,850
Payments for equity issuance costs		(13,832)
Payments for debt financing costs		(29,185)
Payments for tax withholdings from restricted stock vesting and stock option exercises	(2,690)	(810)
Payments of contingent consideration and deferred purchase price from acquisitions	(5,563)	(22,211)
Distributions to noncontrolling interests	(2,000)	(1,070)
Payments for debt prepayment penalties		(16,135)
Net cash (used in) provided by financing activities	(50,460)	1,620,449
Net (decrease) increase in cash and cash equivalents	(38,889)	236,692
Cash and cash equivalents at beginning of period	149,627	99,962
Cash and cash equivalents at end of period	110,738	336,654
Supplemental disclosures:
Cash paid for interest	97,389	67,409
Cash paid for income taxes	10,490	13,799
Noncash investing and financing activities:
Equipment acquired under finance lease obligations	1,335	22,902
Unpaid equipment and other fixed asset purchases at end of period	50,864	12,688
Assets subject to operating lease obligations	5,411	11,340
Operating lease obligations	(5,411)	(11,340)
Equity consideration issued in connection with acquisitions		1,261,200
Contingent purchase price in connection with acquisitions		2,000
Deferred purchase price in connection with acquisitions	$ 422	$ 1,162

XML

General Information

9 Months Ended

Sep. 30, 2022

General Information

General Information

(1)          General Information

AdaptHealth Corp. and subsidiaries (AdaptHealth or the Company), a Delaware Corporation, is a national leader in providing patient-centered, healthcare-at-home solutions including home medical equipment (HME), medical supplies, and related services. AdaptHealth focuses primarily on providing (i) sleep therapy equipment, supplies and related services (including CPAP and bi PAP services) to individuals suffering from obstructive sleep apnea (OSA), (ii) medical devices and supplies to patients for the treatment of diabetes (including continuous glucose monitors (CGM) and insulin pumps), (iii) home medical equipment to patients discharged from acute care and other facilities, (iv) oxygen and related chronic therapy services in the home, and (v) other HME devices and supplies on behalf of chronically ill patients with wound care, urological, incontinence, ostomy and nutritional supply needs. AdaptHealth services beneficiaries of Medicare, Medicaid and commercial insurance payors.

The interim consolidated financial statements are unaudited, but reflect all normal recurring adjustments that are, in the opinion of management, necessary to fairly present the information set forth herein. The interim consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related notes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021. Interim results are not necessarily indicative of the results for a full year.

There have been no material changes in the Company’s significant accounting policies as compared to the significant accounting policies described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021.

(a)          Basis of Presentation

The interim consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP). In the opinion of management, the interim consolidated financial statements include all necessary adjustments for a fair presentation of the financial position and results of operations for the periods presented.

(b)         Basis of Consolidation

The accompanying interim consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.

(c)          Concentration of Credit Risk

Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents and trade accounts receivable. The Company maintains its cash in bank deposit accounts, which, at times, may exceed federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to any significant credit risk on cash and cash equivalents.

(d)          Accounting Estimates

The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and reported amounts of revenues and expenses during the reporting period. Management bases these estimates and assumptions upon historical experience, existing and known circumstances, authoritative accounting pronouncements and other factors that management believes to be reasonable. Significant areas requiring the use of management estimates relate to revenue recognition and the valuation of accounts receivable (implicit price concession), income taxes, equity-based

compensation, interest rate swaps, warrant liability and long-lived assets, including goodwill and identifiable intangible assets. Actual results could differ from those estimates.

(e)          Valuation of Goodwill

The Company has a significant amount of goodwill on its balance sheet that resulted from the business acquisitions the Company has made in recent years. Goodwill is not amortized and is assessed for impairment annually and upon the occurrence of a triggering event or change in circumstances indicating a possible impairment. Such triggering events potentially warranting an interim goodwill impairment assessment include, among other factors, declines in historical or projected revenue, operating income or cash flows, and declines in the Company’s stock price or market capitalization. Such changes in circumstance can include, among others, changes in the legal environment, reimbursement environment, operating performance, and/or future prospects. The Company performs its annual impairment assessment of goodwill during the fourth quarter of each year. The impairment assessment can be performed on either a quantitative or qualitative basis. The Company first assesses qualitative factors to determine whether it is necessary to perform a quantitative goodwill impairment analysis. If determined necessary, the Company applies the quantitative impairment test to identify and measure the amount of impairment, if any. During the three months ended March 31, 2022, the Company experienced a decline in its market capitalization as a result of a decline in the Company’s stock price. The Company considered such decline to represent a triggering event requiring management to perform a quantitative goodwill impairment assessment as of March 31, 2022. No such triggering events were identified during the three months ended September 30, 2022. Refer to note 5, Goodwill and Identifiable Intangible Assets, for additional details.

(f) Long-Lived Assets

The Company’s long-lived assets, such as equipment and other fixed assets, operating lease right-of-use assets and definite-lived identifiable intangible assets, are assessed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the asset.

Definite-lived identifiable intangible assets consist of tradenames, payor contracts, contractual rental agreements and developed technology. These assets are amortized using the straight-line method over their estimated useful lives, which reflects the pattern in which the economic benefits of the assets are expected to be consumed. In addition to consideration of impairment upon the events or changes in circumstances described above, management regularly evaluates the remaining useful lives of its long-lived assets. The following table summarizes the useful lives of the Company’s identifiable intangible assets acquired:

Tradenames	5 to 10	years
Payor contracts	10	years
Contractual rental agreements	2	years
Developed technology	5	years

The Company did not incur any impairment charges on long-lived assets for the three and nine months ended September 30, 2022 and 2021.

(g)          Business Segment

The Company’s chief operating decision-makers are its Chief Executive Officer and President, who make resource allocation decisions and assess performance based on financial information presented on an aggregate basis. There are no segment managers who are held accountable by the chief operating decision-makers, or anyone else, for any planning, strategy and key decision-making regarding operations. The corporate office is responsible for contract negotiation with vendors and payors, corporate compliance with healthcare laws and regulations, and revenue cycle management, among other corporate supporting functions. Accordingly, the Company has a single reportable segment and operating segment structure.

(h)          Accounting for Leases

The Company adopted FASB Accounting Standards Update (ASU) No. 2016-02, Leases (Topic 842) (ASC 842) with an effective date of January 1, 2021, using the modified retrospective approach, for leases that existed on January 1, 2021. ASC 842 requires the Company to recognize a lease liability, which represents the discounted obligation to make future minimum lease payments, and a corresponding right-of-use (ROU) asset on its consolidated balance sheet for most leases, and disclose key information about leasing arrangements. The Company elected to apply certain practical expedients permitted under the transition guidance within ASC 842 to leases that commenced before January 1, 2021, including the package of practical expedients, which, among other things, permits lease agreements that are twelve months or less to be excluded from the balance sheet, and permits the Company not to reassess under the new standard its prior conclusions about lease identification, lease classification and initial direct costs. Due to the Company’s election of these practical expedients, the Company carried forward certain historical conclusions for existing contracts, including conclusions related to the existence and classification of leases and to initial direct costs. ASC 842 applies to a number of arrangements to which the Company is a party.

Whenever the Company enters into a new arrangement, it must determine, at the inception date, whether the arrangement is or contains a lease. This determination generally depends on whether the arrangement conveys to the Company the right to control the use of an explicitly or implicitly identified asset for a period of time in exchange for consideration. Control of an underlying asset is conveyed to the Company if the Company obtains the rights to direct the use of and obtain substantially all the economic benefits from the use of the underlying asset.

If a lease exists, the Company must then determine the separate lease and non-lease components of the arrangement. Each right to use an underlying asset conveyed by a lease arrangement should generally be considered a separate lease component if it both: (i) can benefit the Company without depending on other resources not readily available to the Company and (ii) does not significantly affect and is not significantly affected by other rights of use conveyed by the lease. Aspects of a lease arrangement that transfer other goods or services to the Company but do not meet the definition of lease components are considered non-lease components. The consideration owed by the Company pursuant to a lease arrangement is generally allocated to each lease and non-lease component for accounting purposes. However, the Company has elected, for all of its leases, to not separate lease and non-lease components. Each lease component is accounted for separately from other lease components, but together with the associated non-lease components.

For each lease, the Company must then determine the lease term, the present value of lease payments and the classification of the lease as either an operating or finance lease.

The lease term is the period of the lease not cancellable by the Company, together with periods covered by: (i) renewal options the Company is reasonably certain to exercise, (ii) termination options the Company is reasonably certain not to exercise, and (iii) renewal or termination options that are controlled by the lessor.

The present value of lease payments is calculated based on:

● Lease payments – lease payments include fixed and certain variable payments, less lease incentives, together with amounts probable of being owed by the Company under residual value guarantees and, if reasonably certain of being paid, the cost of certain renewal options and early termination penalties set forth in the lease arrangement. Lease payments exclude consideration that is not related to the transfer of goods and services of the Company.

● Discount rate – the discount rate must be determined based on information available to the Company upon the commencement of the lease. Lessees are required to use the rate implicit in the lease whenever such rate is readily available; however, as the implicit rate in the Company’s leases is generally not readily determinable, the Company generally uses the hypothetical incremental borrowing rate it would have to pay to borrow an amount equal to the lease payments, on a collateralized basis, over a timeframe similar to the lease term.

In making the determination of whether a lease is an operating lease or a finance lease, the Company considers the lease term in relation to the economic life of the leased asset, the present value of lease payments in relation to the fair value of the leased asset and certain other factors, including the lessee’s and lessor’s rights, obligations, and economic incentives over the term of the lease.

Generally, upon the commencement of a lease, the Company will record a lease liability and a ROU asset. However, the Company has elected, for all underlying leases with initial terms of twelve months or less (known as short-term leases), to not recognize a lease liability or ROU asset. Lease liabilities are initially recorded at lease commencement as the present value of future lease payments. ROU assets are initially recorded at lease commencement as the initial amount of the lease liability, together with the following, if applicable: (i) initial direct costs incurred by the lessee and (ii) lease payments made by the lessor net of lease incentives received, prior to lease commencement.

Over the lease term, the Company generally increases its lease liabilities using the effective interest method and decreases its lease liabilities for lease payments made. For finance leases, amortization and interest expense are recognized separately in the consolidated statements of operations, with amortization expense generally recorded on a straight-line basis over the lease term and interest expense recorded using the effective interest method. For operating leases, a single lease cost is generally recognized in the consolidated statements of operations on a straight-line basis over the lease term unless an impairment has been recorded with respect to a leased asset. Lease costs for short-term leases not recognized in the consolidated balance sheets are recognized in the consolidated statements of operations on a straight-line basis over the lease term. Variable lease costs not initially included in the lease liability and ROU asset impairment charges are expensed as incurred. ROU assets are assessed for impairment, similar to other long-lived assets.

(i)        Recently Issued Accounting Pronouncements

In March 2020, the FASB issued ASU No. 2020-04, Reference Rate Reform (Topic 848), which provides optional guidance to ease the potential burden in accounting for (or recognizing the effects of) reference rate reform on financial reporting. Specifically, the guidance permits an entity, when certain criteria are met, to consider amendments to contracts made to comply with reference rate reform to meet the definition of a modification under U.S. GAAP. It further allows hedge accounting to be maintained and a one-time transfer or sale of qualifying held-to-maturity securities. The expedients and exceptions provided by the amendments are permitted to be adopted any time through December 31, 2022 and do not apply to contract modifications made and hedging relationships entered into or evaluated after December 31, 2022, except for certain optional expedients elected for certain hedging relationships existing as of December 31, 2022. In October 2022, the FASB approved a proposed amendment to Topic 848 which defers the required adoption date of Topic 848 to December 31, 2024, with early adoption permitted. The Company is currently evaluating the effect that this standard will have on its consolidated financial statements and related disclosures.

XML

Revenue Recognition and Accounts Receivable

9 Months Ended

Sep. 30, 2022

Revenue Recognition and Accounts Receivable

Revenue Recognition and Accounts Receivable

(2)         Revenue Recognition and Accounts Receivable

Revenue Recognition

The Company generates revenues for services and related products that the Company provides to patients for home medical equipment, related supplies, and other items. The Company’s revenues are recognized in the period in which services and related products are provided to customers and are recorded either at a point in time for the sale of supplies and disposables, or over the fixed monthly service period for equipment.

Revenues are recognized when control of the promised good or service is transferred to customers, in an amount that reflects the consideration to which the Company expects to receive from patients or under reimbursement arrangements with Medicare, Medicaid and third-party payors, in exchange for those goods and services.

The Company determines the transaction price based on contractually agreed-upon amounts or rates, adjusted for estimates of variable consideration, such as implicit price concessions. The Company utilizes the expected value method to determine the amount of variable consideration that should be included to arrive at the transaction price, using contractual agreements and historical reimbursement experience within each payor type. The Company applies constraint to the transaction price, such that net revenue is recorded only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in the future. If actual amounts of consideration ultimately received differ from the Company’s estimates, the Company adjusts these estimates, which would affect net revenue in the period such adjustments become known.

Sales revenue is recognized upon transfer of control of products or services to customers in an amount that reflects the consideration the Company expects to receive in exchange for those products or services. Revenues for the sale of sleep therapy equipment supplies (including CPAP resupply products), home medical equipment and related supplies (including wheelchairs, hospital beds and infusion pumps), diabetic medical devices and supplies (including continuous glucose monitors (CGM) and insulin pumps), and other HME products and supplies are recognized when control of the promised good or service is transferred to customers, which is generally upon shipment for direct to consumer medical devices and supplies and upon delivery to the home for home medical equipment.

The Company provides certain equipment to patients which is reimbursed periodically in fixed monthly payments for as long as the patient is using the equipment and medical necessity continues (in certain cases, the fixed monthly payments are capped at a certain amount). The equipment provided to the patient is based upon medical necessity as documented by prescriptions and other documentation received from the patient’s physician. The patient generally does not negotiate or select the manufacturer or model of the equipment prescribed by their physician and delivered by the Company. Once initial delivery of this equipment is made to the patient for initial setup, a monthly billing process is established based on the initial setup service date. The Company recognizes the fixed monthly revenue ratably over the service period as earned, less estimated adjustments, and defers revenue for the portion of the monthly bill that is unearned. No separate revenue is earned from the initial setup process. Included in fixed monthly revenue are unbilled amounts for which the revenue recognition criteria had been met as of period-end but were not yet billed to the payor. The estimate of net unbilled fixed monthly revenue recognized is based on historical trends and estimates of future collectability.

The Company’s billing system contains payor-specific price tables that reflect the fee schedule amounts in effect or contractually agreed upon by various government and commercial insurance payors for each item of equipment or supply provided to a customer. Revenues are recorded based on the applicable fee schedule. The Company has established a contractual allowance to account for adjustments that result from differences between the payment amount received and the expected realizable amount. If the payment amount received differs from the net realizable amount, an

adjustment is recorded to revenues in the period that these payment differences are determined. The Company reports revenues in its consolidated financial statements net of such adjustments.

The Company recognizes revenue in the consolidated statements of operations and contract assets on the consolidated balance sheets only when services have been provided. Since the Company has performed its obligation under the contract, it has unconditional rights to the consideration recorded as contract assets and therefore classifies those billed and unbilled contract assets as accounts receivable.

Fixed monthly payments that the Company receives from customers in advance of providing services represent contract liabilities. Such payments primarily relate to patients who are billed monthly in advance and are recognized over the period as earned.

The Company disaggregates net revenue from contracts with customers by payor type and by core service lines. The Company believes that disaggregation of net revenue into these categories depicts how the nature, amount, timing and uncertainty of revenue and cash flows are affected by economic factors. The payment terms and conditions within the Company’s revenue-generating contracts vary by payor type and payor source.

The composition of net revenue by payor type for the three and nine months ended September 30, 2022 and 2021 are as follows (in thousands):

	Three Months Ended September 30,				Nine Months Ended September 30,
	2022			2021	2022		2021
Insurance	$	465,625	$	399,748	$	1,322,694	$	1,061,627
Government		198,841		180,511		576,829		491,564
Patient pay		92,029		73,034		290,789		199,238
Net revenue	$	756,495	$	653,293	$	2,190,312	$	1,752,429

The composition of net revenue by core service lines for the three and nine months ended September 30, 2022 and 2021 are as follows (in thousands):

	Three Months Ended September 30,				Nine Months Ended September 30,
	2022			2021	2022		2021
Net sales revenue:
Sleep	$	198,206	$	173,359	$	585,234	$	465,372
Diabetes		169,075		134,228		482,693		352,559
Supplies to the home		47,793		42,441		131,539		126,479
Respiratory		9,734		6,228		25,770		25,003
HME		29,463		29,919		89,828		82,588
Other		58,252		45,996		166,068		98,032
Total net sales revenue	$	512,523	$	432,171	$	1,481,132	$	1,150,033
Net revenue from fixed monthly equipment reimbursements:
Sleep	$	72,423	$	62,755	$	196,022	$	177,199
Diabetes		4,211		3,722		12,191		9,791
Respiratory		130,618		117,918		392,063		312,900
HME		25,482		26,043		76,754		70,854
Other		11,238		10,684		32,150		31,652
Total net revenue from fixed monthly equipment reimbursements	$	243,972	$	221,122	$	709,180	$	602,396
Total net revenue:
Sleep	$	270,629	$	236,114	$	781,256	$	642,571
Diabetes		173,286		137,950		494,884		362,350
Supplies to the home		47,793		42,441		131,539		126,479
Respiratory		140,352		124,146		417,833		337,903
HME		54,945		55,962		166,582		153,442
Other		69,490		56,680		198,218		129,684
Total net revenue	$	756,495	$	653,293	$	2,190,312	$	1,752,429

Certain prior period amounts in the table above have been reclassified to conform to the current period presentation. These reclassifications are considered immaterial to all periods presented.

In response to the COVID-19 pandemic and the National Emergency Declaration, dated March 13, 2020, the Company increased its cash liquidity by, among other things, seeking recoupable advance payments of $45.8 million made available by the Centers for Medicare & Medicaid Services (CMS) under the Coronavirus Aid, Relief, and Economic Security Act (the CARES Act) legislation, which was received in April 2020. In addition, in connection with an acquisition completed in July 2020, the Company assumed a liability of $3.7 million relating to CMS recoupable advance payments received by the acquired company prior to the date of acquisition. The recoupment of the advance payments by CMS began in April 2021 and were applied to services provided and revenue recognized during the period in which the recoupment occurred, which impacted the Company’s cash receipts for services provided during the period in which amounts were recouped. As of September 30, 2022 the recoupment period has ended, and any remaining amounts not recouped will be repaid by the Company to CMS. During the three and nine months ended September 30, 2022, CMS recouped $0.5 million and $9.6 million, respectively, of the advance payments. During the three and nine months ended September 30, 2021, CMS recouped $11.1 million and $27.0 million, respectively, of the advance payments. As of September 30, 2022, the remaining amount of the CMS advance payments that had not yet been recouped was $3.2 million, which is included in other current liabilities in the consolidated balance sheets.

Accounts Receivable

Due to the continuing changes in the healthcare industry and third-party reimbursement environment, certain estimates are required to record accounts receivable at their net realizable values. Inherent in these estimates is the risk that they will have to be revised or updated as additional information becomes available. The complexity of third-party billing arrangements and laws and regulations governing Medicare and Medicaid may result in adjustments to amounts originally recorded.

The Company performs a periodic analysis to review the valuation of accounts receivable and collectability of outstanding balances. Management’s evaluation takes into consideration such factors as historical cash collections experience, business and economic conditions, trends in healthcare coverage, other collection indicators and information about specific receivables. The Company’s evaluation also considers the age and composition of the outstanding amounts in determining their estimated net realizable value.

Receivables are considered past due when not collected by established due dates. Specific patient balances are written off after collection efforts have been followed and the account has been determined to be uncollectible. Revisions in reserve estimates are recorded as an adjustment to net revenue in the period of revision.

Included in accounts receivable are earned but unbilled accounts receivables. Billing delays, ranging from several days to several weeks, can occur due to the Company’s policy of compiling required payor specific documentation prior to billing for its services rendered. As of September 30, 2022 and December 31, 2021, the Company’s unbilled accounts receivable was $22.9 million and $23.8 million, respectively.

XML

Acquisitions

9 Months Ended

Sep. 30, 2022

Acquisitions

Acquisitions

(3)          Acquisitions

During the nine months ended September 30, 2022 and 2021, the Company completed several acquisitions to strengthen its current market share in existing markets or to expand into new markets. Each of the Company’s acquisitions was accounted for using the acquisition method pursuant to the requirements of FASB ASC Topic 805, Business Combinations, and are included in the Company’s consolidated financial statements since the respective acquisition date. The goodwill generated from these acquisitions is attributable to expected growth and cost synergies and the expected contribution of each acquisition to the Company’s overall strategy. The goodwill recorded during the nine months ended September 30, 2022 is not expected to be deductible for tax purposes. The estimated fair values of the net assets of acquired businesses as described below are subject to change resulting from such items as final analysis of valuations and working capital adjustments post-acquisition. As a result, the acquisition accounting for certain acquired businesses could change in subsequent periods resulting in adjustments to goodwill once finalized. Also, see subsection, “Pro forma information” of this Note 3 for pro forma information on net revenue and operating income.

Nine Months Ended September 30, 2022

During the nine months ended September 30, 2022, the Company acquired 100% of the equity interests of two providers of HME and acquired certain assets of the home medical equipment businesses of five providers of HME.

The following table summarizes the consideration paid at closing for all acquisitions during the nine months ended September 30, 2022 (in thousands):

Cash	$	16,477
Deferred payments		422
Total	$	16,899

The Company allocated the consideration paid to the net assets acquired based on their estimated acquisition date fair values. The Company is still evaluating the fair value of certain assets and liabilities for which provisional amounts were recorded and expects to finalize such valuations during the remainder of 2022. Based upon management’s evaluation, which is preliminary and subject to completion of working capital and other adjustments, the consideration paid for all acquisitions during 2022 was allocated as follows (in thousands):

Cash	$	155
Accounts receivable		2,206
Inventory		686
Prepaid and other current assets		16
Equipment and other fixed assets		4,502
Goodwill		11,788
Identifiable intangible assets		500
Accounts payable and accrued expenses		(2,820)
Contract liabilities		(134)
Net assets acquired	$	16,899

During the nine months ended September 30, 2022, the Company received net cash of $0.2 million relating to working capital and other adjustments associated with businesses that were acquired during 2021, which was recorded as a decrease to goodwill during the period.

Nine Months Ended September 30, 2021

On February 1, 2021, the Company acquired 100% of the equity interests of AeroCare Holdings, Inc. (AeroCare). AeroCare is a leading national technology-enabled respiratory and home medical equipment distribution platform in the United States and offers a comprehensive suite of direct-to-patient equipment and services including CPAP and BiPAP machines, oxygen concentrators, home ventilators, and other home medical equipment products. The total consideration paid consisted of (i) cash payments of $1.2 billion, (ii) the issuance of 13,992,615 shares of the Company’s Class A Common Stock, (iii) the issuance of 130,474.73 shares of the Company’s Series C Convertible Preferred Stock, and (iv) the issuance of 3,959,892 fully vested options to purchase shares of the Company’s Class A Common Stock in the future, which had a weighted-average exercise price of $6.24 per share and a weighted-average remaining exercise period of approximately 7 years from the date of closing. Refer to Note 10, Stockholders’ Equity, for additional discussion of the Series C Convertible Preferred Stock issued in connection with the acquisition of AeroCare.

On April 30, 2021, the Company acquired 100% of the equity interests of Spiro Health Services, LLC (Spiro). Spiro is a provider of home medical equipment and supplies. The total consideration paid at closing consisted of a cash payment of $66.1 million, the issuance of 244,641 shares of the Company’s Class A Common Stock, and a potential contingent consideration payment of up to $1.0 million, which was determined to be the fair value at the acquisition date and such amount was recorded as a contingent consideration liability in connection with the Company’s acquisition accounting.

On June 1, 2021, the Company acquired 100% of the equity interests of Healthy Living Medical Supply, LLC (Healthy Living). Healthy Living is a provider of continuous glucose monitors and insulin pumps. The total consideration paid at closing consisted of a cash payment of $47.0 million and the issuance of 196,779 shares of the Company’s Class A Common Stock.

On July 1, 2021, the Company acquired 100% of the equity interests of Agilis Med Holdings, LLC (Agilis). Agilis is an e-commerce retailer of sleep apnea and respiratory equipment in the United States. The total consideration paid at closing consisted of a cash payment of $30.8 million, the issuance of 538,079 shares of the Company’s Class A Common Stock, and a potential contingent consideration payment of up to $1.0 million, which was determined to be the

fair value at the acquisition date and such amount was recorded as a contingent consideration liability in connection with the Company’s acquisition accounting. Such amount is included in other current liabilities in the accompanying consolidated balance sheets at September 30, 2022 based on the expected payment date. In October 2020, the Company acquired a minority interest in Agilis, which was being accounted for under the equity method of accounting prior to the July 2021 transaction. The carrying value of such investment was $8.1 million at the July 2021 transaction date. The fair value of the equity method investment was $10.0 million at the July 2021 transaction date. In connection with the accounting for the July 2021 transaction, the Company recorded goodwill of $10.0 million and eliminated the carrying value of the equity method investment of $8.1 million and recorded a gain on equity method of investment of $1.9 million, which is included in other loss (income), net in the accompanying consolidated statements of operations during the three and nine months ended September 30, 2021.

On July 1, 2021, the Company acquired 100% of the equity interests of WeCare Medical, LLC (WeCare). WeCare is a distributor of durable medical equipment and supplies in the United States. The total consideration paid at closing consisted of a cash payment of $34.8 million and the issuance of 231,866 shares of the Company’s Class A Common Stock.

In addition, during the nine months ended September 30, 2021, the Company acquired 100% of the equity interests of ten providers of home medical equipment and acquired certain assets of the durable medical equipment business of a provider of home medical equipment. The aggregate total consideration paid for these acquisitions consisted of cash payments of $121.7 million, the issuance of 306,569 shares of the Company’s Class A Common Stock, and deferred payment liabilities of $1.2 million.

The following table summarizes the consideration paid at closing for all acquisitions during the nine months ended September 30, 2021 (in thousands):

	AeroCare		Spiro		Healthy Living		Agilis		We Care		Other		Total
Cash	$	1,152,768	$	66,101	$	47,048	$	30,842	$	34,833	$	121,710	$	1,453,302
Equity		1,220,342		7,109		5,057		14,668		6,321		7,703		1,261,200
Contingent consideration		—		1,000		—		1,000		—		—		2,000
Deferred payments		—		—		—		—		—		1,162		1,162
Total	$	2,373,110	$	74,210	$	52,105	$	46,510	$	41,154	$	130,575	$	2,717,664

The Company allocated the consideration paid to the net assets acquired based on their estimated acquisition date fair values. Based upon management’s evaluation, which was preliminary and subject to completion of working capital and other adjustments, the consideration paid for all acquisitions during the nine months ended September 30, 2021 was allocated as follows during that period (in thousands):

	AeroCare		Spiro		Healthy Living		Agilis		We Care		Other		Total
Cash	$	27,686	$	2,132	$	580	$	1,170	$	458	$	2,673	$	34,699
Accounts receivable		75,916		8,526		7,471		—		6,355		20,900		119,168
Inventory		27,612		4,939		2,948		2,478		1,488		6,219		45,684
Prepaid and other current assets		3,522		152		254		—		—		2,466		6,394
Equipment and other fixed assets		190,755		2,148		1,201		—		8,170		13,076		215,350
Operating lease right-of-use assets		55,132		2,738		1,366		490		970		12,176		72,872
Goodwill		2,096,850		62,640		41,955		52,938		29,080		102,688		2,386,151
Identifiable intangible assets		122,800		1,000		1,300		500		400		2,400		128,400
Other assets		1,178		16		—		—		—		—		1,194
Deferred tax liabilities		(64,916)		—		—		—		(3,358)		425		(67,849)
Accounts payable and accrued expenses		(82,722)		(5,148)		(3,604)		(576)		(1,439)		(13,921)		(107,410)
Contract liabilities		(14,495)		—		—		—		—		(124)		(14,619)
Other current liabilities		(10,021)		—		—		—		—		(1,555)		(11,576)
Other long-term liabilities		(1,055)		—		—		—		—		—		(1,055)
Operating lease obligations		(55,132)		(2,738)		(1,366)		(490)		(970)		(12,176)		(72,872)
Capital lease obligations		—		(2,195)		—		—		—		(4,672)		(6,867)
Net assets acquired	$	2,373,110	$	74,210	$	52,105	$	56,510	$	41,154	$	130,575	$	2,727,664

During the nine months ended September 30, 2021, the Company received net cash of $0.7 million relating to working capital and other adjustments associated with businesses that were acquired during 2020, which was recorded as a decrease to goodwill during the period.

Pro-Forma Information

The unaudited pro-forma financial information presented below has been prepared by adjusting the historical results of the Company to include the historical results of the acquisitions described above and to give effect to the GAAP accounting for the acquisitions had they been owned in the earliest period presented below. The unaudited pro-forma financial information is presented for illustrative purposes only and may not be indicative of the results of operations that would have actually occurred. In addition, future results may vary significantly from the results reflected in the pro-forma information. The unaudited pro-forma financial information does not reflect the impact of future events that may occur after the acquisitions, such as the impact of cost savings or other synergies that may result from these acquisitions, and does not include interest expense associated with debt incurred to fund the acquisitions.

(in thousands) (unaudited)	Three Months Ended September 30,				Nine Months Ended September 30,
	2022		2021		2022		2021
Net revenue	$	756,495	$	722,406	$	2,195,434	$	2,140,382

Operating income $ 52,949 $ 83,788 $ 163,630 $ 195,945

Results of Businesses Acquired

The following table presents the amount of net revenue and operating income (loss) in the period of acquisition since the respective acquisition dates for the acquisitions described above that is included in the Company’s consolidated statements of operations for the three and nine months ended September 30, 2022 and 2021:

(in thousands)	Three Months Ended September 30,				Nine Months Ended September 30,
	2022		2021		2022		2021
Net revenue	$	5,062	$	289,604	$	10,764	$	680,460
Operating income (loss)	$	(726)	$	37,454	$	(333)	$	95,143

XML

Equipment and Other Fixed Assets

9 Months Ended

Sep. 30, 2022

Equipment and Other Fixed Assets

Equipment and Other Fixed Assets

(4)          Equipment and Other Fixed Assets

Equipment and other fixed assets as of September 30, 2022 and December 31, 2021 are as follows (in thousands):

	September 30,		December 31,
	2022		2021
Patient medical equipment	$	711,300	$	533,760
Delivery vehicles		36,089		36,213
Other		83,816		50,208
		831,205		620,181
Less accumulated depreciation		(358,149)		(221,604)
	$	473,056	$	398,577

For the three months ended September 30, 2022 and 2021, the Company recorded depreciation expense of $82.4 million and $59.7 million, respectively. For the nine months ended September 30, 2022 and 2021, the Company recorded depreciation expense of $218.9 million and $146.5 million, respectively.

XML

Goodwill and Identifiable Intangible Assets

9 Months Ended

Sep. 30, 2022

Goodwill and Identifiable Intangible Assets

Goodwill and Identifiable Intangible Assets

(5)          Goodwill and Identifiable Intangible Assets

Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. The change in the carrying amount of goodwill for the nine months ended September 30, 2022 was as follows (in thousands):

	Gross carrying
	amount
Balance at December 31, 2021	$	3,512,567
Goodwill from acquisitions		11,788
Net cash receipts relating to prior acquisitions		(188)
Net increase relating to measurement period adjustments		832
Balance at September 30, 2022	$	3,524,999

Management is required to perform an assessment of the recoverability of goodwill on an annual basis and upon the identification of a triggering event. Triggering events potentially warranting an interim goodwill impairment assessment include, among other factors, declines in historical or projected revenue, operating results or cash flows, and

declines in the Company’s stock price or market capitalization. While management cannot predict if or when future goodwill impairments may occur, a non-cash goodwill impairment charge could have a material adverse effect on the Company’s operating results, net assets and the Company’s cost of, or access to, capital. During the three months ended March 31, 2022, the Company experienced a decline in its market capitalization as a result of a decline in the Company’s stock price. The Company considered such decline to represent a triggering event requiring management to perform a quantitative goodwill impairment assessment as of March 31, 2022. Based on the results of the quantitative goodwill impairment assessment, it was concluded that the estimated fair value of the Company’s reporting unit was greater than its carrying value, as such, the Company did not record a goodwill impairment charge during the three months ended March 31, 2022. No such triggering events were identified during the three months ended September 30, 2022. The Company did not record a goodwill impairment charge during the three and nine months ended September 30, 2022 and 2021. Subsequent to September 30, 2022, the Company has not experienced a decline in its market capitalization, however, if the Company were to experience a decline for a sustained period of time, the Company may be required to perform a quantitative goodwill impairment assessment at an interim or annual period and could be required to recognize a non-cash goodwill impairment charge at that time, which could be material.

As discussed in Note 3, Acquisitions, during the nine months ended September 30, 2022, the Company received net cash of $0.2 million relating to working capital and other adjustments associated with businesses that were acquired during 2021, which was recorded as a decrease to goodwill during the period.

Identifiable intangible assets that are separable and have determinable useful lives are valued separately and amortized over the period which reflects the pattern in which the economic benefits of the assets are expected to be consumed. Identifiable intangible assets consisted of the following at September 30, 2022 and December 31, 2021 (in thousands):

	September 30, 2022
			Weighted-Average
			Remaining Life (Years)
Tradenames, net of accumulated amortization of $22,294	$	90,506	7.7
Payor contracts, net of accumulated amortization of $17,966		64,034	7.8
Contractual rental agreements, net of accumulated amortization of $39,433		14,767	1.0
Developed technology, net of accumulated amortization of $2,835		3,465	2.8
Identifiable intangible assets, net	$	172,772

	December 31, 2021
			Weighted-Average
			Remaining Life (Years)
Tradenames, net of accumulated amortization of $12,705	$	99,595	8.4
Payor contracts, net of accumulated amortization of $11,816		70,184	8.6
Contractual rental agreements, net of accumulated amortization of $26,158		28,042	1.8
Developed technology, net of accumulated amortization of $1,890		4,410	3.5
Identifiable intangible assets, net	$	202,231

Amortization expense related to identifiable intangible assets, which is included in depreciation and amortization, excluding patient equipment depreciation, in the accompanying statements of operations, was $10.0 million and $30.0 million for the three and nine months ended September 30, 2022, respectively. Amortization expense related to identifiable intangible assets, which is included in depreciation and amortization, excluding patient equipment depreciation, in the accompanying statements of operations, was $10.1 million and $34.4 million for the three and nine months ended September 30, 2021, respectively.

Future amortization expense related to identifiable intangible assets is estimated to be as follows (in thousands):

Twelve months ending September 30,
2023	$	37,043
2024		22,276
2025		21,828
2026		19,618
2027		18,190
Thereafter		53,817
Total	$	172,772

The Company recorded no impairment charges related to identifiable intangible assets during the three and nine months ended September 30, 2022 and 2021.

XML

Fair Value of Assets and Liabilities

9 Months Ended

Sep. 30, 2022

Fair Value of Assets and Liabilities

Fair Value of Assets and Liabilities

(6)          Fair Value of Assets and Liabilities

FASB ASC Topic 820, Fair Value Measurements and Disclosures (ASC 820), creates a single definition of fair value, establishes a framework for measuring fair value in U.S. GAAP and expands disclosures about fair value measurements. Assets and liabilities adjusted to fair value in the balance sheet are categorized based upon the level of judgment associated with the inputs used to measure their fair value. Level inputs, as defined by ASC 820, are as follows:

Level input	Input Definition
Level 1	Inputs are unadjusted, quoted prices for identical assets or liabilities in active markets at the measurement date.
Level 2	Inputs, other than quoted prices included in Level 1 that are observable for the asset or liability through corroboration with market data at the measurement date.
Level 3	Unobservable inputs that reflect management’s best estimate of what market participants would use in pricing the asset or liability at the measurement date.

The following table presents the valuation of the Company’s financial assets and liabilities as of September 30, 2022 and December 31, 2021 measured at fair value on a recurring basis. The fair value estimates presented herein are based on information available to management as of September 30, 2022 and December 31, 2021. These estimates are not necessarily indicative of the amounts the Company could ultimately realize.

(in thousands)	Level 1		Level 2		Level 3
September 30, 2022
Assets
Money market accounts	$	11	$	—	$	—
Interest rate swap agreements-short term		—		4,471		—
Interest rate swap agreements-long term		—		5,621		—
Total assets measured at fair value	$	11	$	10,092	$	—
Liabilities
Acquisition-related contingent consideration-short term	$	—	$	—	$	14,527
Warrant liability		—		—		38,516
Total liabilities measured at fair value	$	—	$	—	$	53,043

(in thousands)	Level 1		Level 2		Level 3
December 31, 2021
Assets
Money market accounts	$	14	$	—	$	—
Total assets measured at fair value	$	14	$	—	$	—
Liabilities
Acquisition-related contingent consideration-short term	$	—	$	—	$	13,500
Acquisition-related contingent consideration-long term		—		—		6,800
Interest rate swap agreements-short term		—		5,098		—
Interest rate swap agreements-long term		—		2,359		—
Warrant liability		—		—		57,764
Total liabilities measured at fair value	$	—	$	7,457	$	78,064

Interest Rate Swaps

The Company uses interest rate swap agreements to manage interest rate risk by converting a portion of its variable rate borrowings to a fixed rate and recognizes these derivative instruments as either assets or liabilities in the accompanying consolidated balance sheets at fair value. The valuation of these derivative instruments is determined using widely accepted valuation techniques, including discounted cash flow analysis on the expected cash flows of each derivative. This analysis reflects the contractual terms of the derivatives, including the period to maturity, and uses observable market-based inputs, including interest rate curves and implied volatilities. The fair value of the Company’s interest rate swaps are determined using the market standard methodology of netting the discounted future fixed cash payments and the discounted expected variable cash payments receipts. The variable cash receipts are based on an expectation of future interest rates (forward curves) derived from observable market interest rate curves. To comply with the provisions of FASB ASC Topic 820, Fair Value Measurement, the Company incorporates credit valuation adjustments to appropriately reflect both its own nonperformance risk and the respective counterparty’s nonperformance risk in the fair value measurements. In adjusting the fair value of its derivative contracts for the effect of nonperformance risk, the Company has considered the impact of netting and any applicable credit enhancements, such as collateral postings, thresholds, mutual puts and guarantees.

Although the Company has determined that the majority of the inputs used to value its derivatives fall within Level 2 of the fair value hierarchy, the credit valuation adjustments associated with the Company’s derivatives utilize Level 3 inputs, such as estimates of current credit spreads to evaluate the likelihood of default by the Company and the respective counterparties. The Company has determined that the significance of the impact of the credit valuation adjustments made to its derivative contracts, which determination was based on the fair value of each individual contract, was not significant to the overall valuation. As a result, all of the Company’s derivatives held as of September 30, 2022 and December 31, 2021 were classified as Level 2 of the fair value hierarchy. Refer to Note 7, Derivative Instruments and Hedging Activities, for additional information regarding the Company’s derivative instruments.

Acquisition-Related Contingent Consideration

The Company estimates the fair value of acquisition-related contingent consideration liabilities by applying the income approach using a probability-weighted discounted cash flow model. This fair value measurement is based on significant inputs not observed in the market and thus represents a Level 3 measurement. Level 3 instruments are valued based on unobservable inputs that are supported by little or no market activity and reflect the Company’s own assumptions in measuring fair value. Each period, the Company evaluates the fair value of acquisition-related contingent consideration obligations and records any changes in the fair value of such liabilities in other income in the Company’s consolidated statements of operations. At September 30, 2022, contingent consideration liabilities of $14.5 million were included in other current liabilities in the accompanying consolidated balance sheets. At December 31, 2021, contingent

consideration liabilities of $13.5 million and $6.8 million were included in other current liabilities and other long-term liabilities, respectively, in the accompanying consolidated balance sheets.

A reconciliation of the Company’s contingent consideration liabilities related to acquisitions for the nine months ended September 30, 2022 and 2021 is as follows (in thousands):

Nine Months Ended September 30, 2022	Beginning Balance		Additions		Payments		Change in Fair Value		Other activity		Ending Balance
Contingent consideration - Level 3 liabilities	$	20,300	$	—	$	(6,250)	$	477	$	—	$	14,527
Nine Months Ended September 30, 2021
Contingent consideration - Level 3 liabilities	$	33,540	$	2,000	$	(18,200)	$	1,135	$	173	$	18,648

Warrant Liability

The warrant liability represents the estimated fair value of the Company’s outstanding private warrants. The fair value of the private warrants was estimated using the Black-Scholes option pricing model. Refer to Note 10, Stockholders’ Equity, for additional discussion of the warrant liability.

Non-Financial Assets Measured at Fair Value on a Non-Recurring Basis

The following table presents the Company’s hierarchy for non-financial assets measured at fair value on a non-recurring basis (in thousands):

	September 30,		December 31,
	2022		2021
Assets:
Goodwill (Level 3)	$	3,524,999	$	3,512,567
Identifiable intangible assets, net (Level 3)	$	172,772	$	202,231

The fair value allocation related to the Company’s acquisitions are determined using a discounted cash flow approach, or a replacement cost approach, which are based on significant unobservable inputs (Level 3). These valuation methods required management to make various assumptions, including, but not limited to, future profitability, cash flows, replacement costs, and discount rates. The Company’s estimates are based upon historical trends, management’s knowledge and experience and overall economic factors, including projections of future earnings potential.

Developing discounted future cash flows in applying the income approach requires the Company to evaluate its intermediate to longer-term strategies, including, but not limited to, estimates of revenue growth, operating margins, capital requirements, inflation and working capital management. The development of appropriate rates to discount the estimated future cash flows requires the selection of risk premiums, which can materially impact the present value of future cash flows.

The Company estimated the fair value of acquired identifiable intangible assets using discounted cash flow techniques that included an estimate of future cash flows, consistent with overall cash flow projections used to determine the purchase price paid to acquire the business, discounted at a rate of return that reflects the relative risk of the cash flows. The Company estimated the fair value of certain acquired identifiable intangible assets based on the cost approach using estimated costs consistent with historical experience. The Company believes the estimates and assumptions used in the valuation methods are reasonable.

XML

Derivative Instruments and Hedging Activities

9 Months Ended

Sep. 30, 2022

Derivative Instruments and Hedging Activities

Derivative Instruments and Hedging Activities

(7)          Derivative Instruments and Hedging Activities

The Company records all derivatives on its consolidated balance sheet at fair value. As of September 30, 2022 and December 31, 2021, the Company had outstanding interest rate derivatives with third parties in which the Company pays a fixed interest rate and receives a rate equal to the one-month LIBOR. The notional amount associated with interest rate swap agreements that were outstanding as of September 30, 2022 and December 31, 2021 was $250 million and have maturity dates in February 2023 and March 2024. In April 2022, the Company entered into additional forward-dated interest rate swap agreements with third parties in which the Company will pay a fixed interest rate and receive a rate equal to the one month-LIBOR. The purpose of these forward-dated interest rate swap agreements is to ensure that the Company operates within its derivatives policy by maintaining a total notional amount of $250 million under the Company’s outstanding interest rate swap agreements through the maturity date of the Company’s current credit agreement. These forward-dated interest rate swap agreements become effective in February 2023 and March 2024 and mature in January 2026. The Company has designated its swaps as effective cash flow hedges of interest rate risk. Accordingly, changes in the fair value of the interest rate swaps are recorded as a component of accumulated other comprehensive income within stockholders’ equity and subsequently reclassified into interest expense in the same period during which the hedged transaction affects earnings.

The table below presents the fair value of the Company’s derivatives related to its interest rate swap agreements, which are designated as hedging instruments, as well as their classification in the consolidated balance sheets at September 30, 2022 and December 31, 2021 (in thousands):

		September 30, 2022		December 31, 2021
Balance Sheet Location	Asset (Liability)
Other current assets	$	4,471	$	—
Other long-term assets		5,621		—
Other current liabilities		—		(5,098)
Other long-term liabilities		—		(2,359)
Total	$	10,092	$	(7,457)

During the three months ended September 30, 2022 and 2021, as a result of the effect of cash flow hedge accounting, the Company recognized a gain of $8.5 million and $1.4 million, respectively, in other comprehensive income. In addition, during the three months ended September 30, 2022 and 2021, $0.8 million and $0.8 million, respectively, was reclassified from other comprehensive income and recognized as a reduction to interest expense, net, in the accompanying consolidated statements of operations. During the nine months ended September 30, 2022 and 2021, as a result of the effect of cash flow hedge accounting, the Company recognized a gain of $17.5 million and $5.4 million, respectively, in other comprehensive income. In addition, during the nine months ended September 30, 2022 and 2021, $2.2 million and $2.1 million, respectively, was reclassified from other comprehensive income and recognized as a reduction to interest expense, net, in the accompanying consolidated statements of operations.

XML

Accounts Payable and Accrued Expenses

9 Months Ended

Sep. 30, 2022

Accounts Payable and Accrued Expenses

Accounts Payable and Accrued Expenses

(8)          Accounts Payable and Accrued Expenses

Accounts payable and accrued expenses as of September 30, 2022 and December 31, 2021 consisted of the following (in thousands):

	September 30,		December 31,
	2022		2021
Accounts payable	$	238,203	$	248,027
Employee-related accruals		50,539		34,370
Accrued interest		9,924		30,103
Other		48,254		45,884
Total	$	346,920	$	358,384

XML

Debt

9 Months Ended

Sep. 30, 2022

Debt

Debt

(9)          Debt

The following is a summary of long term-debt as of September 30, 2022 and December 31, 2021 (in thousands):

	September 30,		December 31,
	2022		2021
Secured term loans	$	770,000	$	785,000
Senior unsecured notes		1,450,000		1,450,000
Unamortized deferred financing fees		(27,912)		(31,448)
		2,192,088		2,203,552
Current portion		(30,000)		(20,000)
Long-term portion	$	2,162,088	$	2,183,552

On January 20, 2021, the Company refinanced its then existing debt borrowings and entered into a new credit agreement with its existing bank group, which was amended in April 2021 (the 2021 Credit Agreement). The 2021 Credit Agreement included borrowings of $800 million under a term loan (the 2021 Term Loan), and $450 million in commitments for revolving credit loans (the 2021 Revolver). The 2021 Revolver has a $55 million letter of credit sublimit. The 2021 Term Loan and the 2021 Revolver both have maturities in January 2026. Borrowings under the 2021 Term Loan were used in part to partially finance the cash portion of the purchase price for the acquisition of AeroCare, to repay amounts outstanding under the Company’s then existing credit agreement of $301.9 million plus accrued interest, to repay amounts outstanding under revolving credit loans under the 2021 Credit Agreement which were borrowed prior to the April 2021 amendment, and to pay related fees and expenses. Amounts borrowed under the 2021 Credit Agreement bear interest quarterly at variable rates based upon the sum of (a) the Adjusted LIBOR Rate (subject to a zero percent floor) equal to the LIBOR (as defined) for the applicable interest period multiplied by the statutory reserve rate, plus (b) an applicable margin (as defined) ranging from 1.50% to 3.25% per annum based on the Consolidated Senior Secured Leverage Ratio (as defined). The 2021 Revolver carries a commitment fee during the term of the 2021 Credit Agreement ranging from 0.25% to 0.50% per annum of the average daily undrawn portion of the 2021 Revolver based on the Consolidated Senior Secured Leverage Ratio. On August 16, 2021, the Company amended the 2021 Credit Agreement to expressly permit the issuance of the 5.125% Senior Notes (see discussion below) and the prepayment of the outstanding principal amount under a then existing promissory note with the proceeds of the 5.125% Senior Notes. In connection with the 2021 Credit Agreement, the Company paid financing costs of $7.6 million. Further, in connection with executing the 2021 Credit Agreement, the Company recognized a loss on debt extinguishment of $2.1 million consisting of the write off unamortized deferred financing costs related to the Company’s then existing credit agreement and other lender fees, which is included in loss on extinguishment of debt in the accompanying consolidated statements of operations for the nine months ended September 30, 2021.

Under the 2021 Credit Agreement, the Company is subject to a number of restrictive covenants that, among other things, impose operating and financial restrictions on the Company. Financial covenants include a Consolidated Total Leverage Ratio and a Consolidated Interest Coverage Ratio, both as defined in the 2021 Credit Agreement. The 2021 Credit Agreement also contains certain customary events of default, including, among other things, failure to make

payments when due thereunder, failure to observe or perform certain covenants, cross-defaults, bankruptcy and insolvency-related events, and non-compliance with healthcare laws. Any borrowing under the 2021 Credit Agreement may be repaid, in whole or in part, at any time and from time to time without premium or penalty, other than customary breakage costs, and any amounts repaid under the 2021 Revolver may be reborrowed. Mandatory prepayments are required under the 2021 Revolver when borrowings and letter of credit usage exceed the total commitments for revolving credit loans. Mandatory prepayments are also required in connection with the disposition of assets to the extent not reinvested, unpermitted debt transactions, and excess cash flow, as defined, if certain leverage tests are not met. The Company was in compliance with all debt covenants as of September 30, 2022.

Secured Term Loans

The borrowings under the 2021 Term Loan require quarterly principal repayments of $5.0 million beginning June 30, 2021 through March 31, 2023, increasing to $10.0 million beginning June 30, 2023 through December 31, 2025, and the unpaid principal balance is due at maturity in January 2026. At September 30, 2022 and December 31, 2021, there was $770 million and $785 million, respectively, outstanding under the 2021 Term Loan. The interest rate under the 2021 Term Loan was 4.56% at September 30, 2022.

Revolving Credit Facility

During the nine months ended September 30, 2022, the Company had no borrowings under the 2021 Revolver, and there was $0 outstanding under the 2021 Revolver at September 30, 2022. During the nine months ended September 30, 2021, the Company borrowed $365.0 million under revolving credit loans pursuant to the 2021 Credit Agreement, which were all repaid during the period. Borrowings under the 2021 Revolver may be used for working capital and other general corporate purposes, including for capital expenditures and acquisitions permitted under the 2021 Credit Agreement. At September 30, 2022, after consideration of stand-by letters of credit outstanding of $17.4 million, the remaining maximum borrowings available pursuant to the 2021 Revolver was $432.6 million.

Senior Unsecured Notes

On August 19, 2021, the Company issued $600.0 million aggregate principal amount of 5.125% senior unsecured notes due 2030 (the 5.125% Senior Notes). The 5.125% Senior Notes will mature on March 1, 2030. Interest on the 5.125% Senior Notes is payable on March 1st and September 1st of each year, beginning on March 1, 2022. The 5.125% Senior Notes will be redeemable at the Company’s option, in whole or in part, at any time on or after March 1, 2025, and the redemption price for the 5.125% Senior Notes if redeemed during the 12 months beginning (i) March 1, 2025 is 102.563%, (ii) March 1, 2026 is 101.281%, (iii) March 1, 2027 and thereafter is 100.000%, in each case together with accrued and unpaid interest. The Company may also redeem some or all of the 5.125% Senior Notes before March 1, 2025 at a redemption price of 100% of the principal amount of the 5.125% Senior Notes, plus a “make-whole” premium, together with accrued and unpaid interest. In addition, the Company may redeem up to 40% of the original aggregate principal amount of the 5.125% Senior Notes before March 1, 2025 with the proceeds from certain equity offerings at a redemption price equal to 105.125% of the principal amount of the 5.125% Senior Notes, together with accrued and unpaid interest. Furthermore, the Company may be required to make an offer to purchase the 5.125% Senior Notes upon the sale of certain assets or upon specific kinds of changes of control. Borrowings under the 5.125% Senior Notes were used to repay existing amounts outstanding under the 2021 Revolver, to prepay the outstanding principal amount under a then existing promissory note, and to pay related fees and expenses. In connection with the issuance of the 5.125% Senior Notes, the Company paid financing costs of $11.1 million.

On January 4, 2021, the Company issued $500.0 million aggregate principal amount of 4.625% senior unsecured notes due 2029 (the 4.625% Senior Notes). The 4.625% Senior Notes will mature on August 1, 2029. Interest on the 4.625% Senior Notes is payable on February 1st and August 1st of each year, beginning on August 1, 2021. The 4.625% Senior Notes will be redeemable at the Company’s option, in whole or in part, at any time on or after February 1, 2024, and the redemption price for the 4.625% Senior Notes if redeemed during the 12 months beginning (i) February

1, 2024 is 102.313%, (ii) February 1, 2025 is 101.156%, (iii) February 1, 2026 and thereafter is 100.000%, in each case together with accrued and unpaid interest. The Company may also redeem some or all of the 4.625% Senior Notes before February 1, 2024 at a redemption price of 100% of the principal amount of the 4.625% Senior Notes, plus a “make-whole” premium, together with accrued and unpaid interest. In addition, the Company may redeem up to 40% of the original aggregate principal amount of the 4.625% Senior Notes before February 1, 2024 with the proceeds from certain equity offerings at a redemption price equal to 104.625% of the principal amount of the 4.625% Senior Notes, together with accrued and unpaid interest. Furthermore, the Company may be required to make an offer to purchase the 4.625% Senior Notes upon the sale of certain assets or upon specific kinds of changes of control. Borrowings under the 4.625% Senior Notes were used to partially finance the cash portion of the purchase price for the acquisition of AeroCare, and to pay related fees and expenses. In connection with the issuance of the 4.625% Senior Notes, the Company paid financing costs of $10.4 million.

On July 29, 2020, the Company issued $350.0 million aggregate principal amount of 6.125% senior unsecured notes due 2028 (the 6.125% Senior Notes). The 6.125% Senior Notes will mature on August 1, 2028. Interest on the 6.125% Senior Notes is payable on February 1st and August 1st of each year, beginning on February 1, 2021. The 6.125% Senior Notes will be redeemable at the Company’s option, in whole or in part, at any time on or after August 1, 2023, and the redemption price for the 6.125% Senior Notes if redeemed during the 12 months beginning (i) August 1, 2023 is 103.063%, (ii) August 1, 2024 is 102.042%, (iii) August 1, 2025 is 101.021% and (iv) August 1, 2026 and thereafter is 100.000%, in each case together with accrued and unpaid interest. The Company may also redeem some or all of the 6.125% Senior Notes before August 1, 2023 at a redemption price of 100% of the principal amount of the 6.125% Senior Notes , plus a “make-whole” premium, together with accrued and unpaid interest. In addition, the Company may redeem up to 40% of the original aggregate principal amount of the 6.125% Senior Notes before August 1, 2023 with the proceeds from certain equity offerings at a redemption price equal to 106.125% of the principal amount of the 6.125% Senior Notes, together with accrued and unpaid interest. Furthermore, the Company may be required to make an offer to purchase the 6.125% Senior Notes upon the sale of certain assets or upon specific kinds of changes of control.

Note Payable

In March 2019, the Company signed a Note and Unit Purchase Agreement with an investor. Pursuant to the agreement, the Company issued a promissory note with a principal amount of $100 million (the Promissory Note). In connection with the transactions completed as part of the Business Combination, the Promissory Note was replaced with a new amended and restated promissory note with a principal amount of $100 million, and the investor converted certain of its members’ interests to a $43.5 million promissory note. The new $100 million promissory note, together with the $43.5 million promissory note, are collectively referred to herein as the New Promissory Note. In June 2021, the Company repaid $71.8 million of the outstanding principal balance under the New Promissory Note. In connection with such repayment, the Company paid a debt prepayment penalty of $8.5 million, reflecting the previously disclosed 10% prepayment penalty plus an incremental amount negotiated as part of the prepayment transaction. In addition, the Company wrote off $1.4 million of unamortized deferred financing costs relating to the principal balance that was repaid. The prepayment penalty and the write-off of the unamortized deferred financing costs are included in loss on extinguishment of debt in the accompanying consolidated statements of operations for the nine months ended September 30, 2021. In August 2021, the Company repaid the remaining outstanding principal balance of $71.7 million under the New Promissory Note. In connection with such repayment, the Company paid a debt prepayment penalty of $7.7 million, reflecting the previously disclosed 10% prepayment penalty plus an incremental amount negotiated as part of the prepayment transaction. In addition, the Company wrote off $0.6 million of unamortized deferred financing costs relating to the principal balance that was repaid. The prepayment penalty and the write-off of the unamortized deferred financing costs are included in loss on extinguishment of debt in the accompanying consolidated statements of operations for the three and nine months ended September 30, 2021. The outstanding principal balance under the New Promissory Note bore interest at 12%.

XML

Stockholders' Equity

9 Months Ended

Sep. 30, 2022

Stockholders' Equity

Stockholders' Equity

(10)        Stockholders’ Equity

AdaptHealth, f/k/a DFB Healthcare Acquisitions Corp. (DFB), was originally formed in November 2017 as a publicly traded special purpose acquisition company for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination involving one or more businesses. On July 8, 2019, AdaptHealth Holdings LLC (AdaptHealth Holdings) entered into an Agreement and Plan of Merger (the Merger Agreement), as amended on October 15, 2019, with DFB, pursuant to which AdaptHealth Holdings combined with DFB (the Business Combination). The Business Combination closed on November 8, 2019. In connection with the Business Combination, the name of the combined company was changed to AdaptHealth Corp.

Following the Closing of the Business Combination, AdaptHealth Corp. owned 56% of the combined company with the remaining 44% owned by the former owners of AdaptHealth Holdings in the form of common units representing limited liability company interests in AdaptHealth Holdings from and after the Closing of the Business Combination (New AdaptHealth Units). The former owners of AdaptHealth Holdings held New AdaptHealth Units and a corresponding number of non-economic Class B Common stock, which enabled the holder to one vote per share, and were exchangeable on a one-to-one basis for shares of Class A Common Stock. Subsequent to the Business Combination, all of the common unit interests of AdaptHealth Holdings and a corresponding number of shares of Class B Common Stock were exchanged for shares of Class A Common Stock, of which the final 13,218,758 of the exchanges occurred on January 1, 2021. As a result, the prior holders of the common unit interests of AdaptHealth Holdings no longer own a direct noncontrolling economic interest in AdaptHealth Holdings. In connection with the January 2021 exchanges, the Company recorded a decrease to the noncontrolling interest of $77.9 million in the accompanying consolidated statements of stockholders’ equity.

The Company filed its Third Amended and Restated Certificate of Incorporation (the Certificate of Incorporation) on July 28, 2021. Among other things, the Certificate of Incorporation (x) increased the authorized number of shares of Common Stock from 245,000,000 shares of Common Stock to 300,000,000 shares of Common Stock and (y) (i) deleted provisions no longer applicable following the exchange of all outstanding New AdaptHealth Units and shares of Class B Common Stock for shares of Class A Common Stock and (ii) renamed the Company’s Class A Common Stock to Common Stock. Holders of Common Stock are entitled to one vote for each share. The shares of Preferred Stock (see below) shall be issued with such designations, voting and other rights and preferences as may be determined from time to time by the Company’s board of directors.

Common Stock

In January 2021, the Company issued 8,450,000 shares of Class A Common Stock at a price of $33.00 per share pursuant to an underwritten public offering (the 2021 Stock Offering) for gross proceeds of $278.9 million. In connection with this transaction, the Company received proceeds of $265.0 million which is net of the underwriting discount. A portion of the proceeds from the 2021 Stock Offering were used to partially finance the cash portion of the purchase price for the acquisition of AeroCare, and to pay related fees and expenses. In connection with the 2021 Stock Offering, the Company paid offering costs, inclusive of the underwriting discount, of $13.8 million.

Preferred Stock

In June 2020, the Company entered into an exchange agreement (the Exchange Agreement) with an investor pursuant to which the investor exchanged 15,810,547 shares of the Company’s Class A Common Stock for 158,105.47 shares of Series B-1 Preferred Stock, par value $0.0001 per share. The Series B-1 Preferred Stock liquidation preference is limited to its par value of $0.0001 per share. The Series B-1 Preferred Stock will participate equally and ratably on an as-converted basis with the holders of Common Stock in all cash dividends paid on the Common Stock. The Series B-1 Preferred Stock is non-voting. The holder may convert each share of Series B-1 Preferred Stock into 100 shares of Common Stock (subject to certain anti-dilution adjustments) at its election, except to the extent that following such

conversion, the number of shares of Common Stock held by such holder and its affiliates exceed 4.9% of the outstanding Common Stock of the Company. During the nine months ended September 30, 2021, 39,500 shares of Series B-1 Preferred Stock were converted into 3,950,000 shares of Common Stock. There were no such conversions during the nine months ended September 30, 2022.

As discussed in Note 3, Acquisitions, the Company issued 130,474.73 shares of Series C Convertible Preferred Stock in connection with the acquisition of AeroCare. The Series C Convertible Preferred Stock liquidation preference was limited to its par value of $0.0001 per share. The Series C Convertible Preferred Stock participated equally and ratably on an as-converted basis with the holders of Common Stock in all potential cash dividends paid on the Common Stock. The Series C Convertible Preferred Stock was non-voting. On March 3, 2021, the Company’s stockholders approved, for purposes of complying with Nasdaq Listing Rule 5635, the issuance of shares of the Company’s Common Stock, representing equal to or greater than 20% of the outstanding Common Stock or voting power of the Company issuable upon conversion of the Series C Convertible Preferred Stock issued to the former equity holders of AeroCare, by removal of the conversion restriction that prohibits such conversion of Series C Convertible Preferred Stock. Following the receipt of the approval of the Company’s stockholders, the holders were able to elect to convert, and the Company was able to elect to effect a mandatory conversion of, each share of Series C Convertible Preferred Stock into 100 shares of Common Stock (subject to certain anti-dilution adjustments). The Company elected to effect a mandatory conversion of the Series C Convertible Preferred Stock, and the conversion of 130,474.73 shares of Series C Convertible Preferred Stock to 13,047,473 shares of Common Stock occurred on March 18, 2021.

Treasury Stock

On May 9, 2022, the Company’s board of directors authorized a share repurchase program for up to $200 million of the Company’s Common Stock through December 31, 2022 (the Share Repurchase Program). The timing and actual number of shares to be repurchased will depend upon market conditions and other factors. Shares of the Company’s Common Stock may be purchased from time to time on the open market, through privately negotiated transactions or otherwise. Purchases of the Company’s Common Stock may be started or stopped at any time without prior notice depending on market conditions and other factors. During the nine months ended September 30, 2022, the Company purchased 750,835 shares of the Company’s Common Stock for $14.0 million under the Share Repurchase Program, which is reflected in Treasury Stock in the accompanying consolidated statements of stockholders’ equity.

Warrants

At the Closing of the Business Combination, the Company had 12,666,666 warrants outstanding. Each warrant is exercisable into one share of Common Stock at a price of $11.50 per share. The exercise price and number of shares of Common Stock issuable upon exercise of the warrants may be adjusted in certain circumstances including in the event of a share dividend, or recapitalization, reorganization, merger or consolidation. However, the warrants will not be adjusted for the issuance of Common Stock at a price below its exercise price. During the nine months ended September 30, 2022, 184,870 warrants were exercised in cashless transactions resulting in the issuance of 87,553 shares of Common Stock. There were no warrants exercised during the nine months ended September 30, 2021. As of September 30, 2022, the Company had 3,871,557 warrants outstanding, which have an expiration date of November 20, 2024.

The Company classifies its warrants as a liability in its consolidated balance sheets because of certain terms included in the corresponding warrant agreement. The estimated fair value of the warrants is recorded as a liability, with such fair value reclassified to stockholders’ equity upon the exercise of such warrants. Prior to exercise, the change in the estimated fair value of such warrants each period is recognized as a non-cash charge or gain in the Company’s consolidated statements of operations.

A reconciliation of the changes in the warrant liability during the nine months ended September 30, 2022 and 2021 was as follows (in thousands):

Estimated fair value of warrant liability at December 31, 2021	$	57,764
Change in estimated fair value of the warrant liability		(17,145)
Reclassification of warrant liability to equity for exercised warrants		(2,103)
Estimated fair value of warrant liability at September 30, 2022	$	38,516
Estimated fair value of warrant liability at December 31, 2020	$	113,905
Change in estimated fair value of the warrant liability		(57,359)
Estimated fair value of warrant liability at September 30, 2021	$	56,546

Contingent Consideration Common Shares

Pursuant to the Merger Agreement, the former owners of AdaptHealth Holdings who received Class A Common Stock and Class B Common Stock in connection with the Business Combination are entitled to receive earn-out consideration to be paid in the form of Common Stock, if the average price of the Company’s Common Stock for the month of December prior to each measurement date equals or exceeds certain hurdles set forth in the Merger Agreement (Contingent Consideration Common Shares). The former owners of AdaptHealth Holdings were entitled to receive 1,000,000 shares of Common Stock on each of December 31, 2021 and 2020 based on an average stock price hurdle of $18 and $15, respectively. The average stock price of the Company’s Common Stock was greater than these hurdles for the applicable measurement periods as of the December 31, 2021 and 2020 measurement dates, which triggered the issuance of 1,000,000 shares of Common Stock on such dates. In addition, the former owners of AdaptHealth Holdings are entitled to receive an additional 1,000,000 shares of Common Stock on December 31, 2022 if the average stock price of the Company’s Common Stock equals or exceeds $22 during the month of December 2022.

The Contingent Consideration Common Shares would be issued immediately in the event of a change of control as defined in the Merger Agreement. The estimated fair value of the Contingent Consideration Common Shares was previously recorded as a liability in the Company’s consolidated balance sheets, with such fair value reclassified to stockholders’ equity upon the issuance of any shares that are earned. Prior to issuance, the change in the estimated fair value of such shares each period was recognized as a non-cash charge or gain in the Company’s consolidated statements of operations.

The Company estimated the fair value of the contingent consideration common shares liability using a Monte-Carlo simulation analysis. A Monte-Carlo simulation is a tool used to project asset prices based on a widely accepted drift calculation, the volatility of the asset, incremental time-steps and a random component known as a Weiner process that introduces the dynamic behavior in the asset price. In this framework, asset prices follow a log-normal distribution as they fluctuate through time, which the simulation process captures. A specific model can be developed around the projected stock price to capture the effects of any market performance conditions on value. Price path specific conditions can be captured in this type of open form model. The Monte-Carlo process expresses potential future scenarios that when simulated thousands of times can be viewed statistically to ascertain fair value. The contingent consideration common shares contain market conditions to determine whether the shares are earned based on the Company’s Common Stock price during specified measurement periods. Given the path-dependent nature of the requirement in which the shares are earned, a Monte-Carlo simulation was used to estimate the fair value of the liability. The Company’s Common Stock price was simulated to each measurement period based on the methodology described above. In each iteration, the simulated stock price was compared to the conditions under which the shares are earned. In iterations where the stock price corresponded to shares being earned, the future value of the earned shares was discounted back to present value. The fair value of the liability was estimated based on the average of all iterations of the simulation.

As discussed above, on each of December 31, 2021 and 2020, 1,000,000 shares of Common Stock were issued in connection with the portion of the Contingent Consideration Common Shares which were earned as of such dates. As a result, the estimated fair value related to such shares was reclassified to stockholders’ equity, with such shares reflected as issued and outstanding Common Stock. In accordance with U.S. GAAP, the estimated fair value related to the remaining 1,000,000 Contingent Consideration Common Shares was reclassified to stockholders’ equity at December 31, 2021. Since the fair value of these potential shares was reclassified to stockholders’ equity on December 31, 2021, these potential shares are no longer liability classified and therefore the changes in the estimated fair value of such potential shares are not recognized as a non-cash charge or gain in the Company’s consolidated statements of operations subsequent to December 31, 2021.

A reconciliation of the changes in the contingent consideration common shares liability during the nine months ended September 30, 2021 was as follows (in thousands):

Estimated fair value of contingent consideration common shares liability at December 31, 2020	$	70,477
Change in estimated fair value of the contingent consideration common shares liability		(34,050)
Estimated fair value of contingent consideration common shares liability at September 30, 2021	$	36,427

Equity-based Compensation

In connection with the Company’s 2019 Stock Incentive Plan (the 2019 Plan), the Company provides equity-based compensation to attract and retain employees while also aligning employees’ interest with the interests of its stockholders. The 2019 Plan permits the grant of various equity-based awards to selected employees and non-employee directors. At September 30, 2022, the 2019 Plan permits the grant of up to 10,000,000 shares of Common Stock, subject to certain adjustments and limitations. At September 30, 2022, 2,124,163 shares of the Company’s Common Stock were available for issuance under the 2019 Plan.

Stock Options

There were no stock options granted during the nine months ended September 30, 2022. The following table provides the activity regarding the Company’s outstanding stock options during the nine months ended September 30, 2022 that were granted in connection with the 2019 Plan (in thousands, except per share data):

			Weighted-Average
			Grant Date		Weighted-Average	Weighted-Average
	Number of		Fair Value		Exercise Price	Remaining
	Options		per Share		per Share	Contractual Term
Outstanding, December 31, 2021	2,219	$	3.75	$	19.36
Activity - none	—
Outstanding, September 30, 2022	2,219	$	3.75	$	19.36	6.3 Years

The following table provides the activity for all outstanding stock options during the nine months ended September 30, 2022 (in thousands, except per share data):

			Weighted-Average	Weighted-Average
	Number of		Exercise Price	Remaining
	Options		per Share	Contractual Term
Outstanding, December 31, 2021	5,766	$	11.26
Exercised	(509)	$	6.79
Outstanding, September 30, 2022	5,257	$	11.72	5.7 Years

During the nine months ended September 30, 2022, 194,002 stock options were exercised resulting in $1.4 million of cash proceeds received by the Company and the issuance of 194,002 shares of the Company’s Common Stock. Also, during the nine months ended September 30, 2022, 315,349 stock options were exercised on a cashless basis resulting in the issuance of 131,741 shares of the Company’s Common Stock.

Restricted Stock

During the nine months ended September 30, 2022, the Company granted 212,883 shares of restricted stock to various employees which vest ratably over the three or four-year periods following the vesting commencement date (which is generally the grant date), subject to the employees’ continuous employment through the applicable vesting date, and if applicable, subject to certain performance conditions. The grant-date fair value of these awards was $3.9 million. During the nine months ended September 30, 2022, the Company granted 81,347 shares of restricted stock to its non-employee directors, which vest approximately one year following the grant date. The grant-date fair value of these awards was $1.5 million.

During the nine months ended September 30, 2022, the Company granted 317,554 shares of restricted stock units to senior executive management of the Company. These awards vest ratably over the three-year period following the grant date, subject to the employees’ continuous employment through the applicable vesting date. The grant-date fair value of these awards was $5.7 million. In addition, during the nine months ended September 30, 2022, the Company granted 317,554 shares of performance-vested restricted stock units (Performance RSUs) to senior executive management of the Company. The Performance RSUs will vest on the third anniversary of the grant date subject to the achievement of specified goals relative to the Company’s three-year relative total shareholder return (Relative TSR) performance versus the Company’s defined peer group (the Peer Group), and is also subject to the employees’ continuous employment through the vesting date. The grant-date fair value of these awards, using a Monte-Carlo simulation analysis, was $8.7 million. The payout of shares on the vesting date are as follows based on the Company’s Relative TSR versus the Peer Group (for performance between the stated goals noted below, straight-line interpolation will be applied):

● Less than 25^th Percentile – No payout

● Greater than or equal to 25^th Percentile – 50% of Performance RSUs

● Equal to 50^th Percentile – 100% of Performance RSUs

● Greater than or equal to 75^th Percentile – 200% of Performance RSUs

Activity related to the Company’s non-vested restricted stock grants for the nine months ended September 30, 2022 is presented below (in thousands, except per share data):

	Number of Shares of		Weighted-Average Grant Date
	Restricted Stock		Fair Value per Share
Non-vested balance, December 31, 2021	2,195	$	19.58
Granted	929	$	21.26
Vested	(461)	$	24.43
Forfeited	(96)	$	21.96
Non-vested balance, September 30, 2022	2,567	$	22.60

Incentive Units

AdaptHealth Holdings granted Incentive Units in June 2019 (the 2019 Incentive Units) to certain members of management. The 2019 Incentive Units were intended to constitute profits interests and were granted for purposes of enabling such individuals to participate in the long-term growth and financial success of the Company and were issued

in exchange for services to be performed. The grant date fair value of the 2019 Incentive Units, as calculated under an Option Pricing Method, was $4.5 million. With respect to the 2019 Incentive Units, 50% of the awards were scheduled to vest in equal annual installments on each of the first four anniversaries of the Vesting Commencement Date as defined in the agreements (May 20, 2019). The first 25% of this portion of the 2019 Incentive Units vested in May 2020, and in January 2021, the vesting of the remaining unvested units associated with this portion of the 2019 Incentive Units was accelerated. The Company recorded $1.5 million of equity-based compensation expense during the nine months ended September 30, 2021 in connection with such acceleration. The remaining 50% of the awards had initial vesting terms based upon a performance condition. In connection with the Business Combination, the vesting condition for this portion of the 2019 Incentive Units was changed to vest quarterly during the one-year period subsequent to the closing of the Business Combination, and as such all of the units associated with this portion of the 2019 Incentive Units were fully vested in November 2020.

Equity-Based Compensation Expense

The Company recorded equity-based compensation expense of $5.6 million during the three months ended September 30, 2022, of which $4.0 million and $1.6 million is included in general and administrative expenses and cost of net revenue, respectively, in the accompanying consolidated statements of operations. The Company recorded equity-based compensation expense of $5.4 million during the three months ended September 30, 2021, of which $3.4 million and $2.0 million is included in general and administrative expenses and cost of net revenue, respectively, in the accompanying consolidated statements of operations. The Company recorded equity-based compensation expense of $16.8 million during the nine months ended September 30, 2022, of which $11.5 million and $5.3 million is included in general and administrative expenses and cost of net revenue, respectively, in the accompanying consolidated statements of operations. The Company recorded equity-based compensation expense of $21.4 million during the nine months ended September 30, 2021, of which $14.5 million and $6.9 million is included in general and administrative expenses and cost of net revenue, respectively, in the accompanying consolidated statements of operations. At September 30, 2022, there was $40.5 million of unrecognized compensation expense related to equity-based compensation awards, which is expected to be recognized over a weighted-average period of 2.1 years.

XML

Earnings Per Share

9 Months Ended

Sep. 30, 2022

Earnings Per Share

Earnings Per Share

(11)        Earnings Per Share

Earnings Per Share (EPS) is computed by dividing net income by the weighted average number of common shares outstanding during the period on a basic and diluted basis. The Company computes diluted net income per share using the more dilutive of the treasury stock method and the two-class method after giving effect to all potential dilutive Common Stock.

The Company’s potentially dilutive securities include potential common shares related to outstanding warrants, contingent consideration common shares, unvested restricted stock, outstanding stock options and outstanding preferred stock. Refer to Note 10, Stockholders’ Equity, for additional discussion of these potential dilutive securities.

Diluted net income per share considers the impact of potentially dilutive securities except when the potential common shares have an antidilutive effect. The Company’s outstanding preferred stock are considered participating securities, thus requiring the two-class method of computing diluted net income per share. Computation of diluted net income per share under the two-class method excludes from the numerator any dividends paid or owed on participating securities and any undistributed earnings considered to be attributable to participating securities. The related participating securities are similarly excluded from the denominator.

Computations of basic and diluted net income per share were as follows (in thousands, except per share data):

	Three Months Ended September 30,				Nine Months Ended September 30,
	2022		2021		2022		2021
Numerator
Net income attributable to AdaptHealth Corp.	$	16,122	$	58,092	$	71,904	$	133,233
Less: Earnings allocated to participating securities (1)		1,360		5,002		6,079		12,572
Net income for basic EPS	$	14,762	$	53,090	$	65,825	$	120,661
Change in fair value of warrant liability (2)		—		(16,737)		(17,145)		(57,359)
Change in fair value of contingent consideration common shares liability (2)		—		(8,145)		—		(27,718)
Net income for diluted EPS	$	14,762	$	28,208	$	48,680	$	35,584
Denominator (1) (2)
Basic weighted-average common shares outstanding		134,227		131,684		134,186		124,228
Add: Warrants (2)		—		2,245		1,436		2,598
Add: Contingent Consideration Common Shares (2)		—		2,000		—		2,000
Add: Stock options		2,903		3,794		2,669		4,112
Add: Unvested restricted stock		453		599		308		700
Diluted weighted-average common shares outstanding		137,583		140,322		138,599		133,638
Basic net income per share	$	0.11	$	0.40	$	0.49	$	0.97
Diluted net income per share	$	0.11	$	0.20	$	0.35	$	0.27

(1) The Company’s preferred stock are considered participating securities. Computation of EPS under the two-class method excludes from the numerator any dividends paid or owed on participating securities and any undistributed earnings considered to be attributable to participating securities. The related participating securities are similarly excluded from the denominator.

(2) For the nine months ended September 30, 2022, and the three and nine months ended September 30, 2021, the impact to earnings from the change in fair value of the Company’s warrant liability is excluded from the numerator, and the corresponding security is included in the denominator, for purposes of computing diluted net income per share. For the three and nine months ended September 30, 2021, the impact to earnings from the change in fair value of the Company’s contingent consideration common shares liability is excluded from the numerator, and the corresponding security is considered for inclusion in the denominator, for purposes of computing diluted net income per share. These adjustments are included as the effect of the numerator and denominator adjustments for these derivative instruments is dilutive as a result of the non-cash gains recorded for the change in fair value of these instruments during the periods.

The table below provides the weighted-average number of potential common shares associated with outstanding securities not included in the Company’s computation of diluted net income per share for the three and nine months ended September 30, 2022 and 2021 because to do so would be antidilutive (in thousands):

	Three Months Ended September 30,					Nine Months Ended September 30,
	2022		2021		2022		2021
Preferred Stock		12,406		12,406		12,406		12,944
Warrants		1,706		—		—		—
Stock options		468		—		468		—
Unvested restricted stock		108		—		221		—
Total		14,688		12,406		13,095		12,944

In addition, there are 1,000,000 shares relating to the Contingent Consideration Common Shares that were not included in the diluted net income per share computation for the three and nine months ended September 30, 2022 as the corresponding average stock price hurdle for issuing these contingently issuable shares would not have been met as of the September 30, 2022 reporting date. As discussed in note 10, Stockholders’ Equity, the measurement date is December 31, 2022 for these shares and they will be issued at such time if they are earned.

XML

Leases

9 Months Ended

Sep. 30, 2022

Leases

Leases

(12)        Leases

The Company leases its office facilities and office equipment under noncancelable lease agreements which expire at various dates through March 2033. Some of these lease agreements include an option to renew at the end of the term. The Company also leases certain office facilities on a month-to-month basis. In some instances, the Company is also required to pay its pro rata share of real estate taxes and utility costs in connection with the premises. Some of the leases contain fixed annual increases of minimum rent.

The Company’s leases frequently allow for lease payments that could vary based on factors such as inflation and the incurrence of contractual charges such as those for common area maintenance or utilities.

Renewal and/or early termination options are common in the lease arrangements, particularly with respect to real estate leases. The Company’s right-of-use assets and lease liabilities generally include periods covered by renewal options and exclude periods covered by early termination options (based on the conclusion that it is reasonably certain that the Company will exercise such renewal options and not exercise such early termination options).

The Company is also party to certain sublease arrangements related to real estate leases, where the Company acts as the lessee and intermediate lessor.

The Company has acquired patient medical equipment and supplies, and office equipment through multiple finance leases. The finance lease obligations represent the present value of minimum lease payments under the respective agreement, payable monthly at various interest rates.

The following table presents information about the Company’s right-of-use assets and lease liabilities as of September 30, 2022 and December 31, 2021 (in thousands):

	Consolidated Balance Sheets Line Item	September 30, 2022		December 31, 2021
Right-of-use (ROU) assets:
Operating lease ROU assets	Operating lease right-of-use assets	$	128,635	$	147,760
Finance lease ROU assets	Equipment and other fixed assets, net		1,056		17,410
Total ROU assets		$	129,691	$	165,170
Operating lease liabilities:
Current operating lease liabilities	Current portion of operating lease obligations	$	28,769	$	31,418
Noncurrent operating lease liabilities	Operating lease obligations, less current portion		103,859		120,180
Total operating lease liabilities		$	132,628	$	151,598
Finance lease liabilities:
Current finance lease liabilities	Current portion of finance lease obligations	$	2,695	$	15,446
Noncurrent finance lease liabilities	Other long-term liabilities		—		132
Total finance lease liabilities		$	2,695	$	15,578

The following table presents information about lease costs and expenses and sublease income for the three and nine months ended September 30, 2022 and 2021 (in thousands). The amounts below are included in cost of net revenue in the accompanying consolidated statements of operations for the periods presented.

	Three Months Ended September 30,				Nine Months Ended September 30,
	2022		2021		2022		2021
Operating lease costs	$	9,248	$	9,837	$	28,547	$	27,695
Finance lease costs:
Amortization of ROU assets	$	640	$	8,487	$	7,266	$	27,549
Other lease costs and income:
Variable leases costs (1)	$	3,728	$	3,784	$	12,680	$	10,061
Sublease income	$	336	$	405	$	1,019	$	911
Short-term lease costs	$	—	$	4,093	$	—	$	19,905

(1) Amounts represent variable costs incurred that were not included in the initial measurement of the lease liability such as common area maintenance and utilities costs associated with leased real estate.

The following table provides the weighted average remaining lease terms and weighted average discount rates for the Company’s leases as of September 30, 2022 and December 31, 2021:

	September 30, 2022	December 31, 2021
Weighted average remaining lease term, weighted based on lease liability balances:
Operating leases	6.2 years	6.7 years
Finance leases	0.5 year	1.0 year
Weighted average discount rate, weighted based on remaining balance of lease payments:
Operating leases	3.9%	3.8%

The following table provides the undiscounted amount of future cash flows related to the Company’s operating and finance leases, as well as a reconciliation of such undiscounted cash flows to the amounts included in the Company’s lease liabilities as of September 30, 2022 (in thousands):

	Operating Leases		Finance Leases
2022	$	8,778	$	1,920
2023		31,757		795
2024		26,347		—
2025		21,966		—
2026		16,158		—
Thereafter		47,027		—
Total future undiscounted lease payments	$	152,033	$	2,715
Less: amount representing interest		(19,405)		(20)
Present value of future lease payments (lease liability)	$	132,628	$	2,695

The following table provides certain cash flow and supplemental non-cash information related to the Company’s lease liabilities for the nine months ended September 30, 2022 and 2021, respectively (in thousands):

	Nine Months Ended September 30,
Cash paid for amounts included in the measurement of lease liabilities:	2022		2021
Operating cash payments for operating leases	$	28,416	$	27,154
Financing cash payments for finance leases	$	14,219	$	31,043
Lease liabilities arising from obtaining right-of-use assets:
Operating leases	$	5,411	$	84,212
Finance leases	$	1,335	$	22,902

XML

Income Taxes

9 Months Ended

Sep. 30, 2022

Income Taxes

Income Taxes

(13)          Income Taxes

The Company is subject to U.S. federal, state, and local income taxes. For the three months ended September 30, 2022 and 2021, the Company recorded income tax expense of $5.6 million and $12.1 million, respectively. For the nine months ended September 30, 2022 and 2021, the Company recorded income tax expense of $20.0 million and $22.8 million, respectively.

As of September 30, 2022 and December 31, 2021, the Company had an unrecognized tax benefit of $4.0 million.

Tax Receivable Agreement

AdaptHealth Corp. is party to a Tax Receivable Agreement (TRA) with certain current and former members of AdaptHealth Holdings. The TRA provides for the payment by AdaptHealth Corp. of 85% of the tax savings, if any, that AdaptHealth Corp. realizes (or is deemed to realize in certain circumstances) as a result of (i) certain increases in tax basis resulting from exchanges of New AdaptHealth Units and shares of Class B Common Stock; (ii) certain tax attributes of the corresponding sellers existing prior to an exchange; (iii) imputed interest deemed to be paid by AdaptHealth Corp. as a result of payments it makes under the TRA; and (iv) certain increases in tax basis resulting from payments AdaptHealth Corp. makes under the TRA.

During the nine months ended September 30, 2022, the Company recognized an expense of $4.5 million related to changes in the estimated liability related to the TRA as a result of settling the current portion of the contingent consideration common shares liability during the period, which is included in Other loss (income), net in the accompanying consolidated statement of operations. During the nine months ended September 30, 2021, the Company increased the estimated liability related to the TRA through an aggregate $146.5 million reduction in additional paid-in capital resulting from additional exchanges of New AdaptHealth Units and shares of Class B Common Stock. Correspondingly, during the nine months ended September 30, 2021, the Company increased its deferred tax asset by $163.3 million through an increase in additional paid-in-capital resulting from these exchanges and other increases of AdaptHealth Corp.’s ownership interest in AdaptHealth Holdings.

At September 30, 2022, the Company had a liability recorded relating to the TRA of $304.8 million, of which $5.9 million and $298.9 million is included in other current liabilities and other long-term liabilities, respectively, in the accompanying consolidated balance sheets. At December 31, 2021, the Company had a liability recorded relating to the TRA of $300.3 million, which is included in other long-term liabilities in the accompanying consolidated balance sheets.

XML

Commitments and Contingencies

9 Months Ended

Sep. 30, 2022

Commitments and Contingencies.

Commitments and Contingencies

(14)         Commitments and Contingencies

In the normal course of business, the Company is subject to loss contingencies, such as legal proceedings and claims arising out of its business that cover a wide range of matters. In accordance with FASB ASC Topic 450, Accounting for Contingencies, the Company records accruals for such loss contingencies when it is probable that a liability has been incurred and the amount of loss can be reasonably estimated. Significant judgment is required to determine both probability and the estimated amount. The Company reviews its accruals at least quarterly and adjusts accordingly to reflect the impact of negotiations, settlements, rulings, advice of legal counsel, and updated information. At this time, the Company has no material accruals related to lawsuits, claims, investigations and proceedings. While there can be no assurance, based on the Company’s evaluation of information currently available, the Company’s management believes any liability that may ultimately result from resolution of such loss contingencies will not have a material adverse effect on the Company’s financial conditions or results of operations. However, the Company’s assessment may be affected by limited information. Accordingly, the Company’s assessment may change in the future based upon availability of new information and further developments in the proceedings of such matters. The results of legal proceedings are inherently uncertain, and material adverse outcomes are possible.

In connection with the Company’s acquisition of PPS HME Holdings LLC (PPS), in May 2018, the Company assumed a Corporate Integrity Agreement (CIA) at one of PPS’ subsidiaries, Braden Partners L.P. d/b/a Pacific Pulmonary Services (BP). The CIA was entered into with the Office of Inspector General of the U.S. Department of Health and Human Services (OIG). The CIA has a five-year term which expires as of April 2022. In connection with the acquisition and integration of PPS by AdaptHealth, the OIG confirmed that the requirements of the CIA imposed upon BP would only apply to the operations of BP and therefore no operations of any other AdaptHealth affiliate are subject

to the requirements of the CIA following the acquisition. On December 16, 2021, the OIG-HHS notified PPS that its report for the period ended March 31, 2021 had been accepted and PPS had satisfied its obligations under the CIA as of such date. On May 24, 2022, the Company submitted its report for the period ended March 31, 2022.

On July 25, 2017, the Company was served with a subpoena by the U.S. Attorney’s Office for the United States District Court for the Eastern District of Pennsylvania (EDPA) pursuant to 18 U.S.C. §3486 to produce certain audit records and internal communications regarding ventilator billing. The investigation focused on billing practices regarding one payor that contracted for bundled payments for certain ventilators. The Company has cooperated with investigators and, through agreement with the EDPA, has submitted all information requested in the Company’s possession. An independent third party was retained by the Company that identified overpayments and underpayments for ventilator billings related to the payor, and a remittance was sent to reconcile that account. On October 3, 2019, the Company received a follow-up civil investigative demand from the EDPA regarding a document previously produced to the EDPA and patients included in the review by the independent third party. The Company has responded to the EDPA and supplemented its production as requested with any relevant documents in the Company’s possession. During subsequent communications, the EDPA indicated to the Company that the investigation remained ongoing. The EDPA also requested additional information regarding certain patient services and claims refunds processed by the Company in 2017. The Company produced this information in coordination with the EDPA. The EDPA has also raised questions regarding other aspects of ventilator billing. While the Company cannot provide any assurance as to whether the EDPA will seek additional information or pursue this matter further, it does not believe that the investigation will have a material adverse effect on the Company.

In March 2019, prior to its acquisition by the Company, AeroCare was served with a civil investigative demand (CID) issued by the United States Attorney for the Western District of Kentucky (WDKY). The CID seeks to investigate allegations that AeroCare improperly billed, or caused others to improperly bill, for oxygen tank contents that were not delivered to beneficiaries. The WDKY has requested documents related to such oxygen tank content billing as well as other categories of information. AeroCare has cooperated with the WDKY and has produced documents and provided explanations of its billing practices. In September 2020, the WDKY indicated the investigation includes alleged violations of the federal False Claims Act and as well as alleged violations of state Medicaid false claims acts in ten states. AeroCare has cooperated fully with the investigation and has indicated to the WDKY that concerns raised do not accurately identify Medicare coverage criteria and that state Medicaid coverage requirements generally do not provide for separate reimbursement for portable gaseous oxygen contents in the circumstances at issue. While the Company cannot provide any assurance as to whether the WDKY will seek additional information or pursue this matter further, it does not believe that the investigation will have a material adverse effect on the Company.

The Company and certain of its current and former officers were named as defendants in a lawsuit, as described below. The Company cannot reasonably predict the outcome of this legal proceeding, nor can it estimate the amount of loss or range of loss, if any, that may result. An adverse outcome in this proceeding could have a material adverse effect on the Company’s results of operations, cash flows or financial condition. The results of legal proceedings are inherently uncertain, and material adverse outcomes are possible.

On July 29, 2021, Robert Charles Faille Jr., a purported shareholder of the Company, filed a purported class action complaint against the Company and certain of its current and former officers in the United States District Court for the Eastern District of Pennsylvania (the Complaint). The Complaint purports to be asserted on behalf of a class of persons who purchased the Company’s stock between November 11, 2019 and July 16, 2021. The Complaint generally alleges that the Company and certain of its current and former officers violated federal securities laws by making allegedly false and misleading statements and/or failing to disclose material information regarding the Company’s organic growth trajectory. The Complaint seeks unspecified damages. On October 14, 2021, the Delaware County Employees Retirement System and the Bucks County Employees Retirement System were named Lead Plaintiffs. Pursuant to the scheduling order, Lead Plaintiffs filed a consolidated complaint on November 22, 2021 (the Consolidated Complaint), which asserts substantially the same claim, but adds a number of current and former directors of the Company as additional defendants and a new theory of recovery based on the Company’s alleged failure to disclose

information concerning the Company’s former Co-CEO’s alleged tax fraud arising from certain past private activity (the “Consolidated Class Action”). On January 20, 2022, the defendants filed a motion to dismiss the Consolidated Complaint. Lead Plaintiffs’ opposition to defendants’ motion was filed on March 21, 2022, and defendants’ reply was filed on April 15, 2022. On June 9, 2022, the court issued an opinion and order denying the defendants’ motion to dismiss the Consolidated Complaint.

On July 15, 2022, the court entered a scheduling order providing for, inter alia, a schedule for completing class certification discovery, as well as setting a briefing schedule for motions for class certification. Pursuant to the scheduling order, Lead Plaintiffs filed their motion for class certification on July 28, 2022. The defendants’ opposition to Lead Plaintiffs’ motion for class certification is due to be filed on January 20, 2023; and Lead Plaintiffs’ reply is due to be filed on March 10, 2023.The Company intends to vigorously defend against the allegations contained in the Consolidated Complaint, but there can be no assurance that the defense will be successful.

On December 6, 2021, a putative shareholder of the Company, Carol Hessler, filed a shareholder derivative complaint against certain current and former directors and officers of the Company in the United States District Court for the Eastern District of Pennsylvania (the “Derivative Complaint”). The Derivative Complaint generally alleges that the defendants breached their fiduciary duties owed to the company by allegedly causing or allowing misrepresentations and/or omissions regarding the Company’s organic growth and Luke McGee’s alleged criminal activity, failing to maintain an adequate system of oversight, disclosure controls and procedures, and internal controls over financial reporting and due diligence into the Company’s management team, and engaging in insider trading. The Derivative Complaint also alleges claims for waste of corporate assets and unjust enrichment. Finally, the Derivative Complaint alleges that certain of the individual defendants violated Section 14(a) of the Securities Exchange Act by allegedly negligently issuing, causing to be issued, and participating in the issuance of materially misleading statements to stockholders in the Company’s Proxy Statements on Schedule DEF 14A in connection with a Special Meeting of Stockholders, held on March 3, 2021, and the 2021 Annual Meeting of Stockholders, held on July 27, 2021. The Derivative Complaint seeks, among other things, an award of money damages.

On March 4, 2022, the parties stipulated to stay the Hessler action pending final resolution of the Consolidated Class Action. On March 7, 2022, the court so-ordered the parties’ stipulation.

The Company intends to vigorously defend against the allegations contained in the Derivative Complaint, but there can be no assurance that the defense will be successful.

On May 2, 2022, the U.S. Attorney’s Office for the Southern District of New York issued a civil investigative demand to Community Surgical Supply Inc. (CSS), a subsidiary of the Company, pursuant to the False Claims Act, 31 U.S.C. § 3733 (FCA) surrounding whether CSS submitted false claims in violation of the FCA related to CSS’s billing of, and reimbursements from, federal health care programs for ventilators provided to patients from January 1, 2015 to the present. The Company is fully cooperating with the investigation. Given the investigation is in the early stages, it is not possible to determine whether it will have a material adverse effect on the Company.

XML

Related Party Transactions

9 Months Ended

Sep. 30, 2022

Related Party Transactions

Related Party Transactions

(15)        Related Party Transactions

The Company and one of its executive officers and shareholder own an equity interest in a vendor of the Company that provides automated order intake software. The individual’s equity ownership is less than 1%. The expense related to this vendor was $1.8 million and $1.2 million for the three months ended September 30, 2022 and 2021, respectively. The expense related to this vendor was $4.9 million and $3.4 million for the nine months ended September 30, 2022 and 2021, respectively. The Company accounts for this investment under the cost method of accounting based on its level of equity ownership. As of September 30, 2022 and December 31, 2021, the Company had an immaterial outstanding accounts payable balance to this vendor.

A director of the Company serves on the board of directors of a third-party payor that does business with the Company in the normal course of providing services to patients. Net revenue from this third-party payor was less than 1.0% of the Company’s consolidated net revenue during the three and nine months ended September 30, 2022 and 2021. As of September 30, 2022 and December 31, 2021, the Company had an immaterial outstanding accounts receivable balance from this third-party payor.

A director of the Company is an employee of a beneficial owner of more than 5% of the Company’s Common Stock as of September 30, 2022. This beneficial owner is also a minority shareholder of a vendor that provides equipment and supplies to the Company in the normal course of business. Purchases from this vendor were approximately $20.3 million and $49.8 million, respectively, for the three and nine months ended September 30, 2022. As of September 30, 2022, the Company had $12.6 million in outstanding accounts payable to this vendor. Purchases from this vendor for the three and nine months ended September 30, 2021 and the outstanding accounts payable to this vendor as of December 31, 2021 were immaterial.

A regional manager of the Company is a partial owner of a business which provides contract labor to the Company. Payments to this service provider were $5.7 million and $4.3 million, respectively, for the three months ended September 30, 2022 and 2021, and $16.2 million and $13.7 million, respectively, for the nine months ended September 30, 2022 and 2021. As of September 30, 2022, the Company had $2.2 million in outstanding accounts payable to this service provider. The outstanding accounts payable to this service provider as of December 31, 2021 was immaterial.

XML

Subsequent Events

9 Months Ended

Sep. 30, 2022

Subsequent Events

Subsequent Events

(16)        Subsequent Events

The Company has evaluated subsequent events through the filing of this Quarterly Report on Form 10-Q, and determined that there have been no events that have occurred that would require adjustment or disclosure in the interim consolidated financial statements.

XML

General Information (Policies)

9 Months Ended

Sep. 30, 2022

Summary of Significant Accounting Policies

Basis of Presentation

(a)          Basis of Presentation

The interim consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP). In the opinion of management, the interim consolidated financial statements include all necessary adjustments for a fair presentation of the financial position and results of operations for the periods presented.

Basis of Consolidation

(b)         Basis of Consolidation

The accompanying interim consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.

Concentration of Credit Risk

(c)          Concentration of Credit Risk

Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents and trade accounts receivable. The Company maintains its cash in bank deposit accounts, which, at times, may exceed federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to any significant credit risk on cash and cash equivalents.

Accounting Estimates

(d)          Accounting Estimates

The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and reported amounts of revenues and expenses during the reporting period. Management bases these estimates and assumptions upon historical experience, existing and known circumstances, authoritative accounting pronouncements and other factors that management believes to be reasonable. Significant areas requiring the use of management estimates relate to revenue recognition and the valuation of accounts receivable (implicit price concession), income taxes, equity-based

compensation, interest rate swaps, warrant liability and long-lived assets, including goodwill and identifiable intangible assets. Actual results could differ from those estimates.

Valuation of Goodwill

(e)          Valuation of Goodwill

The Company has a significant amount of goodwill on its balance sheet that resulted from the business acquisitions the Company has made in recent years. Goodwill is not amortized and is assessed for impairment annually and upon the occurrence of a triggering event or change in circumstances indicating a possible impairment. Such triggering events potentially warranting an interim goodwill impairment assessment include, among other factors, declines in historical or projected revenue, operating income or cash flows, and declines in the Company’s stock price or market capitalization. Such changes in circumstance can include, among others, changes in the legal environment, reimbursement environment, operating performance, and/or future prospects. The Company performs its annual impairment assessment of goodwill during the fourth quarter of each year. The impairment assessment can be performed on either a quantitative or qualitative basis. The Company first assesses qualitative factors to determine whether it is necessary to perform a quantitative goodwill impairment analysis. If determined necessary, the Company applies the quantitative impairment test to identify and measure the amount of impairment, if any. During the three months ended March 31, 2022, the Company experienced a decline in its market capitalization as a result of a decline in the Company’s stock price. The Company considered such decline to represent a triggering event requiring management to perform a quantitative goodwill impairment assessment as of March 31, 2022. No such triggering events were identified during the three months ended September 30, 2022. Refer to note 5, Goodwill and Identifiable Intangible Assets, for additional details.

Long-Lived Assets

(f) Long-Lived Assets

The Company’s long-lived assets, such as equipment and other fixed assets, operating lease right-of-use assets and definite-lived identifiable intangible assets, are assessed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the asset.

Definite-lived identifiable intangible assets consist of tradenames, payor contracts, contractual rental agreements and developed technology. These assets are amortized using the straight-line method over their estimated useful lives, which reflects the pattern in which the economic benefits of the assets are expected to be consumed. In addition to consideration of impairment upon the events or changes in circumstances described above, management regularly evaluates the remaining useful lives of its long-lived assets. The following table summarizes the useful lives of the Company’s identifiable intangible assets acquired:

Tradenames	5 to 10	years
Payor contracts	10	years
Contractual rental agreements	2	years
Developed technology	5	years

The Company did not incur any impairment charges on long-lived assets for the three and nine months ended September 30, 2022 and 2021.

Business segment

(g)          Business Segment

The Company’s chief operating decision-makers are its Chief Executive Officer and President, who make resource allocation decisions and assess performance based on financial information presented on an aggregate basis. There are no segment managers who are held accountable by the chief operating decision-makers, or anyone else, for any planning, strategy and key decision-making regarding operations. The corporate office is responsible for contract negotiation with vendors and payors, corporate compliance with healthcare laws and regulations, and revenue cycle management, among other corporate supporting functions. Accordingly, the Company has a single reportable segment and operating segment structure.

Accounting for Leases

(h)          Accounting for Leases

The Company adopted FASB Accounting Standards Update (ASU) No. 2016-02, Leases (Topic 842) (ASC 842) with an effective date of January 1, 2021, using the modified retrospective approach, for leases that existed on January 1, 2021. ASC 842 requires the Company to recognize a lease liability, which represents the discounted obligation to make future minimum lease payments, and a corresponding right-of-use (ROU) asset on its consolidated balance sheet for most leases, and disclose key information about leasing arrangements. The Company elected to apply certain practical expedients permitted under the transition guidance within ASC 842 to leases that commenced before January 1, 2021, including the package of practical expedients, which, among other things, permits lease agreements that are twelve months or less to be excluded from the balance sheet, and permits the Company not to reassess under the new standard its prior conclusions about lease identification, lease classification and initial direct costs. Due to the Company’s election of these practical expedients, the Company carried forward certain historical conclusions for existing contracts, including conclusions related to the existence and classification of leases and to initial direct costs. ASC 842 applies to a number of arrangements to which the Company is a party.

Whenever the Company enters into a new arrangement, it must determine, at the inception date, whether the arrangement is or contains a lease. This determination generally depends on whether the arrangement conveys to the Company the right to control the use of an explicitly or implicitly identified asset for a period of time in exchange for consideration. Control of an underlying asset is conveyed to the Company if the Company obtains the rights to direct the use of and obtain substantially all the economic benefits from the use of the underlying asset.

If a lease exists, the Company must then determine the separate lease and non-lease components of the arrangement. Each right to use an underlying asset conveyed by a lease arrangement should generally be considered a separate lease component if it both: (i) can benefit the Company without depending on other resources not readily available to the Company and (ii) does not significantly affect and is not significantly affected by other rights of use conveyed by the lease. Aspects of a lease arrangement that transfer other goods or services to the Company but do not meet the definition of lease components are considered non-lease components. The consideration owed by the Company pursuant to a lease arrangement is generally allocated to each lease and non-lease component for accounting purposes. However, the Company has elected, for all of its leases, to not separate lease and non-lease components. Each lease component is accounted for separately from other lease components, but together with the associated non-lease components.

For each lease, the Company must then determine the lease term, the present value of lease payments and the classification of the lease as either an operating or finance lease.

The lease term is the period of the lease not cancellable by the Company, together with periods covered by: (i) renewal options the Company is reasonably certain to exercise, (ii) termination options the Company is reasonably certain not to exercise, and (iii) renewal or termination options that are controlled by the lessor.

The present value of lease payments is calculated based on:

● Lease payments – lease payments include fixed and certain variable payments, less lease incentives, together with amounts probable of being owed by the Company under residual value guarantees and, if reasonably certain of being paid, the cost of certain renewal options and early termination penalties set forth in the lease arrangement. Lease payments exclude consideration that is not related to the transfer of goods and services of the Company.

● Discount rate – the discount rate must be determined based on information available to the Company upon the commencement of the lease. Lessees are required to use the rate implicit in the lease whenever such rate is readily available; however, as the implicit rate in the Company’s leases is generally not readily determinable, the Company generally uses the hypothetical incremental borrowing rate it would have to pay to borrow an amount equal to the lease payments, on a collateralized basis, over a timeframe similar to the lease term.

In making the determination of whether a lease is an operating lease or a finance lease, the Company considers the lease term in relation to the economic life of the leased asset, the present value of lease payments in relation to the fair value of the leased asset and certain other factors, including the lessee’s and lessor’s rights, obligations, and economic incentives over the term of the lease.

Generally, upon the commencement of a lease, the Company will record a lease liability and a ROU asset. However, the Company has elected, for all underlying leases with initial terms of twelve months or less (known as short-term leases), to not recognize a lease liability or ROU asset. Lease liabilities are initially recorded at lease commencement as the present value of future lease payments. ROU assets are initially recorded at lease commencement as the initial amount of the lease liability, together with the following, if applicable: (i) initial direct costs incurred by the lessee and (ii) lease payments made by the lessor net of lease incentives received, prior to lease commencement.

Over the lease term, the Company generally increases its lease liabilities using the effective interest method and decreases its lease liabilities for lease payments made. For finance leases, amortization and interest expense are recognized separately in the consolidated statements of operations, with amortization expense generally recorded on a straight-line basis over the lease term and interest expense recorded using the effective interest method. For operating leases, a single lease cost is generally recognized in the consolidated statements of operations on a straight-line basis over the lease term unless an impairment has been recorded with respect to a leased asset. Lease costs for short-term leases not recognized in the consolidated balance sheets are recognized in the consolidated statements of operations on a straight-line basis over the lease term. Variable lease costs not initially included in the lease liability and ROU asset impairment charges are expensed as incurred. ROU assets are assessed for impairment, similar to other long-lived assets.

Recent Accounting Pronouncements

(i)        Recently Issued Accounting Pronouncements

In March 2020, the FASB issued ASU No. 2020-04, Reference Rate Reform (Topic 848), which provides optional guidance to ease the potential burden in accounting for (or recognizing the effects of) reference rate reform on financial reporting. Specifically, the guidance permits an entity, when certain criteria are met, to consider amendments to contracts made to comply with reference rate reform to meet the definition of a modification under U.S. GAAP. It further allows hedge accounting to be maintained and a one-time transfer or sale of qualifying held-to-maturity securities. The expedients and exceptions provided by the amendments are permitted to be adopted any time through December 31, 2022 and do not apply to contract modifications made and hedging relationships entered into or evaluated after December 31, 2022, except for certain optional expedients elected for certain hedging relationships existing as of December 31, 2022. In October 2022, the FASB approved a proposed amendment to Topic 848 which defers the required adoption date of Topic 848 to December 31, 2024, with early adoption permitted. The Company is currently evaluating the effect that this standard will have on its consolidated financial statements and related disclosures.

XML

General Information (Tables)

9 Months Ended

Sep. 30, 2022

General Information

Schedule of useful lives of acquired intangible assets

Tradenames	5 to 10	years
Payor contracts	10	years
Contractual rental agreements	2	years
Developed technology	5	years

XML

Revenue Recognition and Accounts Receivable (Tables)

9 Months Ended

Sep. 30, 2022

Revenue Recognition and Accounts Receivable

Schedule of composition of net revenues by payor type and core service lines

	Three Months Ended September 30,				Nine Months Ended September 30,
	2022			2021	2022		2021
Insurance	$	465,625	$	399,748	$	1,322,694	$	1,061,627
Government		198,841		180,511		576,829		491,564
Patient pay		92,029		73,034		290,789		199,238
Net revenue	$	756,495	$	653,293	$	2,190,312	$	1,752,429

	Three Months Ended September 30,				Nine Months Ended September 30,
	2022			2021	2022		2021
Net sales revenue:
Sleep	$	198,206	$	173,359	$	585,234	$	465,372
Diabetes		169,075		134,228		482,693		352,559
Supplies to the home		47,793		42,441		131,539		126,479
Respiratory		9,734		6,228		25,770		25,003
HME		29,463		29,919		89,828		82,588
Other		58,252		45,996		166,068		98,032
Total net sales revenue	$	512,523	$	432,171	$	1,481,132	$	1,150,033
Net revenue from fixed monthly equipment reimbursements:
Sleep	$	72,423	$	62,755	$	196,022	$	177,199
Diabetes		4,211		3,722		12,191		9,791
Respiratory		130,618		117,918		392,063		312,900
HME		25,482		26,043		76,754		70,854
Other		11,238		10,684		32,150		31,652
Total net revenue from fixed monthly equipment reimbursements	$	243,972	$	221,122	$	709,180	$	602,396
Total net revenue:
Sleep	$	270,629	$	236,114	$	781,256	$	642,571
Diabetes		173,286		137,950		494,884		362,350
Supplies to the home		47,793		42,441		131,539		126,479
Respiratory		140,352		124,146		417,833		337,903
HME		54,945		55,962		166,582		153,442
Other		69,490		56,680		198,218		129,684
Total net revenue	$	756,495	$	653,293	$	2,190,312	$	1,752,429

XML

Acquisitions (Tables)

9 Months Ended

Sep. 30, 2022

Acquisitions.

Schedule of proforma net revenue and operating income

(in thousands) (unaudited)	Three Months Ended September 30,				Nine Months Ended September 30,
	2022		2021		2022		2021
Net revenue	$	756,495	$	722,406	$	2,195,434	$	2,140,382

Operating income $ 52,949 $ 83,788 $ 163,630 $ 195,945

Summary of results of business acquired

(in thousands)	Three Months Ended September 30,				Nine Months Ended September 30,
	2022		2021		2022		2021
Net revenue	$	5,062	$	289,604	$	10,764	$	680,460
Operating income (loss)	$	(726)	$	37,454	$	(333)	$	95,143

Significant Acquisitions In 2022

Acquisitions.

Summary of consideration

Cash	$	16,477
Deferred payments		422
Total	$	16,899

Summary of estimated fair values of the net assets acquired

Cash	$	155
Accounts receivable		2,206
Inventory		686
Prepaid and other current assets		16
Equipment and other fixed assets		4,502
Goodwill		11,788
Identifiable intangible assets		500
Accounts payable and accrued expenses		(2,820)
Contract liabilities		(134)
Net assets acquired	$	16,899

Significant Acquisitions In 2021

Acquisitions.

Summary of consideration

	AeroCare		Spiro		Healthy Living		Agilis		We Care		Other		Total
Cash	$	1,152,768	$	66,101	$	47,048	$	30,842	$	34,833	$	121,710	$	1,453,302
Equity		1,220,342		7,109		5,057		14,668		6,321		7,703		1,261,200
Contingent consideration		—		1,000		—		1,000		—		—		2,000
Deferred payments		—		—		—		—		—		1,162		1,162
Total	$	2,373,110	$	74,210	$	52,105	$	46,510	$	41,154	$	130,575	$	2,717,664

Summary of estimated fair values of the net assets acquired

	AeroCare		Spiro		Healthy Living		Agilis		We Care		Other		Total
Cash	$	27,686	$	2,132	$	580	$	1,170	$	458	$	2,673	$	34,699
Accounts receivable		75,916		8,526		7,471		—		6,355		20,900		119,168
Inventory		27,612		4,939		2,948		2,478		1,488		6,219		45,684
Prepaid and other current assets		3,522		152		254		—		—		2,466		6,394
Equipment and other fixed assets		190,755		2,148		1,201		—		8,170		13,076		215,350
Operating lease right-of-use assets		55,132		2,738		1,366		490		970		12,176		72,872
Goodwill		2,096,850		62,640		41,955		52,938		29,080		102,688		2,386,151
Identifiable intangible assets		122,800		1,000		1,300		500		400		2,400		128,400
Other assets		1,178		16		—		—		—		—		1,194
Deferred tax liabilities		(64,916)		—		—		—		(3,358)		425		(67,849)
Accounts payable and accrued expenses		(82,722)		(5,148)		(3,604)		(576)		(1,439)		(13,921)		(107,410)
Contract liabilities		(14,495)		—		—		—		—		(124)		(14,619)
Other current liabilities		(10,021)		—		—		—		—		(1,555)		(11,576)
Other long-term liabilities		(1,055)		—		—		—		—		—		(1,055)
Operating lease obligations		(55,132)		(2,738)		(1,366)		(490)		(970)		(12,176)		(72,872)
Capital lease obligations		—		(2,195)		—		—		—		(4,672)		(6,867)
Net assets acquired	$	2,373,110	$	74,210	$	52,105	$	56,510	$	41,154	$	130,575	$	2,727,664

XML

Equipment and Other Fixed Assets (Tables)

9 Months Ended

Sep. 30, 2022

Equipment and Other Fixed Assets

Schedule of equipment and other fixed assets

	September 30,		December 31,
	2022		2021
Patient medical equipment	$	711,300	$	533,760
Delivery vehicles		36,089		36,213
Other		83,816		50,208
		831,205		620,181
Less accumulated depreciation		(358,149)		(221,604)
	$	473,056	$	398,577

XML

Goodwill and Identifiable Intangible Assets (Tables)

9 Months Ended

Sep. 30, 2022

Goodwill.

Schedule of change in the carrying amount of goodwill

	Gross carrying
	amount
Balance at December 31, 2021	$	3,512,567
Goodwill from acquisitions		11,788
Net cash receipts relating to prior acquisitions		(188)
Net increase relating to measurement period adjustments		832
Balance at September 30, 2022	$	3,524,999

Schedule of identifiable intangible assets

	September 30, 2022
			Weighted-Average
			Remaining Life (Years)
Tradenames, net of accumulated amortization of $22,294	$	90,506	7.7
Payor contracts, net of accumulated amortization of $17,966		64,034	7.8
Contractual rental agreements, net of accumulated amortization of $39,433		14,767	1.0
Developed technology, net of accumulated amortization of $2,835		3,465	2.8
Identifiable intangible assets, net	$	172,772

	December 31, 2021
			Weighted-Average
			Remaining Life (Years)
Tradenames, net of accumulated amortization of $12,705	$	99,595	8.4
Payor contracts, net of accumulated amortization of $11,816		70,184	8.6
Contractual rental agreements, net of accumulated amortization of $26,158		28,042	1.8
Developed technology, net of accumulated amortization of $1,890		4,410	3.5
Identifiable intangible assets, net	$	202,231

Schedule of future amortization expense related to identifiable intangible assets

Twelve months ending September 30,
2023	$	37,043
2024		22,276
2025		21,828
2026		19,618
2027		18,190
Thereafter		53,817
Total	$	172,772

XML

Fair Value of Assets and Liabilities (Tables)

9 Months Ended

Sep. 30, 2022

Contingent consideration liabilities related to acquisitions

Summary of financial assets and liabilities measured at fair value on a recurring basis

(in thousands)	Level 1		Level 2		Level 3
September 30, 2022
Assets
Money market accounts	$	11	$	—	$	—
Interest rate swap agreements-short term		—		4,471		—
Interest rate swap agreements-long term		—		5,621		—
Total assets measured at fair value	$	11	$	10,092	$	—
Liabilities
Acquisition-related contingent consideration-short term	$	—	$	—	$	14,527
Warrant liability		—		—		38,516
Total liabilities measured at fair value	$	—	$	—	$	53,043

(in thousands)	Level 1		Level 2		Level 3
December 31, 2021
Assets
Money market accounts	$	14	$	—	$	—
Total assets measured at fair value	$	14	$	—	$	—
Liabilities
Acquisition-related contingent consideration-short term	$	—	$	—	$	13,500
Acquisition-related contingent consideration-long term		—		—		6,800
Interest rate swap agreements-short term		—		5,098		—
Interest rate swap agreements-long term		—		2,359		—
Warrant liability		—		—		57,764
Total liabilities measured at fair value	$	—	$	7,457	$	78,064

Summary of non-financial assets measured on a non-recurring basis

	September 30,		December 31,
	2022		2021
Assets:
Goodwill (Level 3)	$	3,524,999	$	3,512,567
Identifiable intangible assets, net (Level 3)	$	172,772	$	202,231

Acquisition Related Contingent Consideration

Contingent consideration liabilities related to acquisitions

Reconciliation of contingent consideration liabilities

Nine Months Ended September 30, 2022	Beginning Balance		Additions		Payments		Change in Fair Value		Other activity		Ending Balance
Contingent consideration - Level 3 liabilities	$	20,300	$	—	$	(6,250)	$	477	$	—	$	14,527
Nine Months Ended September 30, 2021
Contingent consideration - Level 3 liabilities	$	33,540	$	2,000	$	(18,200)	$	1,135	$	173	$	18,648

XML

Derivative Instruments and Hedging Activities (Tables)

9 Months Ended

Sep. 30, 2022

Derivative Instruments and Hedging Activities

Summary of fair value of derivative financial instruments as well as their classification on the consolidated balance sheets

The table below presents the fair value of the Company’s derivatives related to its interest rate swap agreements, which are designated as hedging instruments, as well as their classification in the consolidated balance sheets at September 30, 2022 and December 31, 2021 (in thousands):

		September 30, 2022		December 31, 2021
Balance Sheet Location	Asset (Liability)
Other current assets	$	4,471	$	—
Other long-term assets		5,621		—
Other current liabilities		—		(5,098)
Other long-term liabilities		—		(2,359)
Total	$	10,092	$	(7,457)

XML

Accounts Payable and Accrued Expenses (Tables)

9 Months Ended

Sep. 30, 2022

Accounts Payable and Accrued Expenses

Schedule of components accounts payable and accrued expenses

	September 30,		December 31,
	2022		2021
Accounts payable	$	238,203	$	248,027
Employee-related accruals		50,539		34,370
Accrued interest		9,924		30,103
Other		48,254		45,884
Total	$	346,920	$	358,384

XML

Debt (Tables)

9 Months Ended

Sep. 30, 2022

Debt

Schedule of summary of long term debt

	September 30,		December 31,
	2022		2021
Secured term loans	$	770,000	$	785,000
Senior unsecured notes		1,450,000		1,450,000
Unamortized deferred financing fees		(27,912)		(31,448)
		2,192,088		2,203,552
Current portion		(30,000)		(20,000)
Long-term portion	$	2,162,088	$	2,183,552

XML

Stockholders' Equity (Tables)

9 Months Ended

Sep. 30, 2022

Business Acquisitions

Schedule of changes in warrant liability

A reconciliation of the changes in the warrant liability during the nine months ended September 30, 2022 and 2021 was as follows (in thousands):

Estimated fair value of warrant liability at December 31, 2021	$	57,764
Change in estimated fair value of the warrant liability		(17,145)
Reclassification of warrant liability to equity for exercised warrants		(2,103)
Estimated fair value of warrant liability at September 30, 2022	$	38,516
Estimated fair value of warrant liability at December 31, 2020	$	113,905
Change in estimated fair value of the warrant liability		(57,359)
Estimated fair value of warrant liability at September 30, 2021	$	56,546

Schedule of stock option activity

The following table provides the activity for all outstanding stock options during the nine months ended September 30, 2022 (in thousands, except per share data):

			Weighted-Average	Weighted-Average
	Number of		Exercise Price	Remaining
	Options		per Share	Contractual Term
Outstanding, December 31, 2021	5,766	$	11.26
Exercised	(509)	$	6.79
Outstanding, September 30, 2022	5,257	$	11.72	5.7 Years

Schedule of restricted stock activity

Activity related to the Company’s non-vested restricted stock grants for the nine months ended September 30, 2022 is presented below (in thousands, except per share data):

	Number of Shares of		Weighted-Average Grant Date
	Restricted Stock		Fair Value per Share
Non-vested balance, December 31, 2021	2,195	$	19.58
Granted	929	$	21.26
Vested	(461)	$	24.43
Forfeited	(96)	$	21.96
Non-vested balance, September 30, 2022	2,567	$	22.60

Common Shares Liability

Business Acquisitions

Reconciliation of contingent consideration liabilities

A reconciliation of the changes in the contingent consideration common shares liability during the nine months ended September 30, 2021 was as follows (in thousands):

Estimated fair value of contingent consideration common shares liability at December 31, 2020	$	70,477
Change in estimated fair value of the contingent consideration common shares liability		(34,050)
Estimated fair value of contingent consideration common shares liability at September 30, 2021	$	36,427

2019 Incentive Plan

Business Acquisitions

Schedule of stock option activity

			Weighted-Average
			Grant Date		Weighted-Average	Weighted-Average
	Number of		Fair Value		Exercise Price	Remaining
	Options		per Share		per Share	Contractual Term
Outstanding, December 31, 2021	2,219	$	3.75	$	19.36
Activity - none	—
Outstanding, September 30, 2022	2,219	$	3.75	$	19.36	6.3 Years

XML

Earnings Per Share (Tables)

9 Months Ended

Sep. 30, 2022

Earnings Per Share

Schedule of calculation of basic and diluted earnings per share

	Three Months Ended September 30,				Nine Months Ended September 30,
	2022		2021		2022		2021
Numerator
Net income attributable to AdaptHealth Corp.	$	16,122	$	58,092	$	71,904	$	133,233
Less: Earnings allocated to participating securities (1)		1,360		5,002		6,079		12,572
Net income for basic EPS	$	14,762	$	53,090	$	65,825	$	120,661
Change in fair value of warrant liability (2)		—		(16,737)		(17,145)		(57,359)
Change in fair value of contingent consideration common shares liability (2)		—		(8,145)		—		(27,718)
Net income for diluted EPS	$	14,762	$	28,208	$	48,680	$	35,584
Denominator (1) (2)
Basic weighted-average common shares outstanding		134,227		131,684		134,186		124,228
Add: Warrants (2)		—		2,245		1,436		2,598
Add: Contingent Consideration Common Shares (2)		—		2,000		—		2,000
Add: Stock options		2,903		3,794		2,669		4,112
Add: Unvested restricted stock		453		599		308		700
Diluted weighted-average common shares outstanding		137,583		140,322		138,599		133,638
Basic net income per share	$	0.11	$	0.40	$	0.49	$	0.97
Diluted net income per share	$	0.11	$	0.20	$	0.35	$	0.27

(1) The Company’s preferred stock are considered participating securities. Computation of EPS under the two-class method excludes from the numerator any dividends paid or owed on participating securities and any undistributed earnings considered to be attributable to participating securities. The related participating securities are similarly excluded from the denominator.

(2) For the nine months ended September 30, 2022, and the three and nine months ended September 30, 2021, the impact to earnings from the change in fair value of the Company’s warrant liability is excluded from the numerator, and the corresponding security is included in the denominator, for purposes of computing diluted net income per share. For the three and nine months ended September 30, 2021, the impact to earnings from the change in fair value of the Company’s contingent consideration common shares liability is excluded from the numerator, and the corresponding security is considered for inclusion in the denominator, for purposes of computing diluted net income per share. These adjustments are included as the effect of the numerator and denominator adjustments for these derivative instruments is dilutive as a result of the non-cash gains recorded for the change in fair value of these instruments during the periods.

Schedule of antidilutive securities excluded from computation of earnings per share

	Three Months Ended September 30,					Nine Months Ended September 30,
	2022		2021		2022		2021
Preferred Stock		12,406		12,406		12,406		12,944
Warrants		1,706		—		—		—
Stock options		468		—		468		—
Unvested restricted stock		108		—		221		—
Total		14,688		12,406		13,095		12,944

XML

Leases (Tables)

9 Months Ended

Sep. 30, 2022

Leases

Schedule of assets and lease liabilities

	Consolidated Balance Sheets Line Item	September 30, 2022		December 31, 2021
Right-of-use (ROU) assets:
Operating lease ROU assets	Operating lease right-of-use assets	$	128,635	$	147,760
Finance lease ROU assets	Equipment and other fixed assets, net		1,056		17,410
Total ROU assets		$	129,691	$	165,170
Operating lease liabilities:
Current operating lease liabilities	Current portion of operating lease obligations	$	28,769	$	31,418
Noncurrent operating lease liabilities	Operating lease obligations, less current portion		103,859		120,180
Total operating lease liabilities		$	132,628	$	151,598
Finance lease liabilities:
Current finance lease liabilities	Current portion of finance lease obligations	$	2,695	$	15,446
Noncurrent finance lease liabilities	Other long-term liabilities		—		132
Total finance lease liabilities		$	2,695	$	15,578

	Three Months Ended September 30,				Nine Months Ended September 30,
	2022		2021		2022		2021
Operating lease costs	$	9,248	$	9,837	$	28,547	$	27,695
Finance lease costs:
Amortization of ROU assets	$	640	$	8,487	$	7,266	$	27,549
Other lease costs and income:
Variable leases costs (1)	$	3,728	$	3,784	$	12,680	$	10,061
Sublease income	$	336	$	405	$	1,019	$	911
Short-term lease costs	$	—	$	4,093	$	—	$	19,905

(1) Amounts represent variable costs incurred that were not included in the initial measurement of the lease liability such as common area maintenance and utilities costs associated with leased real estate.

Schedule of weighted average remaining lease terms and weighted average discount rates

	September 30, 2022	December 31, 2021
Weighted average remaining lease term, weighted based on lease liability balances:
Operating leases	6.2 years	6.7 years
Finance leases	0.5 year	1.0 year
Weighted average discount rate, weighted based on remaining balance of lease payments:
Operating leases	3.9%	3.8%

Schedule of operating lease liability maturity

	Operating Leases		Finance Leases
2022	$	8,778	$	1,920
2023		31,757		795
2024		26,347		—
2025		21,966		—
2026		16,158		—
Thereafter		47,027		—
Total future undiscounted lease payments	$	152,033	$	2,715
Less: amount representing interest		(19,405)		(20)
Present value of future lease payments (lease liability)	$	132,628	$	2,695

Schedule of finance lease liability maturity

	Operating Leases		Finance Leases
2022	$	8,778	$	1,920
2023		31,757		795
2024		26,347		—
2025		21,966		—
2026		16,158		—
Thereafter		47,027		—
Total future undiscounted lease payments	$	152,033	$	2,715
Less: amount representing interest		(19,405)		(20)
Present value of future lease payments (lease liability)	$	132,628	$	2,695

Schedule of cash flow and supplemental non-cash information related to our lease liabilities

	Nine Months Ended September 30,
Cash paid for amounts included in the measurement of lease liabilities:	2022		2021
Operating cash payments for operating leases	$	28,416	$	27,154
Financing cash payments for finance leases	$	14,219	$	31,043
Lease liabilities arising from obtaining right-of-use assets:
Operating leases	$	5,411	$	84,212
Finance leases	$	1,335	$	22,902

XML

General Information (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
General Information
Impairment of long-lived assets	$ 0	$ 0	$ 0	$ 0
Lease, Practical Expedients, Package [true false]			true
Payor contracts
General Information
Finite-Lived Intangible Asset, Useful Life			10 years
Contractual rental agreements
General Information
Finite-Lived Intangible Asset, Useful Life			2 years
Developed technology
General Information
Finite-Lived Intangible Asset, Useful Life			5 years
Minimum | Tradenames
General Information
Finite-Lived Intangible Asset, Useful Life			5 years
Maximum | Tradenames
General Information
Finite-Lived Intangible Asset, Useful Life			10 years

XML

Revenue Recognition and Accounts Receivable (Details) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended		9 Months Ended
	Apr. 30, 2020	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021	Jul. 29, 2020
Revenue Recognition
Total net revenues		$ 756,495	$ 653,293	$ 2,190,312	$ 1,752,429
Recoupable Advance Payment, CARES Act	$ 45,800
CARES Act funding recouped		500	11,100	9,600	27,000
CARES Act remaining advance payments not yet recouped		3,200		3,200
Unbilled revenue		22,900		22,900		$ 23,800
Significant Acquisitions In 2020
Revenue Recognition
CARES Act remaining advance payments not yet recouped							$ 3,700
Transferred at Point in Time
Revenue Recognition
Total net revenues		512,523	432,171	1,481,132	1,150,033
Transferred over Time
Revenue Recognition
Total net revenues		243,972	221,122	709,180	602,396
Sleep
Revenue Recognition
Total net revenues		270,629	236,114	781,256	642,571
Sleep | Transferred at Point in Time
Revenue Recognition
Total net revenues		198,206	173,359	585,234	465,372
Sleep | Transferred over Time
Revenue Recognition
Total net revenues		72,423	62,755	196,022	177,199
Diabetes
Revenue Recognition
Total net revenues		173,286	137,950	494,884	362,350
Diabetes | Transferred at Point in Time
Revenue Recognition
Total net revenues		169,075	134,228	482,693	352,559
Diabetes | Transferred over Time
Revenue Recognition
Total net revenues		4,211	3,722	12,191	9,791
Supplies to the home
Revenue Recognition
Total net revenues		47,793	42,441	131,539	126,479
Supplies to the home | Transferred at Point in Time
Revenue Recognition
Total net revenues		47,793	42,441	131,539	126,479
Respiratory
Revenue Recognition
Total net revenues		140,352	124,146	417,833	337,903
Respiratory | Transferred at Point in Time
Revenue Recognition
Total net revenues		9,734	6,228	25,770	25,003
Respiratory | Transferred over Time
Revenue Recognition
Total net revenues		130,618	117,918	392,063	312,900
HME
Revenue Recognition
Total net revenues		54,945	55,962	166,582	153,442
HME | Transferred at Point in Time
Revenue Recognition
Total net revenues		29,463	29,919	89,828	82,588
HME | Transferred over Time
Revenue Recognition
Total net revenues		25,482	26,043	76,754	70,854
Health Care, Other
Revenue Recognition
Total net revenues		69,490	56,680	198,218	129,684
Health Care, Other | Transferred at Point in Time
Revenue Recognition
Total net revenues		58,252	45,996	166,068	98,032
Health Care, Other | Transferred over Time
Revenue Recognition
Total net revenues		11,238	10,684	32,150	31,652
Insurance
Revenue Recognition
Total net revenues		465,625	399,748	1,322,694	1,061,627
Government
Revenue Recognition
Total net revenues		198,841	180,511	576,829	491,564
Patient pay
Revenue Recognition
Total net revenues		$ 92,029	$ 73,034	$ 290,789	$ 199,238

XML

Acquisitions (Details) $ / shares in Units, $ in Thousands					3 Months Ended	9 Months Ended
	Jul. 01, 2021 USD ($) shares	Jun. 01, 2021 USD ($) shares	Apr. 30, 2021 USD ($) shares	Feb. 01, 2021 USD ($) $ / shares shares	Sep. 30, 2021 USD ($)	Sep. 30, 2022 USD ($) item shares	Sep. 30, 2021 USD ($) item shares	Dec. 31, 2021 shares	Jul. 31, 2021 USD ($)	Nov. 08, 2019 $ / shares
Acquisitions.
Contingent consideration paid						$ 477	$ 1,135
Deferred payments						$ 422	1,162
Preferred Stock, Shares Issued | shares						124,060		124,060
Exercise price | $ / shares										$ 11.50
Cash receipt from working capital adjustment						$ (188)
Significant Acquisitions In 2022
Acquisitions.
Cash payment						$ 16,477
Home Medical Equipment Provider Acquired In 2022
Acquisitions.
Interest acquired, as a percent						100.00%
Number of home medical equipment providers acquired | item						2
Number of entities acquired | item						5
Significant Acquisitions In 2021
Acquisitions.
Cash payment							1,453,302
AeroCare Holdings
Acquisitions.
Interest acquired, as a percent				100.00%
Cash payment				$ 1,200,000			1,152,768
Options issued in acquisition, in shares | shares				3,959,892
Exercise price | $ / shares				$ 6.24
Weighted average exercise period				7 years
AeroCare Holdings | Class A Common Stock
Acquisitions.
Issuance of stock for acquisitions (in shares) | shares				13,992,615
AeroCare Holdings | Series C Preferred Stock
Acquisitions.
Preferred Stock, Shares Issued | shares				130,474.73
Spiro Health Services
Acquisitions.
Interest acquired, as a percent			100.00%
Cash payment			$ 66,100				$ 66,101
Issuance of stock for acquisitions (in shares) | shares			244,641
Maximum potential contingent consideration			$ 1,000
Home Medical Equipment Providers, Equity Interests And Assets Acquisitions
Acquisitions.
Interest acquired, as a percent					100.00%		100.00%
Number of home medical equipment providers acquired | item							10
Agilis Med Holdings, LLC
Acquisitions.
Interest acquired, as a percent	100.00%
Investment carrying value									$ 8,100
Fair value of investment									$ 10,000
Gain on equity method investment					$ 1,900		$ 1,900
Cash payment	$ 30,800						30,842
Issuance of stock for acquisitions (in shares) | shares	538,079
Maximum potential contingent consideration	$ 1,000
WeCare Medical, LLC
Acquisitions.
Interest acquired, as a percent	100.00%
Cash payment	$ 34,800						34,833
Issuance of stock for acquisitions (in shares) | shares	231,866
Home Medical Equipment Provider and Diabetes Management Products and Supplies Acquired in 2021
Acquisitions.
Cash payment							$ 121,700
Issuance of stock for acquisitions (in shares) | shares							306,569
Deferred payments							$ 1,200
Healthy Living Medical Supply, L L C
Acquisitions.
Interest acquired, as a percent		100.00%
Cash payment		$ 47,000					$ 47,048
Issuance of stock for acquisitions (in shares) | shares		196,779

XML

Acquisitions - Consideration and Allocation (Details) - USD ($) $ in Thousands					9 Months Ended
	Jul. 01, 2021	Jun. 01, 2021	Apr. 30, 2021	Feb. 01, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Business Combination, Consideration Transferred, Including Equity Interest in Acquiree Held Prior to Combination [Abstract]
Deferred payments					$ 422	$ 1,162
Estimated fair values of net assets acquired
Goodwill					3,524,999		$ 3,512,567
Receipt of working capital adjustment from prior year acquisitions						700
Significant Acquisitions In 2022
Business Combination, Consideration Transferred, Including Equity Interest in Acquiree Held Prior to Combination [Abstract]
Cash					16,477
Deferred payments					422
Total					16,899
Estimated fair values of net assets acquired
Cash					155
Accounts receivable					2,206
Inventory					686
Prepaid and other current assets					16
Equipment and other fixed assets					4,502
Goodwill					11,788
Identifiable intangible assets					500
Accounts payable and accrued expenses					(2,820)
Contract liabilities					(134)
Net assets acquired					16,899
Significant Acquisitions In 2021
Business Combination, Consideration Transferred, Including Equity Interest in Acquiree Held Prior to Combination [Abstract]
Cash						1,453,302
Equity						1,261,200
Contingent consideration						2,000
Deferred payments						1,162
Total						2,717,664
Estimated fair values of net assets acquired
Cash						34,699
Accounts receivable						119,168
Inventory						45,684
Prepaid and other current assets						6,394
Equipment and other fixed assets						215,350
Operating lease right-of-use assets						72,872
Goodwill						2,386,151
Identifiable intangible assets						128,400
Other assets						1,194
Deferred tax liabilities						(67,849)
Accounts payable and accrued expenses						(107,410)
Contract liabilities						(14,619)
Other current liabilities						(11,576)
Other long-term liabilities						(1,055)
Capital lease obligations						(6,867)
Operating lease obligations						(72,872)
Net assets acquired						2,727,664
Receipt of working capital adjustment from prior year acquisitions					$ 200
AeroCare Holdings
Business Combination, Consideration Transferred, Including Equity Interest in Acquiree Held Prior to Combination [Abstract]
Cash				$ 1,200,000		1,152,768
Equity						1,220,342
Total						2,373,110
Estimated fair values of net assets acquired
Cash						27,686
Accounts receivable						75,916
Inventory						27,612
Prepaid and other current assets						3,522
Equipment and other fixed assets						190,755
Operating lease right-of-use assets						55,132
Goodwill						2,096,850
Identifiable intangible assets						122,800
Other assets						1,178
Deferred tax liabilities						(64,916)
Accounts payable and accrued expenses						(82,722)
Contract liabilities						(14,495)
Other current liabilities						(10,021)
Other long-term liabilities						(1,055)
Operating lease obligations						(55,132)
Net assets acquired						2,373,110
Other acquisitions in 2021
Business Combination, Consideration Transferred, Including Equity Interest in Acquiree Held Prior to Combination [Abstract]
Cash						121,710
Equity						7,703
Deferred payments						1,162
Total						130,575
Estimated fair values of net assets acquired
Cash						2,673
Accounts receivable						20,900
Inventory						6,219
Prepaid and other current assets						2,466
Equipment and other fixed assets						13,076
Operating lease right-of-use assets						12,176
Goodwill						102,688
Identifiable intangible assets						2,400
Deferred tax asset						425
Accounts payable and accrued expenses						(13,921)
Contract liabilities						(124)
Other current liabilities						(1,555)
Capital lease obligations						(4,672)
Operating lease obligations						(12,176)
Net assets acquired						130,575
Spiro Health Services
Business Combination, Consideration Transferred, Including Equity Interest in Acquiree Held Prior to Combination [Abstract]
Cash			$ 66,100			66,101
Equity						7,109
Contingent consideration						1,000
Total						74,210
Maximum potential contingent consideration			$ 1,000
Estimated fair values of net assets acquired
Cash						2,132
Accounts receivable						8,526
Inventory						4,939
Prepaid and other current assets						152
Equipment and other fixed assets						2,148
Operating lease right-of-use assets						2,738
Goodwill						62,640
Identifiable intangible assets						1,000
Other assets						16
Accounts payable and accrued expenses						(5,148)
Capital lease obligations						(2,195)
Operating lease obligations						(2,738)
Net assets acquired						74,210
Healthy Living Medical Supply, L L C
Business Combination, Consideration Transferred, Including Equity Interest in Acquiree Held Prior to Combination [Abstract]
Cash		$ 47,000				47,048
Equity						5,057
Total						52,105
Estimated fair values of net assets acquired
Cash						580
Accounts receivable						7,471
Inventory						2,948
Prepaid and other current assets						254
Equipment and other fixed assets						1,201
Operating lease right-of-use assets						1,366
Goodwill						41,955
Identifiable intangible assets						1,300
Accounts payable and accrued expenses						(3,604)
Operating lease obligations						(1,366)
Net assets acquired						52,105
Agilis Med Holdings, LLC
Business Combination, Consideration Transferred, Including Equity Interest in Acquiree Held Prior to Combination [Abstract]
Cash	$ 30,800					30,842
Equity						14,668
Contingent consideration						1,000
Total						46,510
Maximum potential contingent consideration	1,000
Estimated fair values of net assets acquired
Cash						1,170
Inventory						2,478
Operating lease right-of-use assets						490
Goodwill						52,938
Identifiable intangible assets						500
Accounts payable and accrued expenses						(576)
Operating lease obligations						(490)
Net assets acquired						56,510
WeCare Medical, LLC
Business Combination, Consideration Transferred, Including Equity Interest in Acquiree Held Prior to Combination [Abstract]
Cash	$ 34,800					34,833
Equity						6,321
Total						41,154
Estimated fair values of net assets acquired
Cash						458
Accounts receivable						6,355
Inventory						1,488
Equipment and other fixed assets						8,170
Operating lease right-of-use assets						970
Goodwill						29,080
Identifiable intangible assets						400
Deferred tax liabilities						(3,358)
Accounts payable and accrued expenses						(1,439)
Operating lease obligations						(970)
Net assets acquired						$ 41,154

XML

Acquisitions - Pro-forma Financial Information and Results of Business Acquired (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Pro-forma financial information:
Pro-forma net revenue	$ 756,495	$ 722,406	$ 2,195,434	$ 2,140,382
Pro-forma operating income	52,949	83,788	163,630	195,945
Net revenue since acquisition date	5,062	289,604	10,764	680,460
Operating income since acquisition date	$ (726)	$ 37,454	$ (333)	$ 95,143

XML

Equipment and Other Fixed Assets (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Equipment and Other Fixed Assets
Equipment and other fixed assets, gross	$ 831,205		$ 831,205		$ 620,181
Less accumulated depreciation	(358,149)		(358,149)		(221,604)
Equipment and other fixed assets, net	473,056		473,056		398,577
Depreciation and amortization, including patient equipment depreciation	82,400	$ 59,700	218,900	$ 146,500
Patient medical equipment.
Equipment and Other Fixed Assets
Equipment and other fixed assets, gross	711,300		711,300		533,760
Delivery vehicles
Equipment and Other Fixed Assets
Equipment and other fixed assets, gross	36,089		36,089		36,213
Other
Equipment and Other Fixed Assets
Equipment and other fixed assets, gross	$ 83,816		$ 83,816		$ 50,208

XML

Goodwill and Identifiable Intangible Assets - Goodwill and post-closing adjustments (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2022 USD ($)
Net carrying amount
Beginning balance	$ 3,512,567
Goodwill from acquisitions	11,788
Net cash receipts relating to prior acquisitions	(188)
Net increase relating to measurement period adjustments	832
Ending balance	3,524,999
Cash receipt from working capital adjustment	(188)
Solara Medical Supplies, LLC
Net carrying amount
Net cash receipts relating to prior acquisitions	200
Cash receipt from working capital adjustment	$ 200

XML

Goodwill and Identifiable Intangible Assets - Intangible Assets (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Identifiable intangible assets
Amortization of intangible assets	$ 10,000	$ 10,100	$ 30,000	$ 34,400
Future amortization expense related to identifiable intangible assets
2023	37,043		37,043
2024	22,276		22,276
2025	21,828		21,828
2026	19,618		19,618
2027	18,190		18,190
Thereafter	53,817		53,817
Total	172,772		172,772		$ 202,231
Impairment of Intangible Assets, Finite-lived	0	$ 0	0	$ 0
Tradenames
Identifiable intangible assets
Finite-Lived Intangible Assets, Accumulated Amortization	22,294		$ 22,294		$ 12,705
Finite-Lived Intangible Assets, Remaining Amortization Period			7 years 8 months 12 days		8 years 4 months 24 days
Future amortization expense related to identifiable intangible assets
Total	90,506		$ 90,506		$ 99,595
Payor contracts
Identifiable intangible assets
Finite-Lived Intangible Assets, Accumulated Amortization	17,966		$ 17,966		$ 11,816
Finite-Lived Intangible Assets, Remaining Amortization Period			7 years 9 months 18 days		8 years 7 months 6 days
Future amortization expense related to identifiable intangible assets
Total	64,034		$ 64,034		$ 70,184
Contractual rental agreements
Identifiable intangible assets
Finite-Lived Intangible Assets, Accumulated Amortization	39,433		$ 39,433		$ 26,158
Finite-Lived Intangible Assets, Remaining Amortization Period			1 year		1 year 9 months 18 days
Future amortization expense related to identifiable intangible assets
Total	14,767		$ 14,767		$ 28,042
Developed technology
Identifiable intangible assets
Finite-Lived Intangible Assets, Accumulated Amortization	2,835		$ 2,835		$ 1,890
Finite-Lived Intangible Assets, Remaining Amortization Period			2 years 9 months 18 days		3 years 6 months
Future amortization expense related to identifiable intangible assets
Total	$ 3,465		$ 3,465		$ 4,410

XML

Fair Value of Assets and Liabilities - Valuation of Financial Assets and Liabilities (Details) - Recurring - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Level 1
Assets
Total assets measured at fair value	$ 11	$ 14
Level 1 | Money market accounts
Assets
Total assets measured at fair value	11	14
Level 2
Assets
Total assets measured at fair value	10,092
Liabilities
Total liabilities measured at fair value		7,457
Level 2 | Interest Rate Swap Short-term
Assets
Total assets measured at fair value	4,471
Liabilities
Total liabilities measured at fair value		5,098
Level 2 | Interest Rate Swap Long-term
Assets
Total assets measured at fair value	5,621
Liabilities
Total liabilities measured at fair value		2,359
Level 3
Liabilities
Total liabilities measured at fair value	53,043	78,064
Level 3 | Acquisition-related contingent consideration obligations-short term
Liabilities
Total liabilities measured at fair value	14,527	13,500
Level 3 | Acquisition-related contingent consideration obligations-long term
Liabilities
Total liabilities measured at fair value		6,800
Level 3 | Warrant Liability
Liabilities
Total liabilities measured at fair value	$ 38,516	$ 57,764

XML

Fair Value of Assets and Liabilities - Contingent Consideration Rollforward (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Contingent consideration liabilities related to acquisitions
Contingent consideration liability at beginning of period	$ 20,300	$ 33,540
Additions		2,000
Payments	(6,250)	(18,200)
Gain	477	1,135
Other activity		173
Contingent consideration liability at end of period	14,527	$ 18,648
Other current liabilities
Contingent consideration liabilities related to acquisitions
Contingent consideration liability at beginning of period	13,500
Contingent consideration liability at end of period	14,500
Other long-term liabilities
Contingent consideration liabilities related to acquisitions
Contingent consideration liability at beginning of period	$ 6,800

XML

Fair Value of Assets and Liabilities - Non-financial Assets Measured on Non-recurring Basis (Details) - Nonrecurring - Level 3 - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Non-financial assets measured at fair value on a non-recurring basis
Goodwill	$ 3,524,999	$ 3,512,567
Identifiable intangible assets, net	$ 172,772	$ 202,231

XML

Derivative Instruments and Hedging Activities - Financial instruments (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Apr. 30, 2022	Dec. 31, 2021
Derivative financial instruments
Derivative Asset, Statement of Financial Position [Extensible Enumeration]	Prepaid Expense and Other Assets, Current		Prepaid Expense and Other Assets, Current
Derivative Liability, Statement of Financial Position [Extensible Enumeration]			Other Assets, Noncurrent, Other Liabilities, Current, Other Liabilities, Noncurrent, Prepaid Expense and Other Assets, Current
Derivatives designated as hedging instruments | Interest rate swap agreements
Derivative Instruments and Hedging Activities
Notional amount	$ 250,000		$ 250,000
Derivative financial instruments
Fair Value Asset	4,471
Fair Value Liability	10,092		(7,457)
Derivatives designated as hedging instruments | Interest rate swap agreements | Other long-term assets
Derivative financial instruments
Fair Value Asset (Liability)	$ 5,621
Derivatives designated as hedging instruments | Interest rate swap agreements | Other current liabilities
Derivative financial instruments
Fair Value Liability			(5,098)
Derivatives designated as hedging instruments | Interest rate swap agreements | Other long-term liabilities
Derivative financial instruments
Fair Value Liability			$ (2,359)
Derivatives designated as hedging instruments | Forward-dated interest rate swap agreements
Derivative Instruments and Hedging Activities
Notional amount		$ 250,000

XML

Derivative Instruments and Hedging Activities - Effect on Accumulated Other Comprehensive Income (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Derivative Instruments, Gain (Loss)
Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]		Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest	Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest	Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest
Amount of Gain or (Loss) Reclassified from Accumulated OCI into Income	$ 0.8	$ 0.8	$ 2.2	$ 2.1
Derivatives in cash flow hedging relationships
Derivative Instruments, Gain (Loss)
Amount of Gain or (Loss) Recognized in OCI on Derivative	$ 8.5	$ 1.4	$ 17.5	$ 5.4

XML

Accounts Payable and Accrued Expenses (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Accounts Payable and Accrued Expenses
Accounts payable	$ 238,203	$ 248,027
Employee related accruals	50,539	34,370
Accrued interest	9,924	30,103
Other	48,254	45,884
Accounts payable and accrued expenses	$ 346,920	$ 358,384

XML

Debt (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Debt
Unamortized deferred financing fees	$ (27,912)	$ (31,448)
Debt, Net	2,192,088	2,203,552
Current portion	(30,000)	(20,000)
Long-term portion	2,162,088	2,183,552
Term Loan 2021
Debt
Debt, Gross	770,000	785,000
Senior Unsecured Notes 4.625 Per Cent Due 2029
Debt
Debt, Gross	$ 1,450,000	$ 1,450,000

XML

Debt - Credit Facilities (Details) - USD ($) $ in Thousands	1 Months Ended			3 Months Ended	9 Months Ended
	Aug. 31, 2021	Jun. 30, 2021	Apr. 30, 2021	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021	Aug. 19, 2021	Aug. 16, 2021	Jan. 04, 2021
Debt
Write-off of deferred financing costs						$ 4,054
Borrowings on lines of credit						1,165,000
Repayment of loan					$ 15,000	822,271
Loss on extinguishment of debt				$ 8,240		20,189
Credit Agreement 2021 [Member]
Debt
Payments of Debt Issuance Costs						7,600
Write-off of deferred financing costs						$ 2,100
Repayment of loan			$ 301,900
Credit Agreement 2021 [Member] | Minimum
Debt
Commitment fee (as a percent)						0.25%
Credit Agreement 2021 [Member] | Maximum
Debt
Commitment fee (as a percent)						0.50%
Credit Agreement 2021 [Member] | LIBOR | Minimum
Debt
Rate margin (as a percent)						1.50%
Credit Agreement 2021 [Member] | LIBOR | Maximum
Debt
Rate margin (as a percent)						3.25%
Revolving Credit Loans 2021
Debt
Borrowing capacity			450,000
Borrowings on lines of credit					0	$ 365,000
Revolver balance					0
Remaining maximum borrowings available					432,600
Letter Of Credit 2021
Debt
Borrowing capacity			55,000
Term Loan 2021
Debt
Borrowing capacity			$ 800,000
Debt balance outstanding					$ 770,000		$ 785,000
Credit facility Interest rate					4.56%
Term Loan 2021 | First Specified Repayment Period
Debt
Quarterly principal repayments					$ 5,000
Term Loan 2021 | Second Specified Repayment Period
Debt
Quarterly principal repayments					10,000
Senior Unsecured Notes 4.625 Per Cent Due 2029
Debt
Debt balance outstanding					1,450,000		1,450,000
Debt Interest rate										4.625%
Deferred financing costs										$ 10,400
Senior Unsecured Notes 5.125 Per Cent Due 2030
Debt
Debt Interest rate								5.125%	5.125%
Deferred financing costs								$ 11,100
New Promissory Note
Debt
Write-off of deferred financing costs	$ 600	$ 1,400
Repayment of loan	$ 71,700
Term Loan 2020
Debt
Debt balance outstanding							$ 785,000
Revolver Letter Of Credit Sublimit Maturing July 2025
Debt
Debt balance outstanding					$ 17,400

XML

Debt - Notes (Details) - USD ($) $ in Thousands				1 Months Ended		9 Months Ended
	Aug. 19, 2021	Jan. 04, 2021	Jul. 29, 2020	Aug. 31, 2021	Jun. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Aug. 16, 2021	Mar. 31, 2019
Debt
Write-off of deferred financing costs							$ 4,054
Proceeds from the issuance of senior unsecured notes							1,100,000
Loss on extinguishment of debt from prepayment penalty							16,135
Repayment of loan						$ 15,000	822,271
Gain (loss) on extinguishment of debt							$ (16,135)
New Promissory Note
Debt
Face amount					$ 71,800
Write-off of deferred financing costs				$ 600	1,400
Loss on extinguishment of debt from prepayment penalty				(7,700)	8,500
Repayment of loan				71,700
Gain (loss) on extinguishment of debt				$ 7,700	$ (8,500)
Make-whole premium, as a percent				10.00%	10.00%
Note payable
Debt
Face amount									$ 100,000
Note payable | Period starting on the closing date and ending on the seventh anniversary
Debt
Debt Interest rate				12.00%
Promissory Note From Members Interest
Debt
Face amount									$ 43,500
Senior Unsecured Notes 4.625 Per Cent Due 2029
Debt
Face amount		$ 500,000
Debt Interest rate		4.625%
Percentage of original principal that may be redeemed		40.00%
Redemption price, as percent of principal, proceeds from equity offerings		104.625%
Deferred financing costs		$ 10,400
Senior Unsecured Notes 4.625 Per Cent Due 2029 | Redemption Period One
Debt
Redemption price, as percent of principal		100.00%
Senior Unsecured Notes 4.625 Per Cent Due 2029 | Redemption Period Two
Debt
Redemption price, as percent of principal		102.313%
Senior Unsecured Notes 4.625 Per Cent Due 2029 | Redemption Period Three
Debt
Redemption price, as percent of principal		101.156%
Senior Unsecured Notes 4.625 Per Cent Due 2029 | Redemption Period Four
Debt
Redemption price, as percent of principal		100.00%
Senior Unsecured Notes 5.125 Per Cent Due 2030
Debt
Face amount	$ 600,000
Debt Interest rate	5.125%							5.125%
Percentage of original principal that may be redeemed	40.00%
Deferred financing costs	$ 11,100
Senior Unsecured Notes 5.125 Per Cent Due 2030 | Redemption Period One
Debt
Redemption price, as percent of principal	100.00%
Redemption price, as percent of principal, proceeds from equity offerings	105.125%
Senior Unsecured Notes 5.125 Per Cent Due 2030 | Redemption Period Two
Debt
Redemption price, as percent of principal	102.563%
Senior Unsecured Notes 5.125 Per Cent Due 2030 | Redemption Period Three
Debt
Redemption price, as percent of principal	101.281%
Senior Unsecured Notes 5.125 Per Cent Due 2030 | Redemption Period Four
Debt
Redemption price, as percent of principal	100.00%
Senior Notes 6.125 Percent Due 2028
Debt
Face amount			$ 350,000
Debt Interest rate			6.125%
Percentage of original principal that may be redeemed			40.00%
Redemption price, as percent of principal, proceeds from equity offerings			106.125%
Senior Notes 6.125 Percent Due 2028 | Redemption Period One
Debt
Redemption price, as percent of principal			100.00%
Senior Notes 6.125 Percent Due 2028 | Redemption Period Two
Debt
Redemption price, as percent of principal			103.063%
Senior Notes 6.125 Percent Due 2028 | Redemption Period Three
Debt
Redemption price, as percent of principal			102.042%
Senior Notes 6.125 Percent Due 2028 | Redemption Period Four
Debt
Redemption price, as percent of principal			101.021%
Senior Notes 6.125 Percent Due 2028 | Redemption Period Five and thereafter
Debt
Redemption price, as percent of principal			100.00%

XML

Stockholders' Equity - Activity (Details) $ / shares in Units, $ in Thousands					1 Months Ended			3 Months Ended			9 Months Ended
	Jul. 28, 2021 Vote shares	Mar. 18, 2021 shares	Jan. 01, 2021 shares	Nov. 08, 2019 Vote	Jan. 31, 2022 USD ($)	Jan. 31, 2021 USD ($) $ / shares shares	Jun. 30, 2020 $ / shares shares	Sep. 30, 2022 USD ($) $ / shares shares	Jun. 30, 2022 shares	Mar. 31, 2021 USD ($)	Sep. 30, 2022 USD ($) $ / shares shares	Sep. 30, 2021 USD ($) shares	May 09, 2022 USD ($)	Dec. 31, 2021 $ / shares shares	Jul. 27, 2021 shares	Feb. 01, 2021 $ / shares shares
Stockholders' Equity
Stock exchange ratio				1
Exchange of equity interests, in shares			13,218,758
Value of shares exchanged | $					$ 77,900
Common stock shares authorized	300,000,000							300,000,000			300,000,000			300,000,000	245,000,000
Proceeds from sale of stock | $										$ 265,018
Net proceeds | $												$ 278,850
Offering costs | $												$ 13,832
Preferred stock, par value (in dollars per share) | $ / shares								$ 0.0001			$ 0.0001			$ 0.0001
Preferred stock, shares issued (in shares)								124,060			124,060			124,060
Amount of cash authorized for Stock repurchase program | $													$ 200,000
Common stock, shares authorized (in shares)	300,000,000							300,000,000			300,000,000			300,000,000	245,000,000
Number of votes per share | Vote	1
Value of shares repurchase | $								$ 13,992			$ 13,992
Adapt Health Holdings LLC
Stockholders' Equity
Controlling interest, as a percent				56.00%
Adapt Health Holdings LLC | Shareholders of Adapt Health Holdings LLC
Stockholders' Equity
Noncontrolling interest, as a percent				44.00%
Number of votes per share | Vote				1
Treasury Stock
Stockholders' Equity
Number of shares purchased under repurchase program								552,000	199,000		750,835
Value of shares repurchase | $								$ 14,000			$ 14,000
Class A Common Stock
Stockholders' Equity
Exchange of Class A Common Stock for Series B-1 Preferred Stock (in shares)							15,810,547					3,950,000
Conversion Of Series C-1 Preferred Stock to Class A Common Stock (in shares)		13,047,473
Series B-1 Preferred Stock
Stockholders' Equity
Exchange of Class A Common Stock for Series B-1 Preferred Stock (in shares)							158,105.47				0	39,500
Preferred stock, par value (in dollars per share) | $ / shares							$ 0.0001
Preferred stock, liquidation preference (in dollars per share) | $ / shares							$ 0.0001
Shares of common stock received in conversion for each share of preferred stock							100
Preferred stock conversion, ceiling as a percent of outstanding common stock							4.9
Series C Preferred Stock
Stockholders' Equity
Preferred stock, liquidation preference (in dollars per share) | $ / shares																$ 0.0001
Shares of common stock received in conversion for each share of preferred stock		100
Conversion Of Series C-1 Preferred Stock to Class A Common Stock (in shares)		130,474.73
Series C Preferred Stock | AeroCare Holdings
Stockholders' Equity
Preferred stock, shares issued (in shares)																130,474.73
Public Offering
Stockholders' Equity
Shares issued						8,450,000
Share price | $ / shares						$ 33.00
Proceeds from sale of stock | $						$ 278,900
Net proceeds | $						265,000
Offering costs | $						$ 13,800				$ 13,832

XML

Stockholders' Equity - Warrants (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended			9 Months Ended
	Sep. 30, 2022	Jun. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Nov. 08, 2019
Warrants
Warrants outstanding	3,871,557			3,871,557		12,666,666
Common stock for each warrant exercised						1
Warrant exercisable price						$ 11.50
Warrants exercised in cashless transaction, number exercised				184,870	0
Shares issued in cashless exercise of warrants (in shares)				87,553
Warrant liability, beginning				$ 57,764	$ 113,905
Change in fair value of warrant liability (note 10)	$ 1,364		$ (16,737)	(17,145)	(57,359)
Reclassification of warrant liability to equity for exercised warrants	(1,608)	$ (495)		(2,103)
Warrant liability, ending	$ 38,516		$ 56,546	$ 38,516	$ 56,546

XML

Stockholders' Equity - Contingent consideration (Details) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended	3 Months Ended	9 Months Ended		12 Months Ended
	Dec. 31, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021	Dec. 31, 2020
Stockholders' Equity
Earn-out consideration, shares per annual installment			1,000,000		1,000,000	1,000,000
Second stock price hurdle (in dollars per share)					$ 18	$ 15
Third stock price hurdle (in dollars per share)	$ 22
Earn-out consideration, number of shares issued during the period					1,000,000	1,000,000
Common stock par value			$ 0.0001		$ 0.0001
Change in amount of contingent common share liability
Contingent consideration common shares liability, Beginning balance				$ 70,477	$ 70,477
Change in fair value of contingent consideration common shares liability (note 10)		$ (10,006)		(34,050)
Contingent consideration common shares liability, Ending balance		$ 36,427		$ 36,427		$ 70,477

XML

Stockholders' Equity - Equity-based Compensation (Details) - USD ($) $ in Thousands	3 Months Ended				9 Months Ended
	Sep. 30, 2022	Mar. 31, 2022	Sep. 30, 2021	Jun. 30, 2021	Sep. 30, 2022
Equitybased Compensation
Options granted					0
Exercise of stock options (in shares)					509,000
Exercise of stock options	$ 665	$ 723	$ 9,840	$ 2,300	$ 1,400
2019 Incentive Plan
Equitybased Compensation
Shares authorized for issuance	10,000,000				10,000,000
Stock available for issuance	2,124,163				2,124,163

XML

Stockholders' Equity - Stock Option activity (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended				9 Months Ended
	Sep. 30, 2022	Mar. 31, 2022	Sep. 30, 2021	Jun. 30, 2021	Sep. 30, 2022
Number of Options
Outstanding at beginning of period (in shares)		5,766,000			5,766,000
Granted (in shares)					0
Exercised (in shares)					(509,000)
Outstanding at end of period (in shares)	5,257,000				5,257,000
Weighted-Average Exercise Price per Share
Outstanding at beginning of period (in dollars per share)		$ 11.26			$ 11.26
Exercised (in dollars per share)					6.79
Outstanding at end of period (in dollars per share)	$ 11.72				$ 11.72
Weighted Average Remaining Contractual Term
Weighted average remaining contractual term (in years)					5 years 8 months 12 days
Number of shares issued for options exercised on a cash basis					194,002
Exercise of stock options	$ 665	$ 723	$ 9,840	$ 2,300	$ 1,400
Exercise of stock options (in shares)					509,000
Options exercised in cashless basis					131,741
Options exercised cashless basis					194,002
Cashless exercise of options (in shares)					315,349
2019 Incentive Plan
Number of Options
Outstanding at beginning of period (in shares)		2,219,000			2,219,000
Outstanding at end of period (in shares)	2,219,000				2,219,000
Weighted-Average Grant Date Fair Value per Share
Outstanding at beginning of period (in dollars per share)		$ 3.75			$ 3.75
Outstanding at end of period (in dollars per share)	$ 3.75				3.75
Weighted-Average Exercise Price per Share
Outstanding at beginning of period (in dollars per share)		$ 19.36			19.36
Outstanding at end of period (in dollars per share)	$ 19.36				$ 19.36
Weighted Average Remaining Contractual Term
Weighted average remaining contractual term (in years)					6 years 3 months 18 days

XML

Stockholders' Equity - Restricted stock (Details) - USD ($) $ / shares in Units, $ in Millions	1 Months Ended	3 Months Ended		9 Months Ended		12 Months Ended
	May 31, 2020	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2019
Stock Option
Equity-based compensation expense		$ 5.6	$ 5.4	$ 16.8	$ 21.4
Performance Percentage Less Than 25%
Weighted-Average Grant Date Fair Value per Share
Share-based Compensation Arrangement by Share-based Payment Award, Award Performance Payout Percentage				0.00%
Performance Percentage Greater Than or Equal to 25%
Weighted-Average Grant Date Fair Value per Share
Share-based Compensation Arrangement by Share-based Payment Award, Award Performance Payout Percentage				50.00%
Performance Percentage Equal to 50%
Weighted-Average Grant Date Fair Value per Share
Share-based Compensation Arrangement by Share-based Payment Award, Award Performance Payout Percentage				100.00%
Performance Percentage Greater Than or Equal to 75%
Weighted-Average Grant Date Fair Value per Share
Share-based Compensation Arrangement by Share-based Payment Award, Award Performance Payout Percentage				200.00%
Unvested restricted stock
Stock Option
Granted, shares				929,000
Number of Options
Non-vested balance at beginning of period				2,195,000
Granted, shares				929,000
Vested, shares				(461,000)
Forfeited, shares				(96,000)
Non-vested balance at end of period		2,567,000		2,567,000
Weighted-Average Grant Date Fair Value per Share
Non-vested, grant date fair value at beginning of period				$ 19.58
Granted, grant date fair value				21.26
Vested, grant date fair value				24.43
Forfeited, grant date fair value				21.96
Non-vested, grant date fair value at end of period		$ 22.60		$ 22.60
Unvested restricted stock | Various Employees
Stock Option
Granted, shares				212,883
Grant date fair value				$ 3.9
Number of Options
Granted, shares				212,883
Unvested restricted stock | Various Employees Non Employee Directors
Stock Option
Granted, shares		81,347
Grant date fair value		$ 1.5
Number of Options
Granted, shares		81,347
Unvested restricted stock | Senior management employees
Stock Option
Granted, shares				317,554
Vesting period				3 years
Grant date fair value				$ 5.7
Number of Options
Granted, shares				317,554
Unvested restricted stock | Minimum | Various Employees
Stock Option
Vesting period				3 years
Unvested restricted stock | Maximum | Various Employees
Stock Option
Vesting period				4 years
Performance Based Restricted Stock Unit | Senior management employees
Stock Option
Granted, shares				317,554
Vesting period				3 years
Grant date fair value				$ 8.7
Number of Options
Granted, shares				317,554
Vesting based on service (continued employment)
Stock Option
Vesting period						4 years
Vesting percentage	25.00%					50.00%
Vesting based on performance
Stock Option
Vesting period						1 year
Vesting percentage					50.00%

XML

Stockholders' Equity - Incentive units (Details) - USD ($) $ in Millions	1 Months Ended	3 Months Ended		9 Months Ended		12 Months Ended
	May 31, 2020	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2019
Equitybased Compensation
Equity-based compensation expense		$ 5.6	$ 5.4	$ 16.8	$ 21.4
Vesting based on service (continued employment)
Equitybased Compensation
Vesting percentage	25.00%					50.00%
Vesting period						4 years
Accelerated vesting cost					$ 1.5
Vesting based on performance
Equitybased Compensation
Vesting percentage					50.00%
Vesting period						1 year
2019 Incentive Plan
Equitybased Compensation
Grant date fair value						$ 4.5

XML

Stockholders' Equity - Equity-based Compensation Expense (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Stock Option
Equity-based compensation expense	$ 5.6	$ 5.4	$ 16.8	$ 21.4
Unrecognized compensation expense	40.5		$ 40.5
Recognition period			2 years 1 month 6 days
General and administrative expenses
Stock Option
Equity-based compensation expense	4.0	3.4	$ 11.5	14.5
Cost of Sales
Stock Option
Equity-based compensation expense	$ 1.6	$ 2.0	$ 5.3	$ 6.9
2019 Incentive Plan
Stock Option
Stock available for issuance	2,124,163		2,124,163

XML

Earnings Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share
Anti-dilutive securities excluded (in shares)	14,688,000	12,406,000	13,095,000	12,944,000
Anti-dilutive securities excluded diluted net income per share (in shares)			1,000,000
Numerator:
Net income attributable to AdaptHealth Corp	$ 16,122	$ 58,092	$ 71,904	$ 133,233
Less: Earnings allocated to participating securities (1)	1,360	5,002	6,079	12,572
Net income for basic EPS	14,762	53,090	65,825	120,661
Change in fair value of warrant liability	1,364	(16,737)	(17,145)	(57,359)
Change in fair value of contingent consideration - common shares liability, net of tax		(8,145)		(27,718)
Net income for diluted EPS	$ 14,762	$ 28,208	$ 48,680	$ 35,584
Denominator:
Basic weighted-average common shares outstanding	134,227,000	131,684,000	134,186,000	124,228,000
Add: Warrants (2)		2,245,000	1,436,000	2,598,000
Add: Contingent Consideration Shares		2,000,000		2,000,000
Diluted weighted average common shares outstanding	137,583,000	140,322,000	138,599,000	133,638,000
Basic net income per share	$ 0.11	$ 0.40	$ 0.49	$ 0.97
Diluted net income per share	$ 0.11	$ 0.20	$ 0.35	$ 0.27
Preferred Stock
Antidilutive Securities Excluded from Computation of Earnings Per Share
Anti-dilutive securities excluded (in shares)	12,406,000	12,406,000	12,406,000	12,944,000
Warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share
Anti-dilutive securities excluded (in shares)	1,706,000
Stock Options
Antidilutive Securities Excluded from Computation of Earnings Per Share
Anti-dilutive securities excluded (in shares)	468,000		468,000
Denominator:
Add: Stock options	2,903,000	3,794,000	2,669,000	4,112,000
Unvested restricted stock
Antidilutive Securities Excluded from Computation of Earnings Per Share
Anti-dilutive securities excluded (in shares)	108,000		221,000
Denominator:
Add: Unvested restricted stock	453,000	599,000	308,000	700,000

XML

Leases - Balance Sheet (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Leases
Operating lease ROU assets	$ 128,635	$ 147,760
Finance lease ROU assets	$ 1,056	$ 17,410
Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]	Property, Plant and Equipment, Net	Property, Plant and Equipment, Net
Right of use assets, total	$ 129,691	$ 165,170
Current operating lease liabilities	28,769	31,418
Noncurrent operating lease liabilities	103,859	120,180
Total operating lease liabilities	$ 132,628	$ 151,598
Operating Lease, Liability, Statement of Financial Position [Extensible Enumeration]	Current operating lease liabilities, Noncurrent operating lease liabilities	Current operating lease liabilities, Noncurrent operating lease liabilities
Current finance lease liabilities	$ 2,695	$ 15,446
Noncurrent finance lease liabilities		132
Total finance lease liabilities	$ 2,695	$ 15,578
Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]	Other Liabilities, Noncurrent	Other Liabilities, Noncurrent

XML

Leases - Cost (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Leases
Operating lease costs	$ 9,248	$ 9,837	$ 28,547	$ 27,695
Finance lease costs: Amortization of ROU assets	640	8,487	7,266	27,549
Other lease costs and income: Variable leases costs (1)	3,728	3,784	12,680	10,061
Other lease costs and income: Sublease income	$ 336	405	$ 1,019	911
Other lease costs and income: Short-term lease costs		$ 4,093		$ 19,905

XML

Leases - Operating Lease Maturity (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Leases
2022	$ 8,778
2023	31,757
2024	26,347
2025	21,966
2026	16,158
Thereafter	47,027
Operating leases, total payments	152,033
Less: amount representing interest	(19,405)
Operating Lease, Liability	$ 132,628	$ 151,598
Operating Lease, Liability, Statement of Financial Position [Extensible Enumeration]	Operating Lease, Liability, Current, Operating Lease, Liability, Noncurrent	Operating Lease, Liability, Current, Operating Lease, Liability, Noncurrent

XML

Leases - Finance Lease Maturity (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Leases
2022	$ 1,920
2023	795
Finance leases, total payments	2,715
Less: amount representing interest	(20)
Total finance lease liabilities	$ 2,695	$ 15,578

XML

Leases - Wtd Average and Cashflow info (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Leases
Weighted average remaining lease term, weighted based on lease liability balances: Operating leases (in years)	6 years 2 months 12 days		6 years 8 months 12 days
Weighted average remaining lease term, weighted based on lease liability balances: Finance leases (in years)	6 months		1 year
Weighted average discount rate, weighted based on remaining balance of lease payments: Operating leases	3.90%		3.80%
Operating cash payments for operating leases	$ 28,416	$ 27,154
Financing cash payments for finance leases	14,219	31,043
Lease liabilities arising from obtaining right-of-use assets: Operating leases	5,411	84,212
Lease liabilities arising from obtaining right-of-use assets: Finance leases	$ 1,335	$ 22,902

XML

Income Taxes (Details) - USD ($) $ in Thousands		3 Months Ended		9 Months Ended		12 Months Ended
	Nov. 08, 2019	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Income Taxes
Income Tax Expense (Benefit)		$ 5,580	$ 12,147	$ 20,036	$ 22,782
Unrecognized tax benefits		$ 4,000		4,000		$ 4,000
Tax Receivable Agreement, payout percentage	85.00%
Increase in liability due to additional exchanges					146,500
Increase in deferred tax asset					$ 163,300
Liability related to TRA				304,800		$ 300,300
Expenses recognized related to changes in the estimated TRA liability				4,500
Other current liabilities
Income Taxes
Liability related to TRA				5,900
Other long-term liabilities
Income Taxes
Liability related to TRA				$ 298,900

XML

Related Party Transactions (Details) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022 USD ($)	Sep. 30, 2021 USD ($)	Sep. 30, 2022 USD ($) item	Sep. 30, 2021 USD ($)
Vendor Three
Related Party Transactions
Ownership interest, as a percent			5.00%
Expense for related party	$ 20.3		$ 49.8
Outstanding balance due to related party	$ 12.6		$ 12.6
Third Party Payor | Maximum
Related Party Transactions
Net revenue related party	1.00%	1.00%	1.00%	1.00%
Vendor two
Related Party Transactions
Number of executives | item			1
Ownership interest, as a percent			1.00%
Expense for related party	$ 1.8	$ 1.2	$ 4.9	$ 3.4
Business process outsourcing services
Related Party Transactions
Purchases from related party	5.7	$ 4.3	16.2	$ 13.7
Outstanding balance due to related party	$ 2.2		$ 2.2